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Abstract.
Ornithine transcarbamylase (OTC) is the second enzyme in the hepatic urea cycle. As 
such, it is important in the metabolism of neurotoxic waste products into a non—toxic, 
water-soluble compound, urea. In humans deficiency of ornithine transcarbamylase is 
an X-linked single gene disorder associated with a high mortality and morbidity due to 
a severe metabolic disturbance. There are two naturally occuring allelic mouse models 
for OTC deficiency, the sparse fur (Spf) and sparse fur^^^ (Spf^^^) mice.
In this study, the focus was on the use of tissue specific promoters in driving 
recombinant gene expression. The main question addressed was whether expression of 
the OTC gene in a tissue which did not normally express this gene, namely skeletal 
muscle, would correct the phenotype of the deficient mouse models. The approach 
taken was generation of conventional transgenic mice using a creatine kinase driven 
OTC gene construct. In addition as a positive control, supplementation of the 
endogenous hepatic gene expression was also undertaken by means of hepatic-specific 
albumin promoter. Three indices were used as a measure of correction of OTC 
deficiency by transgenesis in the mouse models; a) phenotype of the mice, b) plasma 
ammonia levels and c) direct OTC activity.
Although transgenic mice expressing the OTC cDNA driven by the creatine kinase 
promoter showed high OTC activity in skeletal muscle, no metabolic or phenotypic 
correction of the mice was noted. Interestingly, the albumin driven OTC construct did 
not correct the phenotype of the sparse fur and sparse fur^^^ models either, although in 
some transgenic lines a significant amelioration of plasma ammonia levels was noted. 
However, this partial metabolic correction did not correlate with a significant increase 
in hepatic OTC activity.
In addition to these tissue-specific promoters, the potential of a novel keratin 5 
minigene construct in targeting recombinant gene expression to the epidermis in a tissue 
and cell specific manner was assessed. The gene expression pattern of a Lac Z reporter 
transgenic construct driven by the regulatory sequences of the keratin 5 gene was 
investigated both in adult mice and during embryogenesis.
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1. INTRODUCTION
1.1 G e n e  T h e r apy  f o r  s in g l e  g e n e  d is o r d e r s
The last decade has seen the extension of clinical genetics from a purely diagnostic 
and counselling service to that of a potential therapeutic speciality. This has 
occurred due to the advent of gene therapy, the manipulation of DNA in disease 
conditions. Although initially considered as a means of correcting single germline 
gene disorders such as cystic fibrosis (Tanne 1999), it has now been shown to have 
a role in the treatment of more complex genetic conditions such as cancer (Gene 
Therapy o f Cancer 1998).
In considering gene therapy for a specific single gene disorder two distinct 
approaches can be envisaged. In the first approach it could be postulated that in 
certain conditions demonstrating a dominant inheritance pattern, gene disruption or 
correction could prevent the expression of an endogenous mutant gene product. In 
the second approach, applicable to those disorders demonstrating recessive 
inheritance or haploinsufficiency secondary to loss of gene function, 
supplementation of the deficient gene in the appropriate cells could resolve the 
pathological phenotype. Although this approach is of more limited potential, it has 
already produced results in the clinical sphere. The most advanced clinical trials for 
a single gene disorder have involved patients with a severe combined 
immunodeficiency due to the absence of adenosine deaminase (ADA). 
Supplementation of this enzyme by targeting gene expression and subsequent 
protein production to the patient's peripheral T lymphocytes has indicated a potential 
therapeutic role for this form of treatment, although as yet this approach has not 
been shown to be lasting clinical benefit (Hershfield 1998). Ideally, supplementation 
of an endogenous gene would result in recombinant gene expression in a highly
tissue- and cell-specific manner, which would mimic those of the endogenous gene 
under physiological conditions.
1.1.1 T is s u e -s p e c if ic  p r o m o t e r s  c a n  b e  u s e d  t o  e x p r e s s
RECOMBINANT GENE PRODUCTS
The most efficient method by which tight regulation of gene expression at the 
cellular and tissue level could be achieved is through the use of endogenous gene 
regulatory sequences. It is for this reason that one focus in the gene therapy field is 
in trying to identify genes that are expressed in a tissue-specific manner and to 
dissect out the cis-acting regulatory sequences governing this expression pattern. 
These tissue specific promoters could then be used to express recombinant genes in 
specific target tissues.
The advantage of tissue specific promoters over the use of their general or viral 
counterparts is that, by definition, they only allow gene expression in a limited 
number of tissues. Specific gene regulatory elements have been characterised, which 
can target recombinant gene expression to a variety of tissues such as the epidermis 
(Blessing, Nanney et al. 1993), skeletal muscle (Jaynes, Johnson et al. 1988), 
mammary tissue (Li, Murphy et al. 1998), liver (Pinkert, Omitz et al. 1987) and 
pancreas (Ray, Fagan et al. 1998). As these gene promoter sequences are 
endogenous to the mammalian genome, their expression is not down-regulated by 
the méthylation apparatus which have evolved to silence exogenous viral gene 
promoters (Palmer, Rosman et al. 1991). Tissue-specific promoters are therefore 
capable of long term expression of recombinant genes. In addition, this approach has 
the additional advantage that the mode of gene delivery need be less tissue-specific 
since gene expression pattern is tightly regulated at the cellular level.
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Tissue specific expression cassettes can be integrated into viral vector for delivery to 
the target organ. Although viral vectors have shown good transfection efficiency, 
the immunogenicity of some viral vectors can have a detrimental effect on the 
longevity of gene expression (ïshibashi, Brown et al. 1993; Kozarsky, Grossman et 
al. 1993). Therefore, alternative, non-viral transfection methods have been devised. 
These include liposomes, particle bombardment and direct injection of ‘naked’ 
DNA. These different forms of gene delivery will described in relation to 
appropriate target tissues later in the thesis. However, in general these forms of gene 
delivery result in episomal expression of the recombinant gene which, although 
circumventing the risk of insertional mutagenesis, tend to decrease the time the gene 
is expressed.
The majority of supplementive gene therapy focuses on increasing gene expression 
and hence protein production in the endogenous tissue. In the case of cystic fibrosis 
it is vital that the gene is expressed in the lung epithelium, as it is in this tissue that 
the gene is normally expressed and that pathology is found when the protein is 
absent. At present it is often technically difficult in a clinical setting to deliver a 
recombinant gene to its endogenous target tissue, such as the lung. However, in 
enzymatic reactions or Haemophilia A or B in which the gene-product and/or 
substrate(s) are diffusible, it may not be as important that the gene is expressed in 
the endogenous tissue as long as the gene product is accessible to its substrates, and 
in an environment in which it can function optimally. In this scenario, it may be 
advantageous to express the recombinant gene in a tissue, which is clinically easily 
accessible, such as skin. Tissue-specific promoters can be used to target 
recombinant protein to tissues, which under physiological conditions do not 
normally expresses the gene, in order investigate if their expression in this 
exogenous site may be clinically beneficial.
1.1 .2  O r n it h in e  t r a n s c a r b a m y l a s e  d e f ic ie n c y  is  a  g o o d
CANDIDATE FOR SUPPLEMENTIVE GENE THERAPY
In addition to haemophilia A and B, metabolic disorders are strong candidates for a 
supplementive gene therapy strategy as they are often due to single gene/enzyme 
deficiencies. As their substrates/products are often difftisible, it could envisaged that 
gene expression in an exogenous tissue may have a therapeutic benefit. Such 
disorders include phenylketouria, and deficiencies of a  1 antitrypsin, Haemophilia 
factor IX or ornithine transcarbamylase (OTC).
OTC deficiency is an excellent model system in which to investigate this form of 
treatment. It is an X-linked recessive, single gene disorder with high mortality and 
morbidity. OTC is important in the metabolism of proteins and in particular in 
preventing the accumulation of neurotoxic products during protein degradation. 
Current clinical treatments for OTC deficiency are sub-optimal, which means that 
the scope for devising a more effective treatment is immense. However, the major 
advantage that this condition has over the many other metabolic disorders in the 
study of novel treatment regimes, is that there are two naturally occurring mouse 
models in which to test possible therapeutic strategies.
This thesis concentrates on the use of tissue specific promoters to express 
recombinant ornithine transcarbamylase protein in OTC deficient mouse models. By 
this means it is possible to investigate whether the OTC gene, if expressed in ectopic 
tissue, can have a therapeutic effect. The two tissue-specific promoters, which have 
been previously well characterised, comprise the murine albumin gene promoter and 
enhancer targeting expression to the liver, and the murine creatine kinase gene 
promoter and enhancer driving gene expression to skeletal muscle. Pronuclear
technology was used to test the efficiency of the recombinant OTC expression 
constructs and their effect on the phenotype of the OTC deficient mouse models.
1.2 P r o t e in  m e t a b o l is m  o c c u r s  in  t h e  l iv e r  a n d
PRODUCES INTERMEDIATE NEUROTOXIC METABOLITES
The liver plays a pivotal role in the metabolism of many waste and pharmacological 
substances prior to excretion. In particular, it is active in protein synthesis and the 
interconversion of amino acids. As a result of these metabolic processes the liver is 
involved in the formation of urea, the by-product of amino acid and protein 
metabolism in mammals.
As protein can only be stored to a limited extent, any imbalance in amino- acid 
availability versus requirement is corrected in the liver. The amino acids necessary 
for hepatic synthesis of protein are derived partly from the catabolism of dietary 
protein and partly from the metabolic turnover of endogenous proteins. During 
protein metabolism many neurotoxic nitrogenous compounds, such as ammonia, 
accumulate as by-products. In order to prevent damage due to the accumulation of 
these products they are incorporated into a water-soluble, non-toxic form, namely 
urea. Urea is safely transported to the kidneys and excreted in urine.
The formation of urea is controlled by a series of five biochemical reactions, called 
the urea cycle (Fig 1). This cycle is unidirectional, as the hydrolytic reaction 
catalysed by arginase is irreversible due to the excretion of the urea.
Although, the urea cycle occurs predominantly in the liver, other tissues including 
skeletal muscle, the epithelia of the small intestine and the kidneys also play a more
10
Figure 1. The urea cycle.
The urea cycle comprises five catalytic enzymes which are involved in the 
conversion of nitrogenous products, produced by the catabolism of amino acids, 
into an inert form, urea, that is excreted in the urine.
At the cellular level the urea cycle spans both the cytosolic and mitochondrial 
compartments and therefore involves the transportation of ornithine and citrulline 
across the mitochondrial membrane to complete the cycle.
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Figure 1. The Urea cycle
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peripheral role by producing or excreting many of the substrates or products 
involved in the cycle (Fig 2).
1,2.1 T h e  U r e a  c y c l e  is  in t e g r a l  to  t h e  c o n v e r s io n  o f
NEUROTOXIC METABOLITES TO AN INERT WATER-SOLUBLE PRODUCT, 
UREA.
Within the liver it has been proposed that ureagenesis predominately occurs in the 
periportal rather than perivenular hepatocytes (Jungermann 1986). Within these 
periportal hepatocytes the urea cycle is further compartmentalised at the subcellular 
level between the mitochondria and cytoplasm. The first two enzymes in the urea 
cycle, omithine transcarbamylase and carbamyl phosphate synthetase type 1 (CPS 
I), are mitochondrial matrix proteins, whilst later enzymes, argininosuccinate 
synthetase, arginosuccinate lyase and arginase, are active only in the cytoplasm (Fig 
1).
In most instances, it is the non-protein amino acid, omithine, which initiates the urea 
cycle, providing the molecular foundation on which urea is assembled. The initial 
reaction, incorporating ammonia into the urea cycle, involves the enzyme carbamyl 
phosphate synthetase type I. In the presence of its co-factor N-acetyIglutamate 
(NAG), CPS I catalyses the production of carbamyl phosphate from ammonia and 
similar nitrogenous substrates. It has been suggested (Cooper, Nieves et al. 1988) 
that the extra-hepatic glutamate metabolism, predominately in skeletal muscle, 
provides the major source of ammonia for the carbamyl phosphate synthetase 
reaction, although in the liver deamination of the amino-acids histidine, tryptophan, 
threonine and lysine may also contribute to this ammonia pool.
In the next step in this cycle, OTC catalyses the formation of citrulline by 
transcarbamylation of omithine with carbamyl phosphate. In the absenee of
12
Figure 2. Tissues involved more peripherally in the urea cycle.
Although the urea cycle occurs predominately in the liver, it interacts with many 
other tissues in the body. A large proportion of the metabolic substrates for the 
urea cycle are formed in muscle and other tissues whilst the final product, urea, is 
transported to the kidneys for excretion. In addition, omithine transcarbamylase is 
also expressed in the small intestine forming a partial urea cycle. As can be seen 
from this diagram, disruption to the urea cycle will manifest clinically as a 
multisystemic rather than purely hepatic disorder.
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omithine, CPS I activity has been shown to be impaired, due presumably to the 
accumulation of carbamyl phosphate, producing a negative feedback stimulus 
(Cohen, Cheung et al. 1980).
The citrulline formed by OTC activity is transported from the mitochondrion to the 
cytoplasm where it is complexed with aspartate to form argininosuccinate. This is in 
turn cleaved to form arginine and fumarate. The arginine is then hydrolysed by 
arginase to form urea, which is transported in the blood to the kidneys and excreted 
in urine. Omithine is also released by the arginase reaction, and transported back 
into the mitochondrial matrix to complete the cycle. There is no net gain or loss of 
omithine, as for each molecule of omithine converted to citmlline in the 
mitochondrial matrix, a further molecule of ornithine is released by the metabolism 
of arginine into the cytoplasm.
In order for the urea cycle to function within two subcellular compartments, 
omithine must pass from the cytosol to the mitochondrial matrix and citmlline must 
then leave the mitochondria in order to regenerate omithine in the cytoplasm. This 
exchange between cytoplasm and mitochondrion is achieved by means of an active 
omithine/citmlline carrier protein on the inner mitochondrial membrane (Indiveri, 
Tonazzi et al. 1992).
1.3 O r n it h in e  t r a n s c a r b a m y l a s e  is  t h e  se c o n d
ENZYME IN THE UREA CYCLE.
As has been mentioned, omithine transcarbamylase is the second enzyme of the urea 
cycle and is responsible for the formation of citmlline from the substrates carbamyl 
phosphate and omithine. Citmlline is formed in the mitochondrial matrix of
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hepatocytes through the transfer of the carbamyl moiety of carbamyl phosphate to 
the a-amino-nitrogen of omithine. The major source of omithine is from arginine in 
dietary proteins, and although vital for the urea cycle, it is also involved in other 
metabolic pathways. Omithine metabolism is involved in the synthesis of creatine, 
and pro line via omithine aminotransferase (OAT) activity. Although, OAT activity 
is integral to the mitochondrial omithine concentration in the liver, this enzyme is 
expressed in hepatocytes surrounding the pericentral vein of the hepatic lobules 
which do not express OTC and are not involved in the urea cycle (Kuo and Damell 
1991). Thus, there is no competition between OAT and OTC activity in their 
utilisation of available omithine.
Omithine acts as a substrate for OTC as well as a stimulator of CPS I (Stewart and 
Walser 1980). The concentration of omithine in the mitochondrial matrix is 
dependent on the entry of omithine from the cytoplasm and the activity of OTC. In 
vitro evidence suggests that the transported ornithine and carbamyl phosphate 
molecules are channelled directly to the omithine transcarbamylase enzyme 
suggesting a physical organisation of the elements of the urea cycle within the 
mitochondrial matrix (Cohen, Cheung et al. 1987; Cohen, Cheung et al. 1992).
In addition to its presence in hepatocytes, OTC is also expressed in the small 
intestine in conjunction with CPS I. In this setting, it is thought to act as a nitrogen 
sink for glutamine, an important respiratory fuel of the bowel (Windmueller and 
Spaeth 1980). The citmlline produced is released into the circulation and taken up 
predominantly in the kidneys, where it is converted into arginine.
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1.3.1 THE OTC PROTEIN COMPRISES A HOMOTRIMERIC STRUCTURE 
FOUND IN THE MITOCHONDRIAL MATRIX.
Mature mitochondrial human OTC was first purified in 1978 (Kalousek, Francois et 
al. 1978) and shown to be a homotrimer with 322 amino acids and a molecular 
weight of approximately 36 000 Daltons per polypeptide chain. Human OTC is 
translated on free cytoplasmic ribosomes as a 40 kDa precursor protein. The amino 
terminus of the OTC protein comprises a 32 amino acid 'leader peptide', containing 
eight basic but no acidic amino acids (Conboy and Rosenberg 1981; Mori, Miura et 
al. 1980). The basic nature of the leader peptide appears critical for the uptake of the 
OTC precursor polypeptide into the mitochondrion, as uptake is inhibited in the 
presence of histones and protamines (Mori et al 1982). When the OTC leader amino 
acid sequence is compared between two closely related species; namely human and 
rat, there is 73% sequence identity with the basic residues in the human enzyme 
aligning with those in the rat, again highlighting their functional importance 
(McIntyre, Graf et al. 1984). Site-directed mutagenesis studies indicate that the mid 
portion of the leader sequence with 3 highly conserved arginine residues, in 
particular arginine at amino acid 23, is essential for transportation of the protein 
subunit into the mitochondrial matrix (Horwich, Fenton et al. 1984; Horwich, 
Fenton et al. 1985). During transportation of the precursor protein into the 
mitochondrial matrix, the leader peptide is cleaved off in a two step process 
(Conboy and Rosenberg 1981; Kraus, Conboy et al. 1981). The resulting 36 kDa 
polypeptide forms a functional enzyme by homotrimerization and becomes attached 
to the inner mitochondrial membrane in the mitochondrial matrix. This 
homotrimeric structure has also been reported in rat and bovine ornithine 
transcarbamylase (Marshall and Cohen 1972; Clarke 1976).
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Although the leader peptide only shows 73% amino acid sequence identity between 
rat and human, the remaining protein mRNA is 93% identical, suggesting that 
greater evolutionary constraint has been placed on the structure of the catalytic 
domains compared to the leader sequence. Two regions of particular importance 
correspond to the binding sites for the substrates, carbamyl phosphate and ornithine. 
These regions span amino acids 53-62 and 268-273, and are encoded by exons 3 and 
9 respectively (Kraus, Hodges et al. 1985). These sequences are highly conserved in 
prokaryotic transcarbamylases.
Little is known about the tertiary structure of human ornithine transcarbamylase 
although models have been formed based on the 46% amino acid homology with 
E.coli aspartate transcarbamylase. These have been used to predict how mutations 
may alter the tertiary structure of the protein and thus affect its function (Tuchman, 
Morizono et al. 1995) (Fig 3).
1.3.2 OTC ACTIVITY FLUCTUATES WITH PROTEIN INTAKE
The most important factor influencing OTC activity is protein metabolism. The
amount of nitrogenous waste required to be metabolised by OTC is dependent on 
both endogenous protein breakdown and dietary protein ingestion. A deficiency in 
OTC activity may only manifest when the protein load on the urea cycle exceeds 
that capable of being metabolised. This increase in protein degradation may be due 
to excessive dietary intake of protein or increased endogenous catabolism secondary 
to a systemic illness.
A recently described reaction, which may have a regulatory effect on the urea cycle, 
is the conversion of arginine to nitric oxide and citrulline (Kerwin and Heller 1994). 
This reaction is catalysed by nitric oxide synthetase (NOS) and although NOS plays
17
Figure 3. This is a representation of the speculative tertiary structure of OTC protein 
(Tuchman et al, 1995) based on the structure of E. coli aspartate transcarbamylase, which 
displays 50% and 75% identity at the sequence and amino acid level, respectively. The 
protein is a homotrimer with 322 amino acids and a molecular weight of approximately
36000 Daltons per polypeptide chain. The active protein comprises three identical 
polypeptides that are formed in the mitochondrion after removal of the amino terminal 
leader peptide. This protein model suggests that the catalytic ornithine and carbamyl 
phosphate binding sites form pockets in the internal core of the protein.
Figure 3. Speculative tertiary structure of the OTC 
homotrimeric protein.
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a minor role in citrulline production, it is possible that alterations in its expression 
may be important in modifying the urea cycle disorder phenotypes.
Recent reports (Kay, Hilton-Jones et al. 1986; Honeycutt, Callahan et al. 1992; Leao
1995) have also implicated the anticonvulsant, valproate, in precipitating a 
hyperammonaemic crisis in OTC deficient heterozygotes and hemizygotes. It is 
thought this effect is due to valproate having a direct inhibitory effect on the urea 
cycle as well as a direct toxic effect on mitochondria.
1.3.3 OTC G e n e  E x p r e s s io n  is  f o u n d  p r im a r il y  in  t h e  l iv e r  a n d
SMALL INTESTINE.
Although one or more steps of protein precursor import and processing may 
themselves be subject to certain regulatory controls (Raymond and Shore 1981), the 
main elements regulating the level of OTC expression involve a range of 
developmental, hormonal and dietary controls over the amount of messenger RNA 
which accumulates in the cell (Mori et al, 1981; Cohen, 1970; Pouchelet and Shore 
1981); Rozen, Noel et al. 1983; Ryall et al 1984). Thus, regulation is at the 
transcriptional rather than the post- transcriptional level.
Ornithine transcarbamylase is expressed in the small intestine as well as the liver, 
although intestinal epithelium does not possess a full urea cycle (Ryall, Nguyen et 
al. 1985; Raijman 1974). The citrulline produced in the small intestine due to the 
presence of CPS I and OTC, is primarily an end product of metabolism of ammonia. 
The citrulline is then transported to the peripheral tissues, predominantly the kidneys 
where de novo synthesis of arginine occurs (Windmuellar et al, 1981). Studies have 
shown that rodent intestinal OTC activity varies from 0.02 to 10% of hepatic values 
(Raijman et al. 1975, Jones et al. 1961) (Fig2), whilst intestinal mRNA is about 50%
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of hepatic levels (Ryall, Nguyen et al. 1985). The ornithine transcarbamylase protein 
is thought to have a half-life of 6-9 days (Wallace, Knecht et al. 1986) whilst the life 
span of intestinal epithelium is thought to about 5 days.
1.4 F e a t u r e s  o f  OTC d e f i c i e n c y
1.4.1 OTC DEFICIENCY IS A X-LINKED DISORDER.
Ornithine transcarbamylase deficiency is the commonest inborn error of urea 
synthesis with an estimated incidence of 1:40-80 000 births (Nagata, Matsuda et al. 
1991). Although, mitochondria contain an intrinsic genome encoding 37 genes, the 
majority of mitochondrial proteins are encoded in the nuclear genome, synthesised 
in the cytoplasm and then transported into the mitochondria. All the enzymes in the 
urea cycle are encoded in the nuclear genome.
In contrast to the other enzymes in the urea cycle, which show an autosomal 
recessive inheritance, ornithine transcarbamylase deficiency shows an X-linked 
inheritance pattern. This was first demonstrated in 1972 when Scott (Scott, Teng et 
al. 1972) described two pedigrees which exemplified i) the severe nature of the 
disorder associated with almost complete absence of the protein in males, and ii) the 
wide variation in clinical severity and enzyme levels in heterozygous women 
associated with hepatic mosaicism (Ricciuti, Gelehrter et al. 1976). Further clinical 
studies (Short, Conn et al. 1973; Campbell, Rosenberg et al. 1973) strengthened this 
hypothesis as did the finding in 1976 that the OTC deficiency was X-linked in the 
mouse (DeMars, LeVan et al. 1976).
In 1984 the OTC gene was mapped to Xp21.1 (Lindgren, de Martinville et al. 1984)
and cloned (Horwich, Fenton et al. 1984). By means of segregation analysis
(Bonaiti-Pellie, Pelet et al. 1990) as well as specific mutation analysis (Tuchman,
Matsuda et al. 1995) the proportion of males and females with OTC deficiency
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whose mutation was inherited from one of their parents has been estimated. Of 28 
total cases only 2 (7%) of OTC deficient males as opposed to 12 (80%) of affected 
females had new mutations. Further evidence for this high proportion of de novo 
mutation in heterozygote females has also documented more recently (Leibundgut, 
Liechti-Gallati et al. 1995). This information is of important clinical relevance as it 
suggests that the prior risk of a mother of an affected male being a carrier of the 
condition is about 9/10 or higher, whilst the mother of an affected daughter has only 
a 2/10 risk of being a carrier.
L 4 J A  C l in ic a l  f e a t u r e s  o f  OTC d e f ic ie n c y  v a r y  i n  s e v e r i t y  n o t
ONLY BETWEEN AFFECTED MALES AND FEMALES, BUT ALSO WITHIN THE 
HEMIZYGOUS AFFECTED MALE GROUP,
A deficiency of ornithine transcarbamylase was first identified in 1962 as a cause of 
protein intolerance and hyperammonaemia in children (Russell et al 1962). The 
initial cases described the clinical condition in heterozygous females which was due 
to the higher survival rate in females compared to males allowing time for the 
diagnosis to be made. As an X-linked disorder, OTC deficiency produces different 
clinical pictures in hemizygous males and heterozygous females.
1.4.1.1.1 The classical clinical picture of OTC deficiency occurs in neonatal 
males.
The most dramatic clinical presentation of OTC deficiency occurs in newborn males 
as a catastrophic hyperammonaemic encephalopathy associated with high mortality. 
This is the most commonly described clinical picture. It often occurs within a few 
hours or days of birth when feeding, and thus protein intake, is established. In utero
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the maternal circulation and hepatic pathways are responsible for clearing toxic by­
products of foetal protein metabolism.
Initial symptoms of lethargy, irritability and poor feeding, if not recognised and 
treated, can progress to convulsions, coma, apnoea, areflexia and eventually to 
death. The mortality rate for neonatal hyperammonaemic coma approaches 50%, 
with each subsequent hyperammonaemic crisis carrying a further 10% mortality rate 
(Batshaw, Brusilow et al. 1982). Males who do survive the neonatal period often 
have a poor neurological outcome, with a high incidence of mental retardation, 
cerebral palsy, and seizures (Msall, Batshaw et al. 1984; Nagata, Matsuda et al. 
1991).
1.4.1.1.2 Late Onset presentation in males can be less severe although 
mortality is still high.
There have also been reports of males diagnosed with OTC deficiency without 
neonatal symptoms. The age of first onset of symptoms have ranged from childhood 
to 58 years old (Yoshino, Nishiyori et al. 1990) and the symptoms themselves may 
be initially quite non-specific (Gizumi, Ng et al. 1984). This group of males have 
been further sub-divided into those symptomatic after 28 days old but before the age 
of 5 (group 2) and those symptomatic at a later age (group 3) (Matsuda, Nagata et al. 
1991). In a recent survey, the highest mortality rate was in those males in group 3, 
followed by group 1 (neonatal onset). The causes of higher mortality in this older 
age group may relate to a delay in diagnosis and treatment as well an impaired 
capacity to recover from multisystem organ failure; factors which appear to be age 
dependent. Group 2 had a lower mortality rate and a lower incidence of mental
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abnormality compared to the other groups, which correlated with only a moderate 
OTC enzyme deficiency.
Interestingly, although group 3 patients had a reduction in OTC activity comparable 
with group 1, they had normal citrulline levels. However, it was noted that the 
hepatic OTC enzyme activity in group 3 was measured at post mortem and the 
lability of the OTC protein may preclude accurate OTC activity assessment after 
autolysis. This would explain the lack of correlation between OTC enzyme activity 
and plasma citrulline levels in patients in group 3.
1.4.1.1.3 Female heterozygous carriers are often asymptomatic.
Heterozygous females may be overtly symptomatic or asymptomatic depending on
allelic heterogeneity (Rowe, Newman et al. 1986), the residual hepatic OTC activity 
due to the effect of random X-chromosome inactivation in hepatocytes, and on the 
endogenous and exogenous nitrogen load on the urea cycle. Obligate female carriers 
as determined by pedigree analysis often have an aversion to protein and therefore 
unwittingly often decrease the risk of an acute hyperammonaemic crisis by 
modifying their diet themselves.
Approximately 15% of carrier females are overtly symptomatic. A review of 13 
symptomatic heterozygotes (Rowe, Newman et al. 1986) showed the age of 
presentation could vary greatly from birth to six years old and that, as in the case of 
affected males, the symptoms could be non-specific such as episodic irritability 
(100%), episodic lethargy and vomiting (100%), protein avoidance (92%) and ataxia 
(77%). However, even asymptomatic carriers are thought to be at an increased risk 
of hyperammonaemic coma during pregnancy (Am, Hauser et al. 1990) or due to a 
prolonged catabolic period such as during a severe generalised illness.
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L4,l,2 OTC DEFCIENCY PRODUCES A MARKED BIOCHEMICAL PROFILE 
WHICH OFTEN ALLOWS DIAGNOSIS
1.4.1.2.1 Affected males show a marked elevation in plasma ammonia and 
abnormal pyrimidine metabolism.
In OTC deficiency, a pronounced plasma hyperammonaemia (-2000 mmol/L, 
normal <50 mmol/L) is found in association with an elevation in plasma glutamate 
levels. However, this is not pathognomic for the condition as it is often found in 
association with a more general aminoaciduria. In addition to these changes, there is 
the expected decrease in plasma citrulline and arginine. This metabolic disturbance 
leads to hyperventilation due to cerebral irritation, which exacerbates the situation 
producing a respiratory alkalosis rather than the metabolic acidosis usually seen in 
the organic acidaemias.
A more distinctive metabolic abnormality found in OTC deficiency is an increase in 
pyrimidine metabolites, in particular orotic acid, uridine and uracil. These are 
excreted in urine producing a characteristic orotic aciduria. This accumulation of 
pyrimidine products results from the under-utilisation and overflow of carbamyl 
phosphate produced in the mitochondria into the cytoplasm. These products are 
converted to carbamyl aspartate and thence channelled into the pyrimidine synthesis 
pathways (Fig 1).
In males presenting in the neonatal period, these biochemical indices, in addition to 
the clinical examination, allows the diagnosis to be made. The history of a previous 
neonatal male death within the family further compounds the diagnosis. However, in 
an older male, a liver biopsy may be required to differentiate OTC deficiency from 
Reyes syndrome, which has similar clinical picture but shows a more general
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reduction in hepatic enzymes including carbamyl phosphate synthetase type 1 in 
addition to OTC.
1.4.1.2.2 Female Carriers only show a metabolic disturbance during a 
symptomatic crisis.
Symptomatic carrier females are diagnosed during an acute metabolic crisis when 
their biochemical indices are identical to affected males. The major diagnostic 
problem encountered is in an asymptomatic female with an affected sibling, the 
sister of a mother with an affected son or a mother with an affected daughter, as 
baseline metabolic indices in such cases are normal. As mentioned previously, the 
mothers’ of affected boys have a 9 in 10 chance of being a carrier of an OTC 
mutation. Establishing the carrier status of women ‘at risk’ of ornithine 
transcarbamylase deficiency is important both for determining reproductive as well 
as medical risks for the individual.
The gold standard by which other carrier status assessments are compared is initial 
mutation analysis in the affected boy, followed by genomic screening of the high- 
risk female for this mutation. If direct DNA mutation testing is not feasible, 
metabolic screening procedures are employed which measure the biochemical 
response to hyperstimulation of the urea cycle. This hyperstimulation originally took 
the form of a high protein meal, but as this could trigger an acute symptomatic crisis 
in a heterozygote carrier, it has been replaced by the measurement of urinary 
orotidine or orotic acid excretion after an allopurinol challenge test (Hauser, 
Finkelstein et al. 1990; Burlina, Ferrari et al. 1992). Allopurinol is metabolised to 
oxypurinol ribonucleotide, which has an inhibitory effect on an enzyme in the 
pyrimidine pathway namely orotidine 5’ phosphate decarboxylase. This enzyme
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inhibition causes orotidinuria and orotic aciduria which is more pronounced in 
individuals with OTC deficiency than in normal individuals. These biochemical 
screening procedures are often used in association with molecular linkage analysis 
in suitable families in strengthening and confirming carrier status.
Interestingly, the clonal nature of epithelium found in intestinal crypts has also been 
used as a novel alternative to hepatic biopsy as a possible means of carrier detection 
(Hamano, Kodama et al. 1988). A duodenal biopsy is stained by means of 
immunohistochemistry for the OTC protein and if the carrier female has a null 
mutation two subsets of intestinal crypt cells are seen, those showing the presence of 
the OTC protein and those with absent protein. This technique has the advantage of 
having its own internal control. However, it is highly invasive and will only work if 
the OTC gene encodes a null mutation. Missense mutations may still produce 
protein capable of being recognised by the antibody.
1.5 OTC G e n e  St r u c t u r e
1.5.1 T h e  OTC g e n e  is  73 k b  l o n g  c o m p r is in g  10 e x o n s .
The human OTC cDNA was cloned in 1984 by Horwich et al (Horwich, Fenton et 
al. 1984). Subsequently Hata derived the full human ornithine transcarbamylase 
gene sequence from a human liver genomic library in 1988 (Hata, Tsuzuki et al. 
1988). The genomic sequence is 73 kb long comprising 10 exons, interrupted by 9 
introns of varying sizes. The exons tend to be relatively uniform in size, spanning 
about 140 bp, the last being the largest at 764 bp. The smallest intron, intron 7, is 80 
bp whilst the largest, intron 4, spans 21.7 kb. All intron/exon boundaries comply 
with the well-documented GT-AG splice junction rule (Mount et al 1982). The
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nucleotide sequence of an intron commences with the nucleotide pair ‘GT’ and 
finishes with the ‘AG’ pair. The splicesome recognises these nucleotide pairs as 
flanking an intron and spices out the intervening sequences to join adjacent exons 
together.
Four useful polymorphisms have been described, and approximately 70-80% of 
females are informative for one of these RFLPs (Schwartz, Christensen et al. 1986), 
(Spence, Maddalena et al. 1989).
Studies using a hepatoma cell line. Hep G2, revealed that in the promoter region of 
the rat OTC gene there are two cis-acting elements (Murakami et al, 1990), both of 
which are recognised by at least two members of the steroid receptor superfamily: 
hepatocyte nuclear factor-4 (HNF-4) (Sladek et al 1990) which activates 
transcription of a co-transfected OTC promoter construct, and chicken ovalbumin 
upstream transcription factor (COUP-TF) (Wang, Tsai et al. 1989) which represses 
transcription (Kimura, Nishiyori et al. 1993). The homologous OTC promoter used 
in vivo produced high OTC transcription in the small intestine but the presence of a 
llObp enhancer region 11 kb upstream of the promoter is capable of activating 
transcription in a more endogenous liver-specific manner. This enhancer contains 
four protein binding sites, two for hepatocyte nuclear factor-4 (HNF-4) and two for 
CCAAT/enhancer binding protein (C/EBP), both of which are liver-selective 
transcription factors and both of which have to be present for activation of the 
reconstituted enhancer in non-hepatic cells (Nishiyori et al 1994).
L  5.1 ,1  THE MAJORITY OF O T C  MUTA TIONS ARE NOVEL,
An up to date summary of mutations in the OTC gene currently described can be 
found in the human gene Mutation Database, Cardiff
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(http ://www.uwcm.ac.uk/uwcm/mg/ns/2A. To date there have been 142 mutations 
described. 74% are nucleotide substitutions (missense or nonsense), 15% nucleotide 
substitutions causing aberrant splicing, 7% small deletions, 2% small insertions, 1% 
gross deletions with as yet no descriptions of gross insertions, duplications or 
regulatory mutations, although this may indicate an ascertainment bias. 9 recurrent 
substitutions were observed, R129H, R40H, K88N, P225L, G195R, R92Q, R141Q, 
A209V, N161S, in order of frequency. An increase in substitutions were also noted 
at CpG ‘hot spots’ and it has hypothesised that as méthylation of CpG dinucleotides 
is more pronounced in sperm genes than egg genes (Driscol and Migeon 1990), this 
may predispose mutations to arise more often in the paternal than maternal allele, as 
shown in previous studies into OTC inheritance.
Although the mutations are distributed throughout the OTC gene, there appears to 
be disproportionally higher number in exons 3 (the putative binding site for 
carbamyl phosphate), exon 6 and 5, in decreasing order.
1.5.1.1.1 Genotype/phenotype correlations in OTC deficiency are not always 
possible
Amongst the mutations found in affected males, there are almost twice as many 
associated with a neonatal severe phenotype than have been associated with a milder 
phenotype. This is probably due to a bias of ascertainment as patients with a milder 
phenotype may be under diagnosed and these mutations underrepresented.
Certain mutations such as R40H, R227Q and R277W have been found to be 
associated with a milder later onset of symptoms. It is believed that the arginine at 
codon 227 may interact with a conserved glutamate at position 52 and thus affect the 
overall tertiary structure of the enzyme.
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In vitro Cos cell expression studies (Morizono, Listrom et al. 1997; Matsuura, 
Hoshide et al. 1994) have shown the pathogenic nature of some missense mutations, 
such as R227Q, R277W, T264A, D196V, E154X and G195R by demonstrating a 
relative decrease in mutant OTC activity compared to wild type. The level of OTC 
in this in vitro assay did correlate in general with the clinical history, the greater the 
residual enzymatic activity, the later the onset of clinical symptoms.
In 1995 Tuchman (Tuchman, Morizono et al. 1995)(Fig 3) generated a three 
dimensional model of the human OTC protein from comparisons with the crystalline 
structure of the E.coli aspartate transcarbamylase, by aligning sequences and 
building in gaps. In general, this model suggests that mutations associated with the 
more severe neonatal onset affect one of three regions, namely the interior active 
sites for carbamyl phosphate, the ornithine binding site or the core of the domains at 
the inter-chain interface. The mutations associated with a milder phenotype tend to 
cluster around regions on the outer surface of the protein.
Although a tentative correlation between mutation, protein structure and enzymatic 
function is possible, environmental and additional genetic factors also appear to play 
a role in determining phenotype. In family mutation tracking studies (Matsuda, 
Matsuura et al. 1996) the A40H mutation has been shown to be associated with a 
range of age of onset of symptoms of between 6 to 56 years. A 65-year old 
asymptomatic man was also noted, although the possibility of a mosaic genotype 
could not be excluded as he was at the top of the pedigree. This variation in 
phenotype has also been reported in the A208T mutation (van Diggelen, Zaremba et 
al. 1996).
This expressivity may correlate with dietary protein intake. As different mutations in
the OTC protein reduce its functional capacity to different degrees, the phenotype
associated with a mutation will also be dependent on the requirement of OTC
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function, namely the amount of nitrogenous waste from ingested protein required to 
be metabolised by the urea cycle. Thus, the amount of protein ingested by a person 
may be a predisposing factor in genotype/phenotype correlation. This has been 
suggested by Matsuda (Matsuda, Matsuura et al. 1996) as an explanation to the 
differing phenotypes demonstrated by males with the same mutation. An alternative 
explanation would be the segregation of other modifier genes within the different 
families.
1.5.2 T h e  t r e a t m e n t  o f  OTC d e f ic ie n c y  is  n o t  o p t im a l
Present treatment for OTC deficiency is still sub-optimal with affected boys and 
symptomatic females often still developing neurological sequelae.
L 5,2 ,l A c u t e  P h a s e  T r e a t m e n t  i s  a n  i n t e n s i v e  c a r e  s i t u a t i o n  
In the acute phase the children are treated as a neonatal emergency. All protein 
intake is stopped to reduce the requirement for urea biosynthesis, and the plasma 
ammonia level monitored. Peritoneal- or haemo-dialysis is required if the ammonia 
continues to rise. This will also correct the profound alkalosis. It has been shown 
that haemodialysis is the most effective method of lowering blood ammonia levels 
(Donn, Swartz et al. 1979). Often the children require both ventilatory and 
circulatory support during the acute phase.
L5,2,2 L o n g  t e r m  m a n a g e m e n t  m u s t  b e  m a in t a in e d  a t  h o m e  
After the acute phase, a severely restricted protein intake is initiated, although 
essential amino acids are required for growth and development in young children. In 
the long-term management of these patients pharmacological induction of
30
alternative pathways through oral supplementation, in association with strict protein 
limitation has been shown to be effective. The former is best achieved by oral 
sodium phenylbutyrate or sodium benzoate supplementation. Sodium 
phenylbutyrate is a precursor of phenylacetate which conjugates with glutamine to 
form phenylacetylglutamine, a waste nitrogen compound that is excreted in the 
urine. By this means nitrogen is diverted from the urea cycle, which is suppressed, 
although if residual OTC activity is present, this can be re-activated to maintain 
nitrogen homeostasis (Brusilow and Finkelstien 1993).
This treatment is effective both given intra-venously, in the acute episode, or orally 
for more long-term control. A recent study (Maestri, Brusilow et al. 1996) indicated 
that sodium phenylbutyrate or -acetate was more effective in reducing the frequency 
of hyperammonemic episodes in symptomatic female carriers than sodium benzoate. 
Mortality was also reduced to 10% over 5 years. Prior to this form of treatment a 
high rate of mortality of 82% from hyperammmonaemic-induced coma had been 
reported in affected males (Batshaw et al, 1986).
L 5 ,2 ,3  S u r g i c a l  l i v e r  t r a n s p l a n t a t i o n i s  a n  o p t i o n  
Ultimately for long term correction of OTC deficiency, orthotopic liver 
transplantation has been shown to be successful, both for symptomatic females and 
neonatal onset male patients (Hasegawa, Tzakis et al. 1995). However, this surgical 
procedure, rarely performed due to the paucity of suitable livers, is associated with a 
high mortality and morbidity.
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1.6 OTC DEFICIENCY IS AMENABLE TO GENE T HERAPY
A p p r o a c h e s
Both surgical and pharmacological approaches to the treatment of OTC patients 
have inherent problems. Liver transplantation and subsequent immunosuppressive 
therapy is associated with a high morbidity and mortality, while a pharmacological 
approach is less effective in both the acute and chronic situation. As these treatments 
are sub-optimal, a more novel gene therapeutic approach to treatment would 
certainly be beneficial. Furthermore the study of OTC will advance our 
understanding of gene therapy in general. The advantage of OTC as a model system 
for investigating gene therapeutic strategies is the availability of two naturally 
occurring mouse models.
1.6.1 OTC DEFICIENT M o u se  M o d e l s  o c c u r  in  n a t u r e .
There are two laboratory mouse models for OTC deficiency; namely the sparse fiir 
(Spf) and sparse fur and abnormal skin and hair (Spf^®^). As implied, these mice 
have a distinctive dermatological phenotypes associated with growth retardation, 
reduced survival and biochemical abnormalities seen in OTC deficiency (Fig 4). 
Both mouse models have low OTC activity in the liver and small intestine (Malo, 
Qureshi et al. 1986), (Dubois, Cavard et al. 1988).
1 .6 .1 .1  S p a r s e  F u r  M o u s e
In 1976 DeMars and colleagues (DeMars, Le Van et al. 1976) demonstrated that the 
Spf mouse had a deficiency in OTC. The hepatic enzyme activity in these mice was 
subsequently demonstrated to be 10-15% of normal levels at physiological pH 7.0
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Figure 4. The OTC deficient Spf mouse phenotype.
There are two naturally occurring mouse models of OTC deficiency, namely the 
sparse fur and sparse fur^^^ mice. On the mixed (FVB) x (C57B1/6J) genetic 
background used in this study, there was little difference noted between the 
phenotypes of affected adult males in the two different mouse colonies, although 
there was a higher and earlier mortality rate in the colony. The affected
males are first noted due to growth retardation and delayed hair development at a 
week of age. There is a large variation in both these characteristics within the 
affected male population. The majority of the affected males survive although 
they often have delayed weaning due to their growth retardation. As adults, the 
phenotype improves although the mice often remain small and they have a 
thinner, waxy appearance to their coat. In figure 4 A) Spf pups (SF) are shown at 
3 weeks of age with their larger litter mates (LM). Note the delayed hair growth, 
wrinkled skin and severe growth retardation. Figure 4 B) shows an adult Spf 
affected male (SF) at 6 weeks with litter mate (LM). Note the growth retardation 
and poor hair growth
ài
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Figure 4. The OTC deficient Sparse fur mouse phenotype
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and 200% at pH 10 (Qureshi, Letarte et al. 1979). Molecular analysis characterised 
the mutation as a cytidine to thymidine nucleotide transition causing a histidine to 
asparagine substitution at amino acid 117 (Veres, Gibbs et al. 1987). Recent 
biochemical analysis of these mice (Batshaw, Yudkoff et al. 1995) indicated a mean 
hepatic OTC activity of 13% of normal, plasma glutamate levels 160% of normal 
and citrulline levels 25% of control values. Urinary orotic acid was elevated to a 
mean of 13 fold above controls. The longevity of affected males was documented as 
<10% compared to unaffected males on C3H/Hej and C57B1/6J backgrounds. 
Behavioural and learning deficits were also noted. The level of hepatic OTC activity 
in the mice was found not to be related to age, contrary to results from Gushiken 
(Gushiken, Yoshimura et al. 1985) who demonstrated a mild improvement in OTC 
activity with increasing age.
L 6 ,1 ,2  S p a r s e F ur:^^^M o u s e
A second sex-linked mutation affecting hair development in mice was discovered by 
Hulbert and Doolittle in 1971. This was subsequently found to be allelic to the Spf 
mouse mutation (Doolittle, Hulbert et al. 1974). The molecular cause of this OTC 
deficiency was described in 1989 (Hodges and Rosenberg 1989) as a guanine to 
adenine transition in the last nucleotide of the fourth exon of the OTC gene resulting 
in ~5% of wildtype OTC activity. This mutation causes a dual molecular pathology. 
Firstly, as a splice site mutation, it causes the transcription of two mRNAs, one 
correct mRNA and a second elongated mRNA incorporating 48 bases of the 
subsequent fourth intron. In addition, to the production of two mRNAs, transcription 
is inefficient and the total OTC mRNA level is reduced to about 10% normal. 
Secondly the missense mutation results in a change of the amino acid at position 129
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from arginine to histidine. This alteration appears to have little effect on the activity 
of the OTC protein produced. The total effect is that the hepatic OTC activity in 
gp^sH -g Qp wildtype mice.
Interestingly, two Spanish patients have also been described with the same mutation 
as seen in Spf^®  ^mice (Garcia-Perez, Sanjurjo et al. 1995). These patients have a 
similar residual OTC activity as the murine model when measured in the small 
intestine by jejunal biopsy. Despite low OTC activity, the males that survived the 
initial episode developed normally on treatment and the age of the initial 
symptomatic episode varied from an acute and fatal neonatal form to a milder form 
presenting only age 3 and half years.
1.6 .2  P r e v io u s  A p p r o a c h e s  to  g e n e  m a n ip u l a t io n  o f  O T C
DEFICIENCY HAVE BEEN TRIED IN THESE MURINE MODELS
The two main models for investigating in vivo supplementive gene therapy in the 
Spf and Spf^®  ^mice have been I) the use of adeno-viral vectors, due to their natural 
hepatotrophic properties and II) transgenic mouse generation. Both of these systems 
have been used to target the OTC gene expression to its endogenous target tissues- 
the liver and small intestine. The transgenic model is a powerful system in which to 
study the in vivo efficacy of expression of different promoter/OTC cDNA constructs 
in correcting the enzymatic deficiency, whilst the use of adenoviruses provides a 
good model for delivery of the OTC construct to the liver, which may in the future 
be more directly applicable in the clinical sphere.
L 6 ,2 , l  A d e n o v ir a l  APPROACHS HAVE BEEN SUCCESSFULLY u s e d
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Recombinant adenoviruses have been evaluated as vectors for gene therapy in a 
variety of metabolic disorders (Ishibashi, Brown et al. 1993), (Engelhard!, Yang et 
al. 1993). The advantage of adenoviruses over the very commonly used gene 
transfection vector, the retrovirus, is that they can incorporate much larger gene 
expression constructs, they do not require cell proliferation for productive 
transfection and they can easily be produced and purified at high titres. 
Recombinant retroviruses (Grompe, Jones et al. 1992) and adenoviruses driven by 
the SRa viral promoter (Morsy 1993) have been to shown to correct in vitro cultures 
of both murine Spf and Spf^^^ and human OTC deficient hepatocytes.
Adenovirus is efficiently targeted to hepatocytes in vivo following intravenous 
infusion and high levels of transgene expression can be achieved in virtually 100% 
of hepatocytes, most of which are fully differentiated and non-dividing. However, a 
major drawback in adult mouse model gene transfer to the liver by means of 
adenoviral vectors is that the transgene expression is usually transient, often lasting 
less than 21 days, and it is associated with a severe hepatitis (Ishibashi, Brown et al. 
1993; Kozarsky, Grossman et al. 1993; Yang et al 1994, 1994b). This is probably 
due to immunological rejection of infected cells.
In 1990 Stratford-Perricaudet injected newborn Spf^^^ with adenovirus caiTying the 
rat OTC cDNA under the control of the viral major late promoter (Stratford- 
Perricaudet, Levrero et al. 1990). The mice were then sacrificed at different time 
points. Although the hepatic OTC activity achieved varied greatly, in those five out 
of the seventeen mice whose activity was -50% of normal, phenotypic correction 
was noted. In addition, in the two mice who survived to 15 months, the orotic 
aciduria was also partially corrected. The OTC activity obtained using adenoviral 
expression vectors seemed to vary with different promoters and species of OTC
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cDNA used. A recent report (Kiwaki, Kanegae et al. 1996) infusing the human OTC 
cDNA driven by a CAG promoter (a modified p-actin promoter with CMV-IE 
enhancer) showed good amelioration of the OTC deficiency in Spf^^^ mice, in 
contrast to a similar construct under the transcriptional control of a SRa promoter 
(the SV40 early promoter with the R segment and part of the U5 segment of the 
HTLV-1 LTR).
The use of newborn mice in both this study and the previous Stratford-Perricaudet 
study avoided the issue of adeno-viral induced hepatitis. Newborn mice are more 
tolerant to the immunological sequelae of adenovirus treatment as their immune 
systems are still relatively immature and therefore less likely to mount a full 
reaction to the viral epitopes. This would of course not be the case in the clinical 
setting of adenoviral exposure. In order to address this, Ye et al (Ye, Robinson et al.
1996) took a similar adenoviral approach but targeted mature mice between 6-8 
weeks old. Initial studies using a human OTC cDNA driven from a CMV enhancer 
and P-actin promoter showed little effective correction of the metabolic abnormality 
in Spf male mice, but further studies using stronger CMV promoter and enhancer 
linked to an isogenic murine OTC cDNA produced a marked improvement in the 
metabolic indices, with urine orotate and plasma glutamine normalising within 2-3 
weeks. This improvement persisted for 2-3 months. Obviously when targeting 
mature mice, the phenotypic changes associated with OTC deficiency have already 
been established and therefore they cannot be used as a marker of metabolic 
correction by the OTC construct. In addition, in adult Spf mice the levels of OTC 
produced after adenoviral infusion of the murine OTC cDNA was sufficient to 
protect against the metabolic and neurological insult produced by an intraperitoneal 
ammonium challenge (Ye, Robinson et al. 1997).
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L  6 .2.2 Tr a n g e n i c  a p p r o  a c h e s  h a  v e  a l s o  b e e n  s u c c e s s f u l
1.6.2.2.1 Transgenic technology
The term ‘transgenic’ is used to denote animals that have integrated foreign DNA 
into their genome as a consequence of experimental introduction of DNA. The first 
transgenic mice were produced in 1974 by micro injecting SV40 viral DNA into the 
blastocoele cavity of early embryos (Jaenisch and Mintz 1974). The majority of 
transgenic animals are now produced by micro-injecting recombinant DNA into the 
pronuclei of fertilised eggs as first performed by Gordon et al in 1980 (Gordon, 
Scangos et al. 1980). The DNA integrates into the chromosomal DNA and can be 
transmitted through the germ-line. When more than one transgene copy integrates, 
which is not uncommon with micro-injected DNA, the multiple copies are typically 
arranged in tandem head to tail arrays. This arrangement is thought to be the result 
of homologous recombination between the injected molecules (Brinster, Chen et 
al. 1981). Although the integration of recombinant DNA occurs at random, 
endogenous cis-acting sequences at the site of integration can have an effect on the 
expression pattern of the exogenous transgene. In addition, the integration of the 
transgene may disrupt an endogenous gene and cause embryonic lethality when the 
transgenic line is bred to homozygosity (Jaenisch, Harbers et al. 1983), (Wagner, 
Covarrubias et al. 1983). Thus, the phenotype is not necessarily defined by the 
endogenous characteristics of the transgene, but by the integration site. It is 
therefore important to characterise more than one line to prove a transgene- 
phenotype correlation.
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1.6.2.2.2 OTC transgenic work has relied on general viral promoter
Transgenic research in the OTC field has concentrated on the expression of the OTC
gene in liver by means of the endogenous OTC promoter or a strong general viral 
gene promoter. The first preliminary report of transgenic correction of murine OTC 
deficiency was in 1988 by Cavard et al (Cavard, Grimber et al. 1988) One founder 
mouse was produced which expressed the rat OTC cDNA from a SV40 early 
promoter. Phenotypic and partial metabolic correction of a Spf^^^ phenotype was 
observed in the male progeny from this founder mouse, despite Southern blot results 
which suggested the transgene had been rearranged at the genomic level during 
integration. Transgenic mRNA expression and OTC activity were found in the 
endogenously expressing tissues, namely the small intestine and liver. Despite no 
detectable mRNA, OTC activity was also detected in the spleen and lung. The 
transgene OTC activity in both liver and small intestine was 80% of wildtype 
control mice compared to a mRNA level of only 50%. This result, based on only 
one founder transgenic line was particularly interestingly as the mRNA tissue 
specificity of the transgene was very similar to the endogenous OTC gene 
expression despite being driven from a general viral promoter. This could suggest a 
cell specific mRNA stability phenomenon.
A similar approach was taken by Shimada et al in 1991 (Shimada, Noda et al. 1991). 
In this study a transgenic mouse expressing the rat OTC cDNA driven by 1,3 Kb of 
the 5 ’ flanking region of the rat OTC promoter was bred onto a Spf^^^ background. 
This expression construct had previously shown a low hepatic specificity due to the 
absence of the 110 bp hepatic-specific enhancer element identified 11 Kb upstream 
of the promoter sequence (Murakami, Takiguchi et al. 1989). The transgenic Spf^^^ 
males had corrected phenotypes, with an increase in hepatic OTC activity of 1.9 fold 
(equivalent to 12% of control mice) and in the small intestine of 6.3 fold (27% of
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control mice). In addition, there was a significant decrease in urinary orotic acid 
production and elevation of citrulline. These mice were also studied with regard to 
OTC activity during ovemight-starvation and nitrogen loading (Saheki, Mori et al.
1995). After a nitrogen load the transgenic Spf^^^ male mice excreted much less 
orotic acid than their non-transgenic Spf^^^ littermates, suggesting the transgene had 
an ameliorating but not normalising effect on orotic acid production under stressed 
conditions. The milder stress imposed by overnight starvation was not found to have 
any effect on urinary orotic acid levels in transgenic mice. Further evidence 
suggested the orotic acid levels in the transgenic mice correlated better with 
intestinal rather than hepatic OTC activity, a surprising finding as orotic aciduria is 
also associated with arginosuccinate synthetase and arginase deficiency, which are 
known to be confined to liver and not the small intestine. However, these results 
were only preliminary and may in fact indicate an indirect effect of intestinal OTC 
activity on hepatic production of orotic acid.
A similar transgenic approach was taken by Jones et al resulting in comparable 
findings. Utilising 750 bp of the mouse OTC 5’ flanking region linked to the human 
OTC cDNA, an increased small intestine compared to hepatic OTC activity was 
found, due again to lack of the hepatic specific gene regulatory sequences (Jones, 
Grompe et al. 1990). This increase in intestinal expression alone was sufficient to 
correct the phenotype of the Spf mice and reduce orotic aciduria.
1.7 E c t o p ic  g e n e  e x p r e s s io n
Although, the previously discussed body of work has concentrated on the 
supplementation of OTC gene expression in its endogenous tissue, many studies
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have shown that the expression of genes in target tissues which do not normally 
express them can also produce functional proteins. Two commonly studied organs 
used for this ectopic expression of genes are striated muscle and epidermis. These 
tissues have the advantage of being comprised of a large mass of homogenous cells 
with a good blood supply and relatively easily accessible.
1.7.1 T h e  E p id e r m is  is  a  v e r sa t il e  o r g a n  f o r  e x o g e n o u s  g e n e
EXPRESSION
The epidermis is the outer layer of the skin and, as a stratified squamous epithelium 
arising from cells of ectoderm origin, provides a strong, protective barrier against 
physical, chemical and bacterial insults. It is comprised mainly of kératinocytes 
forming two major compartments, the basal and supra-basal (Fig 5). In the human 
the epidermis is thick and the suprabasal layer can be further subdivided into distinct 
layers, the stratum spinosum, stratum granulosum, and the outer stratum comeum. 
Undifferentiated proliferating kératinocytes reside in the basal layer at the junction 
between the epidermis and dermis. Keratinocyte terminal differentiation, 
concomitant with a movement towards the surface of the epidermis, involves the 
sequential expression of many proteins including keratins, integrins and involucrin, 
until the outermost, stratum comeum, layer comprises flat, anuclear squames. The 
tactile strength of the epidermis is gained from the presence of a strong cytoskeleton 
formed from keratin fibres and tight junction formation between the kératinocytes 
and hemidesmosome contacts to basement membrane
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Figure 5 Histological section of human skin
This histological section is from a normal human skin biopsy stained with 
haematoxylin and eosin. The basal proliferative layer of the epidermis is at 
the junction of the epidermis and dermis, and is the site of Keratin 5 and 
14 co-expression. This layer contains the epidermal stem cells, an 
important target for gene therapy. As the kératinocytes mature, they move 
outward towards the surface of the epidermis and form the suprabasal 
layers in which the keratins Kl/KlO are co-expressed. In comparison to 
mouse skin (Fig 31), note the increased thickness of the human epidermis. 
This is due to the presence of multiple suprabasal layers of kératinocytes, 
which in the human has been classified morphologically into distinct 
layers, the stratum spinosum, stratum granulosum, and the outer stratum 
comeum.
This photograph is courtesy of Dr Fallowfield, Dept, of Dermatology, 
Glasgow.
Cornified squames
Dermis
KI / KI O
K5/KI4
>Epidermis
Rete ridges
Figure 5. Histological section of human skin.
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1 ,7 .1 ,1  Th e  e x p r e s s io n  a n d  f o r m a t io n  o f  k e r a t i n  f ib r e s  i s  c e l l
SPECIFIC
The keratins are a family of about 20 proteins which belong to the family of 
intermediate filament (IF) proteins. They can be subdivided into two distinct groups 
by sequence homology, pH, and chromosomal location. Type I keratins (K9-20) are 
acidic and generally small (40-56kD), whereas the type II (Kl-8) are larger (53- 
67kD) and more basic. Keratins form obligate heterodimers, from the co-expression 
of type 1 and type 2 proteins, which then assemble into a lOnm cytoskeletal or 
nuclear matrix protein (Albers and Fuchs 1992) with the typifying feature of a 
central, 310 amino acid a-helical coil, containing sequences that enable it to entwine 
with a second IF protein. These heterotetramers then interact to form a stable lOnm 
keratin fibre.
1.7.1.1.1 Keratin 5 gene expression is a marker of a stratified epithelium
The keratin co-expression pair, keratins 5 and 14 is ubiquitously expressed by
mitotically active basal epidermal cells in conjunction with specific integrins 
(Breitkreutz, Stark et al. 1997). They are considered to be a marker of stratified 
epithelia. As the keratinocyte differentiates, K5 and K14 gene expression is down 
regulated and supra-basal keratin genes are up-regulated in a cell type specific 
manner, with K1 and KIO being expressed in the suprabasal layers of the skin, K3 
and K12 in the cornea, and K4 and K13 in the suprabasal layers of the oesophagus 
(Makin, Bobrow et al. 1984). These keratins form an early marker of differentiated, 
committed keratinocyte. Hair follicles display a more elaborate pattern of keratin 
expression. K5 and K14 are expressed in the outer root sheath, K1 and KIO in the 
inner root sheath and the hair -specific keratins in the cortex and medulla.
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Mutations in the gene products of either keratins 5 or 14 have been found to be the 
cause of the genetic condition epidermolysis bullosa simplex (Korge and Krieg
1996) (Fig 6), This condition is due to loss of regular stratification in the epidermis 
resulting from an abnormal mitotic basal layer. Mild degrees of trauma to the skin 
cause shearing of the epidermis at the epidermal/dermal boundary and concomitant 
scarring and stricture formation, which can severely affect the child’s quality of life.
1.7.1.1.2 The keratin regulatory sequences have been widely used to drive 
exogenous gene expression
The epidermis has been used as the target organ for the expression of many 
exogenous genes, through the use of both viral and tissue specific promoters 
(Trainer and Alexander 1997). As the regulatory sequences of the keratin genes 
have been well documented (Byrne, Tainsky et al. 1994; LaPres et al. 1996), their 
use allows targeting of ectopic gene expression to the basal as well as the suprabasal 
compartments in the epidermis in a tissue-and differentiation-specific manner. 
Through the use of different keratin gene promoters, kératinocytes have been shown 
to be amenable to the expression of exogenous genes, such as the coagulation 
cascade protein Factor IX (Gerrald et al, 1996) and growth hormone (Wang, Zoppe 
et al. 1997) indicating that kératinocytes have the capability to modify these 
exogenous gene products correctly at a post-translational level. Furthermore, the 
epidermis has been shown to have a secretary capability, allowing recombinant gene 
products expressed in the epidermis to be secreted into the circulation, indicating its 
potential for the treatment of systemic disorders.
Tissue specific promoters have the additional advantage over viral promoters in 
sustaining longer gene expression (Wang, Zoppe et al. 1997). This may be due to
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Figure 6. Histological skin section from patient with epidermolysis bullosa 
simplex.
This histological skin section was obtained from a patient with epidermolysis 
bullosa simplex secondaiy to a mutation in the keratin 5 gene. The mutant gene 
product disrupts the keratinocyte cytoskeleton. Note the lack of organisation 
within the stratified layers caused by an abnormal basal proliferative stratum. The 
skin loses its structure and is sensitive to shear forces, which separate the 
epidermis from the dermis. This causes severe blistering on minimal trauma. As 
keratin 5 is also expressed in other stratified epithelia, these patients also suffer 
severe corneal and oesophageal problems
u : ' V  -
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^Epidermis
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Figure 6. Histological skin section from patient 
with epidermolysis bullosa simplex.
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sensitivity of viral promoter gene expression to down-regulation by méthylation 
(Palmer, Rosman et al. 1991). Although, the epidermis has been used to secrete 
exogenous protein, in theory it also has the potential of acting as a ‘metabolic sink’. 
The introduction of enzymes capable of acting on substrate either present in the skin 
or diffusible into the skin may be an alternative method of correcting metabolic 
insufficiencies.
1.7.2 S t r ia t e d  S k e l e t a l  m u s c l e  is  a n o t h e r  v e r sa t il e  o r g a n  
f o r  e x o g e n o u s  g e n e  e x p r e s s io n
Another tissue which has been widely investigated for its potential to express 
ectopic genes is skeletal muscle. Skeletal muscle forms a large percentage of body 
mass and has a variety of morphological forms, nevertheless all have the same basic 
structure. It is composed of extremely elongated, multinucleate contractile 
unicellular fibres, bound together by collagenous supporting tissue. The individual
muscle fibres are bound together into elongated bundles called fasiculi. During 
embryonic development mesenchymal cells differentiate into myoblasts which 
proliferate and fuse into myotubes. However, the mature muscle cells are highly 
differentiated and, if damaged, have a very limited capacity for repair and 
regeneration. The longevity of the muscle fibre and the ability to express any ectopic 
gene targeted to this tissue has attracted much interest from groups devising a means 
of targeting myocytes by direct DNA injection (Hauser, Amalfitano et al. 1997) with 
the ultimate goal of gene therapy regimes.
In addition, the use of muscle as a target tissue for ectopic expression of metabolic 
genes has increased over the last few years due to the availability of strong muscle
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specific promoters such as creatine kinase (Sattler, Levak-Frank et al. 1996; Hoefler, 
Noehammer et al. 1997; Kuang, Xu et al. 1998; Chang, Benecke et al. 1994; Chang, 
Jensen et al. 1996).
Muscle creatine kinase is critical for energy metabolism of the skeletal muscle as it 
plays a pivotal role in the phosphorylcreatine shuttle between mitochondria and the 
myofibrils (Bessman and Geiger 1981). It occurs as three known isoforms of 
creatine kinase- M (muscle), -B (brain) and -mt (mitochondrial). Creatine kinase 
exists as a dimer and the cytoplasmic, non-mitochondrial forms M and B can form 
homo- or hetero-dimers, BB in the brain, MM in skeletal muscle and MB 
heterodimers in the heart. The mitochondrial form does not dimerise with the two 
cytoplasmic forms. Proliferating myoblast cultures initially show low levels of the 
B-isoform of creatine kinase, which is the predominant form in the brain, whilst 
postmitotic myocyte cultures contain high levels of the M-form of creatine kinase 
which is characteristic of adult muscle (Eppenberger, Eppenberger et al. 1964)
3.3 kb sequence 5’ to the muscle creatine kinase gene has been shown to be 
sufficient to regulate transcription of a heterologous gene product in striated muscle. 
In addition, it has been shown that the mRNA levels and protein levels of the gene 
were under transcriptional rather than posttranscriptional regulation (Jaynes, 
Chamberlain et al. 1986). Later work delineated an enhancer, 1,000-1,250 
nucleotides upstream from the transcription start site, responsible for tissue- and 
differentiation- specific gene transcriptional high levels (Jaynes, Johnson et al. 
1988)
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1.7.3 T h e  L iv e r  is  f o c u s  o f  m a n y  g e n e  su f p l e m e n t iv e
THERAPIES AS IT IS THE SITE OF A PLETHORA OF METABOLIC 
PATHOLOGIES
The albumin and a-fetoprotein genes are evolutionarily related both in protein 
sequence, function and genome map location on chromosome 5 in the mouse. 
During embryonic development both genes are activated in concert in the visceral 
endoderm of the yolk sac, the foetal liver and the foetal gastrointestinal tract 
(Krumlauf, Hammer et al. 1985). However, whereas levels of hepatic albumin 
expression are maintained in the adult mouse, the a-fetoprotein expression level 
declines to undetectable levels shortly after birth. The albumin gene is hepatocyte 
specific in the adult mouse and is regulated primarily at the transcriptional level, 
with its mRNA being amongst the most abundant polymerase II transcripts in the 
liver and encoding for one of the most abundant serum proteins in the adult 
(Tilghman and Belayew 1982).
It had been shown that murine cis-acting albumin promoter sequences, containing 
300 bp of the 5' albumin promoter were sufficient for tissue-speciflcity, (Gorski, 
Cameiro et al. 1986). Further studies by Pinkert et al (Pinkert, Omitz et al. 1987) 
identified another element in the 5’ region of the albumin gene required for high 
level, hepatic gene expression. It was shown that by juxtaposing a 2 Kb enhancer 
region, localised 10.4 Kb upstream of the promoter site, hepatocyte-speciftc 
expression could be obtained comparable to endogenous levels of albumin mRNA.
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1.8 A im  OF THIS RESEARCH
The aims of this research were to investigate the use of tissue specific promoters in 
directing expression of recombinant proteins to different target tissues. OTC 
deficiency was used as the mouse model to test whether exogenous expression of 
recombinant OTC protein targeted to skeletal muscle cells would have a 
physiological effect in ameliorating the mouse OTC deficient phenotypes of Spf and 
Spf^sH addition, the recombinant OTC was also targeted to the liver by means of 
the murine albumin promoter/enhancer as a positive control.
The previous work was possible as the regulatory sequences used to target gene 
expression to skeletal muscle and liver had already been investigated for their tissue 
specificity. However, another potentially interesting target tissue for gene therapy is 
the skin. A novel keratin 5 minigene expression construct was therefore investigated 
as to its ability to drive tissue- and cell-specific gene expression in the epidermis. 
The keratin 5 minigene was linked to a reporter gene cassette and the expression 
pattern of this gene was assayed both in the adult mouse and during embryonic 
development. In the future it is hoped that this expression construct may be used to 
target therapeutic proteins specifically to the epidermal compartment of the skin 
proximal to the basement membrane. This could be used for treatment of keratin 
disorders, or for delivery of diffusible gene products to the blood system.
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2. MATERIAL AND METHODS
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2.1 M a t e r ia l s
2.1.1 C h e m ic a l s
All chemicals were obtained from Sigma and molecular biology reagents from 
Gibco, unless otherwise stated. All solutions were made with Millipore filtered 
water and autoclaved, where applicable.
Solutions, tips and eppendorfs for RNA analysis were soaked overnight in Depc 
water and autoclaved prior to use.
Radioactive Chemicals were obtained from Amersham and were disposed of 
according to local COSSH guidelines
2 .1 .2  T r a n s g e n ic s
All work undertaken was in strict keeping with the Scottish Home Office project 
licence no PPL 60/01479 and personal licence No. PIL 60/04565.
Mice were obtained from Harlan Olac and were maintained on standard rat and 
mouse diet (B and K Universal Ltd) in a strict 12 hrs light and dark regime.
All dissecting equipment, unless otherwise stated, was obtained from Raymond A. 
Lamb or R&J Wood.
2.1 .3  P l a s m id s
The plasmids containing the rat OTC cDNA (pSP019), the murine albumin enhancer 
and promoter (p2335A-l), the murine creatine kinase promoter and enhancer 
(pEtCAT) and the bovine keratin 5 and 6 regulatory elements were kindly donated 
by G. Shore (Nguyen, Argan et al. 1986), R. Palmiter (Pinkert, Ornitz et al. 1987), J. 
Buskin (Jaynes, Johnson et al. 1988) and M. Blessing (Blessing, Nanney et al. 1993) 
respectively.
51
2.1.4 C e l l  CULTURE
Cell culture was performed in a BIOMAT-2 microbiological laminar flow hood. 
Sterile technique was observed throughout. Sterile plastic 10 ml pipettes were 
obtained from Falcon^ (Becton Dickinson) and 25 ml pipettes were obtained from 
Co star and cell culture dishes and flasks from Coming.
The SN161 cell line was kindly donated by A. Balmain, Beatson Institute, Glasgow.
2.2 MICROBIOLOGICAL TECHNIQUES
Unless otherwise specified the methods were based on the laboratory manual by 
Sambrook (Maniatis, Sambrook et al. 1982).
2.2.1 P r e p a r a t io n  OF COMPETENT CELLS
The bacterial strain DH5a was used for all DNA transformations. 10 mis of pre­
warmed L-broth (10 g Bactotryptone, 5 g yeast extract, 5g NaCl per litre, pH7.4), 
inoculated with 10 pi of DH5a glycerol stock was incubated in the orbital shaker at 
37“C overnight. 1ml of this starter culture was expanded to 100 mis with fresh L- 
broth incubated for a further 2-3 hours until the culture reached an optieal density of 
0.3, mid-log phase.
50 mis of the culture were then centrifuged in a sterile Falcon tube (Becton Dickson) 
at 2 500 rpm for 5 mins at 4°C, the supernatant discarded and the bacterial pellet re­
suspended in 10 mis of sterile 10 mM MgSO#. The cells were cooled on ice for 
20mins, centrifuged as previously, supernatant discarded and the cells re-suspended 
in 5 mis of sterile ice-cold 50mM CaCb. They were left on ice for a minimum of 30
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mins. The transformation efficiency was approximately of 10  ^ colony forming 
units/pg DNA.
2.2.2 T r a n s f o r m a t io n  o f  c o m p e t e n t  c e l l s
50 ng of plasmid DNA was added to 100 pi of competent cells, left on ice for 30 
mins after which the cells were heat-shocked at 42°C for 1 min. The cells were 
cooled briefly on ice, 800 pi of L-broth was added and the cells incubated for 45-60 
mins at 37*^ C. After the cells were gently pelleted, all but lOOpl of the supernatant 
was discarded. The cells were re-suspended and spread onto L-agar plates (10 g 
Bactotryptone, 5 g yeast extract, 5g NaCl, 10.5 g Bacto-agar (Difco) per litre, pH 
7.4) containing the appropriate selection antibiotic(s), and allowed to dry before 
being inverted and incubated overnight at 37^C.
After the overnight incubation individual colonies were picked from the plate using 
a sterile loop and used for further culture inoculation.
2.2.3 G l y c e r o l  st o c k s  o f  b a c t e r ia l  c u l t u r e s
700 pi of an overnight bacterial culture was gently mixed with 300 pi of sterile
glycerol and the resultant suspension stored at -70°C. Scrapings from these frozen 
stocks were used to inoculate L-broth used for further culture.
2.2.4 S m a l l  s c a l e  DNA p r e p a r a t io n s  o f  p l a s m id  DNA f r o m
BACTERIAL CULTURE
5 mis of L-broth, containing the appropriate selection antibiotic, was inoculated with 
a single bacterial colony and incubated overnight at 37'^C in an orbital shaker. 1.5 
mis of this culture, in an Eppendorf microtube, was centrifuged at 1 400 rpm for 30 
s before the supernatant was discarded. The cell pellet was re-suspended in 100 pi of
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Solution 1 (50 mM glucose, lOmM EDTA, Tris.HCl pH 8) before 200pl of solution 
II (0.2 M NaOH, 1% SDS, prepared fresh) was added and the tube inverted gently 5 
times. After the further addition of 150 pi of Solution III (3M Potassium acetate 
pH4.8) the solution was gently mixed, left on ice for 1 min and then centrifuged at 
1400 rpm for 15 mins. The supernatant was then removed and added to 350 pi of 
ice-cold isopropanol, vortexed and then immediately centrifuged for 1 min at 1 400 
rpm. The residual pellet was washed in 70% ethanol before being allowed to dry and 
resuspended in 30 pi of TE buffer (10 mM Tris.HCl, 1 mM EDTA pH 7.4).
2.2.5 L a r g e  sc a l e  p r e p a r a t io n s  o f  p l a s m id  DNA f r o m
BACTERIAL CULTURE
Large scale preparations of plasmid from DNA was prepared using Qiagen columns 
(Qiagen™). This was suitable for dsDNA sequencing and eukaryotic cell 
transfection without the need for further purification. DH5a cells containing the 
plasmid of interest were streaked onto an L-agar plate containing the necessary 
selection antibiotic. After the plate had been incubated at 37°C overnight, a single 
colony was used to inoculate 5 mis of L-broth plus selection antibiotic. This seed 
culture was grown overnight at 37°C in a shaker at 200 rpm before 1 ml of it was 
used to inoculate a further 100 ml of L-broth, which was cultured under similar 
conditions.
The bacterial cells were pelleted by centrifugation at 5 000 rpm for 10 min at 4°C 
(Sorvall Rc 5B centrifuge), re-suspended in 10 mis of Solution I (50 mM Glucose, 
25mM Tris-HCl. 10 mM EDTA pH8, 100 pg/ml RNAse A), incubated for 5mins at 
room temp before 10 mis of solution II (0.4 M NaOH, 1% SDS) was added. The 
tube was inverted slowly until the solution cleared and then allowed to incubate for 
a further 5 mins at room temp, before 10 mis of solution III (3 M Potassium acetate -
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acetic acid pH 4.9) was added and the solution left on ice for 15 mins. The plasmid- 
containing supernatant from this solution, obtained by centrifugation at 8 000 rpm 
for 30 mins at 4°C, was added to a Qiagen Maxi column which had been previously 
equilibrated with lOmls of solution QBT (750 mM NaCl, 50 mM MOPS, 15% 
ethanol pH 7.0, 15% Triton-X). The column was then washed twice with 30 mis of 
QC (1 mM NaCl, 50 mM MOPS, 15% ethanol pH 7.0). 15 mis of QF (1.25 M NaCl, 
50 mM MOPS, 15% ethanol pH7.0) was used to elute the plasmid DNA fi-om the 
column which was then precipitated by the addition of 12 mis of ice-cold 
isopropanol and centrifuged at 10 000 rpm for 30 mins at 4°C. The DNA pellet was 
washed twice with 70% ethanol and re-suspended in 100 pi of TE buffer.
The DNA concentration was measured at OD260 and stored at -40°C
2.2.6 R e s t r ic t io n  e n d o n u c l e a s e  d ig e s t io n
In general, restriction enzymes were supplied by Gibco or Boehringer Mannheim 
companies. Digestions were performed at the salt concentrations and temperatures 
recommended and provided by the relevant enzyme buffer system. In circumstances 
where double digestions were necessary, if a mutually compatible buffer was not 
available to give 100% digestion, the enzyme digestion requiring the lower salt 
concentration was performed first. The salt concentration was subsequently adjusted 
using a low-to-medium or low-to-high salt conversion buffer prior to the addition of 
the second enzyme. Plasmid digests were incubated for 2-3 hours, whilst genomic 
were allowed to proceed overnight. Digestion products were either electrophoresed 
directly or reactions were terminated by a phenol/chloroform extraction step 
followed by ethanol precipitation of DNA.
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2.2.7 FILLING IN OF 5’ AND 3’ DNA OVERHANGS
Some restriction enzymes cleave double stranded DNA to leave 3’ or 5’ single 
stranded DNA overhangs which are re-converted to double strand DNA by means of 
either the Klenow fragment of DNA polymerase or T4 polymerase treatment.
2.2.7.1 K l e n o w  t r e a t m e n t
To fill in 3’ recessed termini, the large fragment of the DNA polymerase I (Klenow 
fragment) from E.coli was used. It comprises 5'-3' polymerase activity and 3'-5' 
exonuclease activity but not 5'-3' exonuclease activity.
Blunt ending of 200 ng DNA was performed in a final volume of 20 pi comprising 
10 mM dNTP, IX TMM buffer (lOX: 100 mM Tris-HCl pH7.9, lOOmM MgCb, 10 
mM 2-mercaptoethanol, 50 mM NaCl), and lU large fragment DNA polymerase 1 
(Klenow ) (Gibco). The reaction was incubated at 37°C for one hour and the DNA 
polymerase and free nucleotides were removed subsequently by phenol / chloroform 
extraction.
2.2.7.2 T4 DNA POLYMERASE
This enzyme was used when the restriction enzyme digestion resulted in 
overhanging 5' ends. It has a strong 3'-5' exonuclease activity and a weaker 5'-3' 
polymerase activity. Reactions were incubated in T4 DNA polymerase buffer for 15 
mins at 37°C and the products purified as described previously.
2.2.8 PHENOL/CHLOROFORM EXTRACTION
Phenol (Sigma) was added to the DNA sample (v/v) and vortexed before 
centrifuging at 14 OOOrpm for 5 mins. The supernatant was added to an equal
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volume o f choroform / isoamylalcohol (24:1 v/v), vortexed and again centrifuged
for 5 mins at 14 OOOrpm. The DNA-containing supernatant was stored at -40®C.
2.2.9 L ig a t io n  o f  l in e a r is e d  in se r t  in t o  p l a s m id  v e c t o r
Ligations were performed using a modification of the method of Weiss et al (Weiss, 
Thompson et al. 1968). Ligations were performed in a final volume 20 pi 
comprising 100 ng vector DNA, insert DNA at 1:3 molar excess to the vector DNA, 
Ix T4 ligase buffer (5X: 250 mM Tris-HCl pH 7.6, 50 mM MgCb, 5 mM ATP, 5 
mM DTT, 25% (w/v) polyethylene glycol) (Gibco) and 5 U of T4 ligase (Gibco). 
The ligation was carried out for 16 hrs at 16°C if the DNA termini were compatible 
and 24 hrs at 10“C if the ends were blunt. The ligation mixture was diluted 1:1 with 
TE buffer prior to competent cells transformation.
2.2.10 R e m o v a l  o f  5’ t e r m in a l  p h o sp h a t e  g r o u p s  f r o m  DNA
FRAGMENTS
Calf intestinal alkaline phosphatase (CIP) was used to remove the terminal 5' 
phosphate of restriction endonuclease digested DNA molecules. 200 ng of linearised 
DNA was de-phosphorylated in a final reaction volume of 20pl comprising Ix 
dephosphorylation buffer (lOx: 0.5 M Tris-HCl, 1 mM EDTA pH8.5) (Gibco), and 2 
u CIP (Gibco, BRL). Incubation was carried out at 37°C for 30mins, followed by 
CIP dénaturation at 65°C for 10 min. The DNA was then obtained by two 
phenol/chloroform extractions and ethanol precipitation.
2.2.11 E t h a n o l  PRECIPITATION OF DNA
DNA was precipitated by the addition of 5M sodium acetate pH5.5 to a final 
concentration of 3.5 M. 2 volumes of 100% ethanol were added, the sample left on
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dry ice for 30 mins and then the DNA pelleted by centrifugation at 14 000 rpm for 
15 min. The DNA pellet was then washed in 70% ethanol before being dissolved in 
TE buffer.
2 .2 .12  A g a r o s e  GEL ELECTROPHORESIS
DNA was generally electrophoretically fractionated in IX TAE (5Ox: 2 M Tris, 25 
ml/1 glacial acetic acid, 0.05 M EDTA pH 8.0) agarose gels. Ethidium bromide was 
included in the running buffer at 0.5 pg/ml. The agarose concentration of each gel 
was determined by the fragment sizes to be resolved. DNA samples were 
electrophoresed after the addition of loading buffer (25 mM EDTA, 30% Ficoll, 
0.25% bromophenol blue, 0.25% xylene cyanole) in a Pharmacia LKB gel apparatus 
system at 1-5 V/cm. Unless otherwise indicated a Ikb ladder (Gibco, BRL) was 
used as a size marker. The DNA fragments were then visualised by means of UV 
illumination.
2.2.13 DNA DILUTION FROM AGAROSE GEL
DNA was extracted from agarose gels using a commercial kit QIAquick gel 
extraction kit (Qiagen). In brief, the DNA was excised from the gel with a clean 
scalpel and placed in a sterile microcentrifiige tube. Three volumes of buffer QG 
were added and the tube was incubated at 50°C for 10 min until the gel had 
completely dissolved. One volume of isopropanol was then added prior to the 
sample being applied to a QIAquick column and centrifuged for Imin. The flow­
through was discarded and the column washed with 0.75 ml of buffer PE and 
centrifuged for Imin. The flow-through was discarded and the DNA was eluted 
from the column by the addition of 30 pi of TE buffer, incubation for 1 min at room
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temperature and centrifugation for 1 min at 13 000 rpm.
2.2.14 DNA EXTRACTION FROM TISSUE
This was performed according to Laird et al 1991 (Laird, Zijderveld et al. 1991). 0.5 
cm of murine tail, amputated under general anaesthetic (2% halothanem (Rhone 
Menieux) in 2L O2 (BOG), was added to 600 pi of lysis buffer (lOOmM Tris.HCl 
pH8,5, 5mM EDTA, 0.2% SDS, 200mM NaCl). 100 pg proteinase K/ml 
(Boehringer Mannheim) was added prior to overnight incubation at 55°C. Following 
complete lysis the samples were vortexed and spun at 14,000 rpm for 5 mins. The 
DNA was precipitated from the supernatant by the addition of one volume of 
isopropanol and then re-suspended in 100 pi of TE buffer. Further purification of 
the DNA, if necessary, could be obtained by phenol/choloroform extraction (see 
2.2.2.3.)
2.2.15 S o u t h e r n  B l o t
2 ,2 ,1 5 ,1  Ca p i l l a r y  BLOT TRANSFER TO NYLON
8 pg of genomic DNA was digested in a total volume of 30 pi overnight with the 
appropriate restriction enzyme under optimal conditions. The DNA samples were 
then electrophoretically fractionated. Having electrophoresed the DNA fragments to 
best resolve the size range of interest, gels were photographed alongside a ruler for 
future size correlation. The DNA was denatured by submerging the gel at room 
temperature for 45 min in dénaturation solution (0.5 M NaOH/1.5 M NaCl). The gel 
was then neutralised for 30 mins in 1.5 M Tris.HCl/1.5 M NaCl.
Hybond -N (Amersham) was cut to the size of the gel, wetted in 2xSSC and the gel 
was blotted onto the membrane overnight using 10 x SSC (1.5 M NaCl, 0.015 M Na 
citrate, pH7.0) transfer buffer on a conventional Southern blot apparatus. The DNA
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was then cross linked to the membrane by UV irradiation for 4 mins. The filter was 
then wrapped in Saran wrap and stored at 4°C until further use.
2 .2 .1 5 .2  L a b e l l i n g  o f  D N A  p r o b e  f o r  S o u t h e r n  a n d  N o r t h e r n
FILTERS
DNA random priming was performed using Prime-It™ RmT Random primer 
(Stratagene) as described in their instructions.
50 ng of DNA was added to the commercial Prime-It™ tube in a final volume of 42 
pi, prior to boiling at 95°C for 5 min. 6 pi of ^^^dCTP and 12U of magenta DNA 
polymerase was added and the tube incubated for 15 mins at 37°C. The reaction mix 
was separated through a nick column, which had been previously equilibrated with 2 
mis of TE buffer, in 400 pi of TE buffer and the labelled probe was eluted in 400 pi 
of TE and 2 pi counted in a scintillation counter
2 .2 .1 5 .3  P r o b in g  o f  S o u t h e r n  f il t e r s
This was performed using a commercial hybridisation solution DigEasy Hyb™ 
(Boehringer Mannheim).
The filter was prehybridised in a bottle for one hour in 25 ml of DigEasy Hyb™ at 
50°C in a hybridisation oven (Hybaid). The labelled probe was then added to 100 pi 
of DigEasy Hyb and boiled for 5 mins before being added to 6ml of fresh DigEasy 
Hyb at 50°C. The 25 mis of prehybridisation fluid were replaced with the 6ml of 
DigEasy hyb containg the probe and the filter left to hybridise overnight at 50°C. 
The filter was then washed twice in 2xSSC/0.1%SDS for 5 mins, 0.2 SSC/0.1%SDS 
for 10 mins until the background radioactive count was <5. The filter was wrapped
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in Saran wrap and exposed to X-ray film (X-Omat, Kodak 651454) overnight at - 
20^C, before the film was developed.
2.2.16 RNA EXTRACTION FROM TISSUES
This method is based on the commercial TRIzol™ method (Biogenesis Ltd). All 
equipment and solutions, excluding those containing Tris, were soaked overnight in 
DEPC containing dH20 and then baked/autoclaved for 2 hours at 120^C.
100 mg mouse tissue, stored in liquid N2, was ground in a mortar and pestle, added 
to 2 ml of TRIzol™ and incubated for 5 mins at room temperature. Subsequently 0,4 
ml of chloroform was added, the sample shaken and incubated for a further 3 mins 
at room temperature. The samples were then centrifuged at 12 000 rpm for 15 mins 
at 4°C. The upper aqueous layer was removed to a fresh tube and the RNA 
precipitated from this with 0.5 ml isopropanol by incubating at room temperature for 
10 mins and centrifuged at 12 000 rpm for 10 min at 4°C. The RNA pellet was then 
washed once with 70% ethanol and resuspended in 40 pi of DEPC treated water and 
stored at -70°C.
2.2.16.1 Q u a n t if ic a  TION o f  R N A
In order to ascertain the quality and quantity of RNA obtained, 1 pi of RNA was 
added to 1.3 pi dH20, 1.65pl formaldehyde, 5 pi formamide and 1 pi of lOX MOPS 
running buffer (lOX; 200 mM MOPS, 50 mM sodium acetate, 10 mM EDTA, pH 
7.0), boiled for 10 mins at 60°C, then quenched on ice. 2 pi of RNA loading buffer 
(50% glycerol, 1 mM EDTA, pH8.0, 0.25% bromophenol blue, 0.25% xylene 
cyanole FF) was added, prior to loading into a 1.5% agarose RNA gel (0.45 g 
agarose, 5 ml formaldehyde, 3 ml lOx MOPS, 22 ml H2O) and run for 45 mins in Ix
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MOPS buffer. In addition to the samples 4 fxg of Escherichia coli (E.coli) ribosomal 
RNA (Boehringer Mannheim) was loaded as a standard. After electrophoresis the 
gel was soaked in dHzO for 15min prior to staining in 0.5 jig/ml ethidium bromide 
for 5 mins. The gel was then de-stained in dHiO overnight and the integrity and 
concentration of RNA noted by UV illumination.
2.2.17 N o r t h e r n  BLOTTING
15 |Lig of RNA sample was added to Depc dHsO to a volume of 4.7 |Lil prior to the 
addition of 3.3 |il formaldehyde, 10 |l i 1 formamide and 2 p.1 of lOX MOPS running 
buffer. The sample was loaded onto a 1.5% RNA agarose gel (4.5 g agarose, 50ml 
formaldehyde, 30 ml lOx MOPS, 220 ml H2O) with a size marker and a RNA 
sample of known size (16 |Lig of E. coli RNA) and run at 40 V for 8 hrs. The size 
marker and RNA sample of known size were then separated from the rest of the gel, 
stained in 5 jitg/ml ethidium bromide for 5 mins at room temperature and then de­
stained overnight. This was then used as size comparison for RNA fragment sizes. 
Hybond -N (Amersham) was cut to the size of the remainder of the gel, wetted in 2x 
SSC and the gel was blotted onto the membrane overnight using lOx SSC (1.5 M 
NaCl, 0.015 M Na citrate, pH7.0) transfer buffer on a conventional Southern blot 
apparatus. The RNA was then cross linked to the membrane by UV irradiation for 4 
mins. The filter was then wrapped in Saran wrap and stored at 4°C until further use. 
DNA probes were labelled and hybridised to the Northern blot as has been 
previously described for Southern blot analysis.
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2.2.18 D o u b l e  STRAND SEQUENCING
The modified rat OTC cDNA was sequenced to determine successful site-directed 
mutagenesis as well as to confirm the absence of other unintentionally introduced 
mutations.
Double stranded sequencing was based on the dideoxy chain teremination method 
(Sanger, Nicklen et al. 1977) and performed using Sequenase™ version 2.0 DNA 
sequencing kit (USB).
A final concentration of 0.2 M NaOH and 0.2 mM EDTA (pH 8.0) was added to 4 
p,g of purified dsDNA, incubated for 20 mins at 37°C and then neutralised by the 
addition of 1/10th volume of 3 M sodium acetate (pH5.5). The samples were then 
ethanol precipitated and washed twice with 70% ethanol. The air-dried pellets were 
then re-suspended in 6 |Lil of dH20. 2 p,l of Sequenase^^ reaction buffer was then 
added in addition to 2 pmol of the appropriate sequencing primer. The sample was 
incubated for 2 mins at 65^3 and then allowed to cool to 35°C over 1-2 hours and 
then quenched on ice. 1 jLil of 100 mM DTT was added in addition to 2 |ul of 
labelling mix (diluted 1/5 with dH20), 1 p-Ci of ^^S-dATP and 2 pi of diluted 
Sequenase 2.0 enzyme (diluted 1/15 in TE buffer). The samples were incubated at 
room temperature for 5 mins. 3.5 pi of each sample was added to 2.5 pi of eaeh 
dNTP, in tubes pre-warmed to 37®C, vortexed momentarily and then ineubated for 5 
mins at 37°C. 4 pi of STOP solution was added to each reaction. The samples were 
stored at 4®C until required. Prior to loading the samples, they were incubated at 
75°C for 2 mins and quenched on ice immediately.
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2 .2 .1 8 .1  P r e p a r a t i o n  OF SEQUENCING g e l s
Sequencing gels containing 7.2% polyacrylamide were prepared by mixing 33 g 
urea (Sigma), 13 mis of 40% acrylamide (Sigma), 7.7 mis of lOxTBE and 33 mis 
dHzO. This was polymerised by the addition of 500 pi 10% ammonium persulphate 
and 75 pi TEMED (Sigma). Gels were set between glass plates 4 mm apart, run in 1 
X TBE buffer and pre-heated to 55®C, prior to loading the sample. The samples 
were run at 34 W for a minimum of 2 hours at 55°C, and then fixed in 10% 
methanol, 10% acetic acid for 10 mins prior to transfer onto Whatmann 3mm paper. 
The gel was dried for 30 mins in a Biorad gel drier at 80°C and then exposed to X- 
ray film overnight at room temperature. The gels were then read manually.
2 .2 .19  P o l y m e r a s e  CHAIN REACTION
All primers were ordered from Oswel
2 .2 .1 9 .1  MODIFICATION OF RAT O T C  C D N A  FOR EXPRESSION 
CONSTRUCT
PGR amplification of rat OTC cDNA incorporated the eonsensus Kozak sequenee 
(G C C A/G C C AUG G), and EcoRV restriction sites either end of the cDNA for 
sub-cloning. Additionally a ‘G’ missense mutation was incorporated at position +4 
in order to convert the original sequence fi*om a cytosine to a guanine, thus 
aehieving the consensus optimal Kozak sequenee. This missense mutation had the 
effect of changing the second codon irom ‘CTG’ to ‘GTG’ and thereby altering the 
second amino acid in the OTC polypeptide leader sequence from leucine to valine. 
This was achieved using the primer pair A1 (Oswel).
Rat OTC cDNA PCR primers-A1 
A1 Forward
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5 ’ G G c  G A X A T C  A A G A T G G î T G T c  T A A
EcoRV 
A1 Reverse
5’G G C G A T A T C T T C G T C C T C T T G C A
EcoRV
As fidelity of the PCR product was important, Pfu Polymerase (Stratagene) was 
used in the reaction due to its 3’-5’ exonuclease proofreading activity that enables 
nucleotide-misincorporation errors to be corrected. The reaction was performed on 
100 ng of plasmid template with 2.5 u Pfu in IX buffer (10 mM KCl, 10 mM (NH4)2 
SO4, 20 mM Tris-Cl (pH 8.75), 20 mM MgS04, 0.1% Triton X-100, 100 pg/ml 
BSA), 200 pM each dNTP, 0.5 pM primer. The reaction protocol was 94®C for 3 
mins followed by 30 cycles of 94 for 1 min, 60°C for 1 min and 72 °C for 4 min 
followed by 72 °C for lOmins annealing time. The 1.1 kb PCR product was then 
visualised on a 1% agarose gel, extracted, purified and stored at -20 °C prior to use.
2 ,2 ,1 9 ,2  S c r e e n in g  P C R  f o r  t r a n s g e n ic  b r e e d i n g  
The primers were designed using the GCG software programme. Primers were 
located in different exons so that only the transgene incorporating the OTC cDNA 
and not the endogenous OTC gene was amplified.
OTC Forward
5’ T C C T T C T T T T C T T A C C A C A C
OTC 'Reverse
5’ T G A C T A T A T T A G G A T C T G G C T C
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The PCR was performed on 0.5 pg of genomie DNA using 0.5 U of Taq DNA 
polymerase (Boehringer-Mannheim) in IX buffer (lOmM Tris-HCl, 1.5 mM MgCb, 
50 mM KCl, pH 8.3), 0.2 pM of each dNTP and 0.5pM of each primer in a final 
volume of 100 pi. The reaction protocol was 94°C for 3 mins followed by 30 eyeles 
of 94 ^C for 1 min, 55°C for 1 min and 72 °C for 1 min followed by 72 ®C for 10 
mins annealing time. The PCR product was then visualised on a 1.5% agarose gel.
2 .2 .1 9 .3  2 ,2 ,1 1  A m p l if ic a t io n  r e f r a c t o r y  m u t a t i o n  d e t e c t io n
SYSTEM
In order to confirm a direct correlation between the scoring of the sparse fur 
mouse phenotype and the sparse fur genomic mutation, an amplification 
refractory mutation system was designed for the sparse fur mutation based on 
the protocol by Ferrie et al (Ferrie, Schwarz et al. 1992).
Common primer
5’ CGC ATT ATC TAA GGA GAA GCATCA TOT TOT C 
Wild type Primer (sparse lur)
5’ ACA CGC TTC CTT TCT TCA CAC ACA AGA CAT GC 
Sparse fur primer
5’ ACA CCC TTC CTT TCT TCA CAC ACA AGA CAT GA 
Sparse fur^^^ primer
GTG AAT GAA AGT CTC ACA GAC ACC GCT CA 
Wild type primer (sparse fur^^^)
GTG AAT GAA AGT CTC ACA GAC ACC GCT CG
The penultimate nucleotide in the wildtype primer was altered to destabilise the 
PCR reaction on a Spf and Spf^^^ genomic template.
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The PCR was performed on 0.5 pg of genomic DNA using 0.5 U of Taq DNA 
polymerase (Boehringer-Mannheim) in IX buffer (10 mM Tris-HCl, 1.5 mM 
MgCl], 50 mM KCl, pH 8.3), 0.2 pM of each dNTP and 0.5 pM of each primer in a 
final volume of 100 pi. The reaction protocol was 94°C for 3 mins followed by 30 
cycles of 94 for 1 min, 60°C for 1 min and 72 °C for 1 min followed by 72 °C for 
10 mins annealing time. The 250 bp PCR product was then visualised on a 2% 
agarose gel.
2.2.20 F l u o r e s c e n t  in  s it u  h y b r id isa t io n  (FISH)
Metaphase fluorescent in situ hybridisation was performed to establish the presence 
of dual transgene integration sites in one founder mouse.
2 ,2 ,2 0 ,1  P r o d u c tio n  o f  m u r in e  c h r o m o s o m a l m e ta p h a s e s  
Spleens were obtained from 2 mice from the same founder line. Each spleen was 
collected into PBS. The splenic capsule was pierced with a sterile 22 gauge needle 
and the splenocytes were washed out with a RPMl culture medium. The resultant 
cells were centrifuged at 1 200 rpm for 6 mins at room temperature. The cell pellet 
was re-suspended in 5 ml of RPMl, 20% foetal calf serum, and divided into 2 round 
bottomed plastic universals. 50 mg of lipopolysaccharide (EPS, Sigma) was added 
prior to incubation at 37“C for 44-46hrs. 50 pi colemid (10 mg/ml) was added to the 
culture 30 min prior to harvesting. This was performed by centrifugation of the cells 
at 1 200 rpm for 6 mins. 10 mis of 0.075 M KCl was added to the re-suspended cells 
and incubated for 10 mins at room temperature The cells were eentrifuged as 
described previously and the cells re-suspended in fresh fixative (3:1 methanol; 
acetic acid by volume) and left overnight at 4°C. The cells were pelleted again prior
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to being re-suspended in 1 ml fresh fixative and metaphase spreads were obtained 
by dropping one drop of the suspension onto an alcohol-cleaned slide firom 10 cm 
height. The metaphase slides were air-dried at room temperature for 5 hrs and stored 
at -20°C prior to use.
2 ,2 ,2 0 ,2  L a b e l l i n g  a n d  p r o b in g  o f  c h r o m o s o m a l  m e t a p h a s e s  
The transgenic construct probe was labelled using the Gibco BRL kit, using Biotin 
11 dUTP. 1 pg of linearised construct DNA in a total of 45 pi including 5pi reaction 
mix (A4), 1 pi enzyme (solution C), 3.4 pi biotin-11-dUTP (Sigma) Tris-HCl 
pH7.5. was mixed, and incubated at 15°C for 90 mins and the reaction stopped. The 
DNA was ethanol- precipitated and resuspended in TE buffer to a concentration of 
100 ng/pl. The metaphase slides were dehydrated through a series of ethanols, 50%, 
70%, 90% and 100% for 2 mins in each and denatured for 2mins in 70% 
formamide/30% 2X SCC at 70“C. 2 ng of labelled DNA in 10 pi of Hybridisation 
mix (50% formamide, 10% dextran sulphate, 2xSSC, salmon sperm 10 pl/ml)) was 
layered over the slides, covered, and incubated overnight at 37°C. The slides were 
washed twice in 2xSSC at 42®C for 5 mins, twice in 50% formamide in SCC at 42°C 
for 5 mins, the SSC washes repeated and finally in 4xT. The blocking reagent (15% 
human AB serum in 4XSSC) was then added and the slides incubated for 10-20 
mins at 37°C. The signal was then detected by the addition of avidin-FITC, followed 
by two 4x SSC(T) washes, biotinylated anti-avidin, two 4x SSC(T) washes and 
finally avidin-FITC. The slides were then washed twice in blocking solution, twice 
in 4x SSC(T) and dehydrated 50, 70, 90 and finally 100% ethanol for 1 min each. 
The chromosomes were counter-stained with 0.4 ng/ml DAPl. The slides were
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mounted in Citifluor prior to visualisation using a Zeiss Axioskop epifluoresence 
microscope.
2.3 TRANSGENIC TECHNOLOGY
All animal procedures were carried out under project and personal licence numbers 
PPL 60/01479 and PIL 60/04565 respectively. The techniques described are based 
‘Manipulating the mouse embryo’ by Hogan et al (Hogan, Costantini et al. 1986) An 
overall view is found in Figure 7.
2.3.1 T o x ic it y  TESTING
All solutions were tested for embryo toxicity prior to use. 10-15 healthy fertilised 
eggs were cultured to blastocyst stage (~4 days). If less than 70-80% of eggs 
achieved blastocyst stage or if there was delay in reaching this stage, the solution 
was discarded and a different batch number of the solution ordered and tested
2.3.2 P r e p a r a t io n  o f  DNA f o r  m ic r o in je c t io n
The expression construct was excised from the vector plasmid by restriction enzyme 
digestion, and the digest run out on a 1% TAE agarose gel. The construct was 
purified from the gel as described previously (2,2.13). The DNA was eluted with 30 
pi of sterile injection buffer (10 mM Tris.HCl, 0.1 mM EDTA pH 7.4 in sterile H2O 
(Antigen Ltd) at 55®C by a 20 s centrifugation at 14 000 rpm, then dialysed in
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Figure 7. Summary of transgenic mouse production.
This figure is summary of pronuclear transgenic mouse production. Six week 
old females are supra-ovulated to increase and synchronise egg production. 
Twelve hours after fertilisation the embryos are collected and incubated. The 
DNA expression cassettes are injected into the male pronucleus and the embryos 
are further incubated until the two-cell stage. At this stage, the embryo is 
transferred into the oviduct of a pseudo-pregnant female and the pregnancy is 
allowed to continue until birth of the pups. The pups are screened at weaning for 
genomic integration of the transgene.
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dialysis tubing (Sartorius) at 4^C for 48 hrs against 800 ml of injection buffer (10 
mM Tris.HCl, 0.1 mM EDTA pH 7.4 in sterile H2O (Antigen Ltd) with 3 changes of 
dialysis fluid.
Serial dilutions of the DNA were run against a standard DNA titration set to 
estimate the DNA concentration. The DNA was stored in the concentrated form at - 
40°C and micro-injected at 5 ng/ml.
2.3 .3  P r o d u c t io n  o f  n e e d l e s  f o r  m ic r o in je c t io n
Transfer needles and holding needles: (Clark electromedical Instruments GClOO-15) 
were pulled by hand over a naked flame. Transfer needles were pulled to 1.5X 
diameter of the embryos, broken with a diamond pen and the ends smoothed and 
tapered on a microforge until 0.5-0.8X the diameter of the embryos (Research 
Instruments Ltd).
Injection Needles (Clark electromedical Instruments with inner filamant GCIOOTF- 
15) were pulled daily on a micropipette puller (Faiming Brown Mod. P-87) using a 
cycle which was optimised for the heating filament used.
2 .3 .4  M o u se  VASECTOMY
C57B1/6J male mice, aged 6 weeks were anaesthetised with general anaesthetic 
(2:2:8, Hypnorm (Janssen):Hypovel(Roche):dH20) i.p. An incision was made on the 
ventral surface in the midline at the level of the upper thigh. Both testes were 
identified and externalised, before the vas deferens were then identified and 
cauterised bilaterally. The testes were then replaced in the abdominal eavity and the 
ineision sutured using a dissolvable suture (Ethicon, Vicryl coated 3/0, W91140). 
The mouse was then placed in an incubator at 37°C until fully recovered. In order to 
test the effectiveness of the vasectomy, the male was set up with three fertile female
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mice and coital plugs noted. After three proven matings that did not result in a 
successful pregnancy, the vasectomised male was deemed as infertile.
2.3.5 S u p e r o v u l a t io n  o f  FI m ic e  f o r  e m b r y o  h a r v e s t
Female mice, the progeny of a CBA male X B16 female cross, were used at either 3
or over 6 weeks of age. 5iu of pregnant mare serum in sterile 0.9% saline (Folligon, 
Intervet) was injected intra-peritoneally at time 0 (1600hrs). 46hrs later 5iu of 
human chorionic gonadotrophin (Chorulon, Intervet) in sterile 0.9% saline (Baxter) 
was injected intra-peritoneally and each mouse set up with a C57B1/6J stud male.
2.3.6 H a r v e s t in g  o f  E m b r y o s
Super-ovulated females were sacrificed at 10 hrs post conception by cervical 
dislocation. The abdomen was swabbed with 70% alcohol and the Fallopian tubes 
removed into 0.8% saline pre-warmed to 37°C. Under a dissecting microscope 
(Wild Heering M 8) the embryos within the Fallopian tubes were visualised and 
dissected out into a Petri dish (Falcon 3004 easy grip tissue culture dish, Becton 
Dickson) containing 2 mis H6 medium (Appendix I), pre-warmed to 37°C. Embryos 
transferred into 50 pi H6 medium at 37“C, overlaid with liquid paraffin (colourless, 
light paraffin BDH 294365H). 6pi of hylauronidase (Sigma, 1.5 mg/1 in H6) was 
added to aid dispersion of the cumulus cells, before the embryos were washed 3 
times in 100 pi of fresh H6 medium over-laid with liquid paraffin. The embryos 
were then added to 100 pi T6 (Appendix I) overlaid with liquid paraffin, which had 
been equilibrated for 3 hrs at 37°C in 5% CO2 (Scotlab-VSL incubator), and further 
incubated at 37°C in 5% CO2 for approximately 2-3 hrs until the pronuclei were 
clearly formed.
72
2 .3 .7  M ic r o in je c t io n  o f  e m b r y o s
Microscope slides (Select micro slides Chance propper Ltd, RJ.Wood), washed in 
absolute alcohol, were dipped in silican (Repelcote^*^, BDS) for 10s, allowed to dry 
then washed in dH20. A bilaterally-open chamber was formed on these slides, 
comprising anterior and posterior walls formed from glass rods, held in place with 
vaseline. In the centre of the chamber 300 pi of H6, prewarmed to 30°C, was placed 
and overlaid with a coverslip. Sterile paraffin oil sealed both the open lateral sides 
of the chamber. 20 embryos were transferred into the centre of the H6 medium and 
the slide transferred to the platform of the microscope (Olympus) for microinjection. 
The air-filled holding pipettes by means of mouth control picked up and held an 
embryo, allowing adjustment so that the pronuclei were in the same plane of vision 
as the central circumference of the embryo. The injection needle was then inserted 
into the embryo until it penetrated a pronucleus, and sufficient DNA was injected to 
temporarily inflate the pronucleus. The needle was then quickly withdrawn after 
injection and the embryos were transferred into T6 medium and cultured overnight 
at 37°C in 5% CO2. Those embryos which had cleaved into 2-cell stage were then 
transferred back into a recipient female.
2 .3 .8  T r a n s f e r  OF EGGS
CDl females, due to their natural capacity to rear large litters, were mated with 
vasectomised males. Those females with ‘post coital plugs’ were then anaesthetised 
with 0.6 mis of general anaesthetic (2:2:8VA^ Hypnorm( Jans sen) : 
Hypnovel(Roche) : dH20) i.p.. The flank was swabbed with 70% alcohol and an 
incision made on the left flank. The peritoneum was visualised, incised and 
immobilised with a suture (Ethicon, Vicryl coated 3/0, W9114). The fat pad 
overlying the ovary was identified, externalised and immobilised with a blallock clip
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(Downs surgical). The mouse was then moved under the dissecting microscope 
(Olympus S2H10) and the membrane surrounding the ovary and Fallopian tube 
opened. The presence of multiple corpi lutei in the ovary confirmed ovulation and 
the mouse as a good recipient for egg transfer. The open end of the Fallopian tube 
was identified. 25 eggs were taken up into the transfer needle, followed by an air 
bubble and transferred into the Fallopian tube by mouth pipetting. Successful 
transfer could be monitored by the visualisation of the air bubble in the Fallopian 
tube. The ovary was then returned to the peritoneal cavity and the peritoneum 
sutured. The overlying skin was also sutured and the mouse placed in 37°C 
incubator overnight until recovery was complete.
2 .3 .9  B r e e d in g  o f  T r a n s g e n ic  a n d  O T C  d e f ic ie n t  m o u s e  l in e s  
Matings were set up between 6 week old or older mice and the litters were weaned
at 3 weeks, screened for presence of the transgene from tail DNA. At weaning all
mice were given a unique identification number, which was noted in both personal
and project licence records. At weaning the mice were designated phenotypically
affected or unaffected and this was also entered into the records. All matings and
subsequent dealing with the mice were given a procedure number, and multiple
procedures, other than transgene sereening and mating, were not carried out on a
single mouse.
2.4 BIOCHEMISTRY
2 . 4.1 T o t a l  PROTEIN ASSAY
This was undertaken by a modified version of Lowry et al 1951 using Bio-Rad DC 
protein assay (Bio-Rad).
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0.4 mg of murine tissue was homogenised in 1ml mitochondrial lysis buffer (0.5% 
Triton X-100, 10 mM Hepes, 2 mM DTT), sonicated for 2 min at maximal intensity 
and then incubated on ice for 30 mins. An aliquot was then further diluted 1:50 in 
dHiO and used for protein and OTC assay. The initial concentrate protein solution 
was stored at -70^C.
100 |a1 of protein sample/ bovine serum albumin standard was added to 500 p.1 of 
solution A (2% NaiCOa in 0.1 M NaOH, 1% CUSO4 in water, 2% Na K tartate in 
water, combined just prior to use in a ratio of 98:1:1 respectively) after 20 jil/ml 
Solution C had been added, and vortexed. 4mls of solution B was added, vortexed 
and left to incubate for 15 min at room temperature in the dark. The samples were 
read at OD750 and compared to a standard graph of serial dilutions from 0-1500 
|Lig/ml of bovine serum albumin (Sigma) dissolved in mitoehondrial lysis buffer, to 
estimate protein concentration
2.4.2 OTC ASSAY
This assay was performed according to Lee et al 1989 (Lee and Nussbaum 1989). In 
brief, 2-10 jig total cellular protein, in mitochondrial lysis buffer as described 
previously were added, to 700 jil of OTC reaetion mix (5 mM ornithine, 15 mM 
carbamyl phosphate and 270 mM triethanolamine, pH7.7), which was incubated at 
37°C for 30 mins. The reaction was stopped with the addition of 250 |il of 3:1 
absolute phosphoric acid/sulfuric acid (by volume).
Citrulline production was measured by adding 50 |il of 3% 2,3-butanedione 
monoxime, incubating at 95-100 °C in the dark for 15 mins, and measuring OD 
absorbance at 490 mM. The coneentration of citrulline produced/hr/mg protein 
could then be calculated by means of comparison with a graph of standard citrulline
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concentrations undertaken at the same time. However, as this assay was used to 
comparing relative levels of OTC activity between different mouse populations, an 
arbitrary unit of OTC activity was used OD490 / mg protein. All samples were 
assayed in triplicate and the average was then calculated. Samples from all the 
different mouse populations were used every time the assay was performed.
2 .4 .3  P la s m a  AMMONIA LEVEL ANALYSIS
The mice were anaesthetised in 30% halothane and bled by cardiac puncture (This 
technique was performed by Frances Coussins). The mice were then sacrifieed by 
cervical dislocation prior to tissue removal. The blood was added to a lithium 
heparin-containing tube and taken to the Department of Paediatric Biochemistry, 
within 30 mins, where the ammonia level was measured in the diagnostic laboratory, 
which is the regional centre for metabolic disorders The commercial assay used was 
Vitros AMON slides (Vitros Chemistry products). The Vitros AMON slide is a dry, 
multilayered, analytical element coated onto a polyester support. The ammonium 
ions are converted to gaseous ammonia, which passes through a semi-permeable 
membrane to reach the indicator layer. This is then detected in a colorimetric assay 
at a wave length of 600nm.
2 .4 .4  G a l a c t o s i d a s e  s t a in in g  o f  e m b r y o s  a n d  a d u l t  t i s s u e s
Galactosidase staining of tissues and embryos was performed according to the 
protocol published by Cheng et al (Cheng, Wallace et al. 1993).
Freshly dissected whole embryos from d9.5post-coitum up to dl3pe., or tissues cut 
into 3mm sections, were added immediately to and incubated in fixative (2% 
paraformaldehyde, 0.2% glutaraldehyde, 2 mM MgCk in PBS) for 90 mins at 4^C 
on a rolator (Jencons), washed three times for 3 mins in PBS, prior to being
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incubated in the dark overnight in LacZ stain (5 mM Fe3(CN)6, 5 mM Fe4(CN)6, 2 
mM MgCl], 1 mg/ml X-Gal) at room temperature on the rolator. The tissues were 
the de-stained for 24 hrs in PBS at room temperature before being re-fixed in 10% 
formalin for a minimum of 4 hrs. Whole mount embryos were photographed at this 
stage prior to being sectioned.
2.4.5 W h o le m o u n t  G a l a c t o s i d a s e  s t a in in g  o f  t h e  i n t e s t i n e .
The intestine was removed post morteum and flushed through once with cold PBS. 
Cotton thread was used to close one end of the intestine and cold 4% formalin was 
then infused into the open end of the intestine and the tissue was left to fix for 90 
min. The base of a Petri dish was coated with RalwaxII (BDH) to a depth of 1cm. 
The wax had been softened by the addition of 10% heavy grade liquid paraffin 
(BDH) prior to pouring the dish. Post fixation the intestine was opened up 
longitudinally and pinned onto the wax covered Petri dish. The 4% formalin was 
replaced with a demucifying agent (20% ethanol, 10% glyeerol (Fisons), 0.01 M 
Tris pH8.2, 0.65%w/v NaCl, 3 mg/ml dithiothreitol (Sigma) added immediately 
prior to use) and left to incubate for 30 mins at room temperature. This removes the 
bacteria-containing mucin and thus, any false positive bacterially encoded 
galactosidase activity. The intestine was then stained with lacZ stain as described 
previously in 1.2.4.4, de-stained in PBS and photographed.
2.4.6 TESPA COATING OF MICROSCOPE SLIDES
Microscope slides (Select micro slides Chance Propper Ltd, R.J.Wood) were dipped 
sequentially in 10% HCl in ethanol, distilled H2O, and 95% ethanol, then dried at 
150°C for 30 mins and cooled. The slides were then dipped for 10 s in 2% 3- 
aminopropyltriethoxy-silane (TESPA) (Sigma) in acetone, washed twice in acetone,
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twice in dHaO and dried at 42°C overnight. The slides were stored in a dust proof 
container at 4“C until use.
2 .4 .7  S e c t i o n i n g  o f  t i s s u e  s e c t i o n s
Embryos and tissues, which were previously fixed in 10% formalin for p- 
galactosidase staining, were placed in histosettes (Simport) and processed further by 
a Shandon Citadel Automatic Processor, courtesy of the Department of Pathology. 
This processing comprised 3 washes in methylated spirit for 90 min, and 150 min x 
2 respeetively, followed by a 2 hr dehydration in absolute alcohol, three 30min 
washes in xylene and lastly 2 paraffin washes for 2 hrs and 4 hrs respectively, before 
the tissue was mounted by hand in paraffin wax and stored at 4 °C prior to 
sectioning.
7 jiiM tissue sections were cut, floated on water at 45°C and mounted on TESPA 
coated slides. The slides were then left to dry at 52°C for 5-6 hrs and stored at 4^C.
2 .4 .8  C o u n t e r - S t a in in g  o f  T is s u e  S e c t i o n s  w i t h  E o s in
Tissue section slides had the paraffin removed by two 10 min washes in Histoclear
(National Diagnostics) prior to being dehydrated through a series of alcohols, 2 mins 
in 100% x2, 90%, 70%, 50%, 30% alcohol in dH20 respectively. The sections were 
then incubated in freshly filtered eosin (BDH) for 2 mins, with intermittent checks 
for optimal staining, before the sections were re-hydrated through the alcohols and 
washed for 10 min X2 in Histoclear. The sections were then mounted in DeePeeX 
(Sigma) and left to dry overnight before being visualised and photographed.
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2.5 IN VITRO CELL CULTURE
2.5.1 C u l t u r e  OF SN161 CELL LINE
Transient transfection of the SN161 cell line was undertaken with this keratin 
5/LacZ expression construct prior to the formation of transgenic founder murine 
lines.
The SN161 cell line, a squamous carcinoma cell line known to express the keratin 5 
gene, was kindly obtained from Prof. Balmain, Beatson CRC Institute, Glasgow.
The SN161 cell line was cultured in 25 cm^ flasks (Nunc) at 37°C, 5% CO2 in a 
Sanyo incubator in 14 mis of Dulbecco’s modified Eagle medium (DMEM)(Gibco) 
with 10% bovine fetal serum (Gibco), 2 mM glutamine, 1% penicillin and 
streptomycin (Gibco) The culture was never allowed to become fully confluent. 
Fresh medium was added every third day after the culture was washed twice in PBS 
(Gibco). The culture was passaged at 80% confluency level by the addition of 2.5 
mis of IX Trypsin-EDTA (Gibco) and incubation until the cells lose their 
adherence. 9 mis of culture medium was added and pipetted to form a single cell 
suspension. 1 ml of cell suspension was added to 13 mis of fresh culture medium in 
a 50cm^ flask (Nunclon™) and incubated at 37°C, 5% C02 as normal.
2.5.2 T r a n s f e c t i o n  OF SN161 CELLS
2,5,2.1 R e m o v a l  o f  l ip o p o l y s a c c h a r id e s(LPS) f r o m  DNA
PREPARATION,
As contamination of plasmid DNA with bacterial lipopolysaccharides(LPS) can be
toxic to mammalian cells during transfection, LPS was removed by means of Triton-
X I14 to improve transfection efficiency. 0.01 volumes of Triton X-114 was added
to DNA (1 mg/ml), mixed gently and incubated on ice for 5 mins, followed by a
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further incubation at 37‘^ C for 5 min. Centifugation at 14 000 rpm for 5 mins at room 
temperature was performed and the upper phase removed and extracted twice more 
with Triton X-114. The DNA was then ethanol-precipitated and re-suspended in TE 
buffer.
2.5.2.2 Tr a n s ie n t  t r a n s f e c t io n  o f S N l61 c e ll  l in e
This technique is based on O’Mahoney and Adams 1994. 20 p,g of LPS-free plasmid 
DNA, was added to 0.5 ml of 0.25 M CaCb and gently mixed. The DNA solution 
was added dropwise to 0.2 ml of 2 x Hepes buffered saline pH7.04, gently shaken to 
form a fine precipitate and then added immediately, in fresh culture medium, to a 
25-50% confluent cell culture. The cells were left to incubate for 15-20 hours at 
37°C, 5% CO2, then washed in PBS, prior to having fresh culture medium added and 
incubated for a further 24 hrs before any assay being performed.
2.5.2.3 X-GAL STAINING OFSN161 CELLS
Cell cultures at 50-80% confluency, were fixed in cell fixative (2% formaldehyde, 
0.1% glutaraldehyde in PBS) for 10 mins at room temperature, washed three times 
with PBS and then incubated with 14 ml of X-gal stain (5mM Fe3(CN)6, 5mM 
Fe4(CN)6, 2mM MgCh, 1 mg/ml X-Gal) for 2 hours at room temperature The cell 
eultures were then de-stained by washing three times in PBS prior to examination 
for X-Gal staining.
2.5.3 2 .5 . CRYOPRESERVATION OF CELL CULTURES
Cells cultured until 80% confluency were washed twiee in PBS and incubation at 
37°C in 2.5 mis of trypsin for 3 minutes. The cell suspension was then centrifuged at
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1 200 rpm for 5 mins and the supernatant discarded. The cell pellet was then gently 
re-suspended in 1ml cryoprotectant medium (10% dimethyl sulphoxide (DMSO) in 
foetal calf serum), placed in a 2 ml Biofreeze vial (Costar) and placed at -70°C 
overnight before transferring to liquid nitrogen for long term storage.
2.5.4 S t a t i s t i c a l  A n a l y s i s  o f  OTC a c t i v i t y  a n d  p la s m a  
A m m o n ia  r e s u l t s
All statistical analysis of plasma ammonia levels and OTC activity was performed 
using the computer statistics programme package SPSS for windows 8.0 (SPSS Inc. 
444n Michigan Ave, Chicago, Illinois 60611). As it was not possible to confirm the 
parametric basis of the spread of OTC activity or plasma ammonia levels within a 
population, non-parametric index which analyses the results obtained within two 
independent groups was used, namely the Mann Whitney test.
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3. RESULTS
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3.1 DESIGN OF TRANSGENIC EXPRESSION CONSTRUCT
3.1.1 GENERATION OF MODIFIED RAT O TC CDNA (OTC’'^ ®®) WAS 
ACHIEVED BY SITE-DIRECTED MUTAGENESIS.
The rat OTC cDNA (Accession No. Ml 1266) comprises the entire 1.1 kb open 
reading frame from nucleotides -40 from the AUG to 1170, including 40 bp and 360 
bp of the 5' and 3' untranslated region respectively. This OTC cDNA had been 
cloned previously into the pSP64 plasmid and designated pSP019 (Nguyen, Argan 
et al. 1986).
In order to maximise protein production and OTC activity, the rat OTC cDNA was 
modified to potentially enhance translation. Site-directed mutagenesis was achieved 
by incorporating a single nucleotide mismatch into the 5' end of the OTC cDNA 
forward PCR primer sequence. The nucleotide at position +4 of the Kozak 
translation initiation motif of the rat OTC cDNA was converted from a cytosine to a 
guanine, thus achieving the consensus optimal Kozak sequence. This missense 
mutation had the effect of changing the second codon from ‘CTG’ to ‘GTG’ and 
thereby altering the second amino acid in the OTC polypeptide leader sequence 
from leucine to valine. This is a very conservative amino acid change involving the 
loss of one methyl group. There was no overall change in amino acid polar charge.
In addition to this modification, the PCR primer sequences used to amplify the OTC 
cDNA were designed to truncate the 5’ and 3’ non-coding sequences The resultant 
PCR encoded the entire open reading frame of the rat OTC cDNA and only 3 bp of 
the 5' and 6 bp of the 3’ untranslated sequence. This modified rat OTC cDNA was 
termed OTC^^^ and used to form the transgenic expression constructs after cloning 
into pIC20H plasmids by means of EcoRV restriction enzyme recognition sites, 
placed into the 5' ends of both the forward and reverse A1 primer sequences.
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The incorporation of the nucleotide substitution at position +4, as well as the 
absence of any other PCR-introduced mutations was confirmed by manual double­
stranded direct sequencing of the rat OTC cDNA in the pIC20H plasmid clones (Fig 
8). A total of 10 clones were sequenced before a high fidelity clone (pP20MOD) 
was identified. This OTC cDNA clone was then used in the formation of the tissue- 
specific expression vectors.
3.1.2 GENERATION OF GENE EXPRESSION CONSTRUCTS
The tissue-specificity of the OTC gene expression constructs resides in
promoter/enhancer regulatory sequences used to drive expression of the cDNA. In 
addition to being tissue-specific, the promoters required to be associated with a high 
level of gene transcription. As the rationale for the expression of OTC activity in 
exogenous tissues required the diffusion of the substrates to the target tissues, an 
exeellent blood supply to the target tissue was a prerequisite. In addition, tissues 
were chosen that had previously been shown to integrate, transcribe and post- 
translationally modify other exogenous genes. The two target tissues identified in 
which to express recombinant OTC protein were skeletal muscle and, as a positive 
control, the liver. The rationale for using the murine creatine kinase 
promoter/enhancer was to target the OTC gene expression to skeletal muscle. This 
tissue is large and homogenous with a good blood supply and low cellular turnover 
rate. This has the advantage that ectopic gene expression should be highly persistent 
even if terminally differentiated cells are targeted. The good blood supply should 
enable the appropriate enzyme substrates to diffuse into the targeted cells.
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Figure 8. Sequence modification of ra t OTC cDNA
The OTC^^° cDNA was produced by incorporating a mutation in the Kozak 
sequence into the PCR primers used to amplify the sequence. Incorporation of 
the mutation was confirmed by manual double strand sequencing of Kozak 
translation consensus sequence of reverse strand of OTC cDNA. Figure 8A 
shows the endogenous sequence of the reverse strand of rat OTC cDNA at the 
translation initiation codon. Figure 8B shows the rat OTC cDNA with 
incorporation of ‘C’ at +4 and ‘G’ at ^  (OTC^°°). Site-directed mutagenesis 
was used to convert the normal OTC Kozak sequence to a form thought to be 
associated with a higher translational efficiency. This sequence change caused 
a leucine to valine missense change in the second amino acid of the OTC 
leader sequence in the expression constructs. The ‘G’ at -4 was formed from 
the EcoRV site incorporated into the 5’ end of the primer for subcloning 
purposes.
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Figure 8. Sequence modification of rat OTC cDNA.
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3 ,1 ,2 .1  Th e  L iv e r - t a r g e t e d  e x p r e s s io n  c o n s t r u c t
The plasmid (p2335A-l), containing 2.3 Kb of the murine albumin promoter and 
enhancer sequences was obtained from R.D. Palmiter (Pinkert, Omitz et al. 1987). 
This plasmid included 22 bp of the albumin gene 5' untranslated region, which had 
previously been used to express the human growth hormone as a reporter gene, 
producing high gene and protein expression levels, and consequent overgrowth of 
the transgenic mice.
The strategy used to clone the albumin driven OTC cDNA expression vector is 
shown in figure 9. In brief, the albumin promoter/enhancer sequence was removed 
from its plasmid vector by double restriction enzyme digestion with Sad and 
EcoRV. This fragment was ligated into a pIC 20H/SV40 plasmid which contains the 
SV40 polyadenylation/intron sequence cloned into pIC20H and kindly provided by 
another member of the group, Dr D. Fowlis. The OTC^°^ cDNA was then ligated 
between the albumin enhancer/promoter sequences and the SV40 polyadenylation 
sequence at a unique EcoRV restriction site, and the correct orientation and mapping 
of the final expression cassette (pAOP) was confirmed by restriction enzyme 
digestion (Fig 10).
The inclusion of a 3 ’ S V40 polyadenylation consensus sequence and small intron in 
the expression constructs was due to previous work suggesting a splice event and 
polyadenylation of primary mRNA transcripts to be important in stabilisation of the 
mRNA, transport of the mRNA to the cytoplasm and transcription of micro-injected 
genes (Brinster, Allen et al. 1988). In addition, polyadenylation may facilitate 
translation (Jackson and Standart 1990; Bachvarova 1992).
The complete transgene was released from the parental vector by a Nrul / Notl 
double digestion prior to purification for micro-injection (Fig 10).
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Figure 9. Formation of albumin-OTC*^*^*  ^expression cassette
AMP 
3.55 kb
Sac I 
icoRV
SV40PA
Nru I
liac I,
ind
AMP
5.3 kb
Alb
EcoRV
PIC-20H/SV40 Digest Sacl/EcoRV
Ligate
P2335A-1
EcoRV EcoRV
AMP
5.85 kb
Nru I Alb
PA
Digest EcoRV
LigateEcoRV
pAP
lot I
AMP
6.95 kbNrul
ALBPA
OTC
pAOP
Figure 9. Formation of albumin-OTC'^®*^ expression cassette.
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Figure 10 Formation of albumin-OTC'^°^ expression cassette
A. Restriction enzyme map of the albumin-OTC^^° expression construct in 
plasmid pIC20H.
B. B) Diagnostic restriction enzyme digestions of the resultant albumin-OTC'^^^ 
expression construct in pIC20H H:HindIII, B:BamH I, X:Xho I, EV:EcoR V, 
II,Hc:Hinc II, N:NruI, No: Notl, Bglll; BgIL The Xho I and Hind III digests 
indicate the correction orientation of the OTC cDNA.
No, H
B X Bg H X X Bg
1 Kb
Albumin promoter /enhancer
OTC cDNA
SV40 Polyadenylation/intron
A. I
S N+
EV N H B glIX  NO
B.
Figure 10. Restriction enzyme digestion map of 
albumin-OTC^°^expression cassette.
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3 .1 .3  S k e l e t a l  M u s c l e  d ir e c t e d  e x p r e s s io n
The pEtCAT plasmid containing 3.3 Kb of the murine creatine kinase promoter
(mCK) and enhancer was obtained from J. Buskin (Jaynes, Johnson et al. 1988). The 
strategy for the formation of the creatine kinase driven OTC cDNA expression 
construct is summarised in figure 11. In brief, the mCK promoter and enhancer were 
excised from the pEtCAT vector with a Hindlll/BSYTEII digestion. The 5’ ssDNA 
overhangs were filled with Klenow enzyme and ligated into pIC20H/SV40. The 
OTCMod cDNA was then subcloned into the unique EcoRV site and the correct 
orientation selected (pMOP). The expression construct could then be excised at 
unique EcoRI and Nrul prior to use. Correct orientation and mapping of the 
construct was confirmed by restriction enzyme analysis (Fig 12).
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Figure 11. Formation of creatine kinase-OTC'^^° expression cassette.
PIC-20H/SV40
pEtCAT
Hindlll, EcoRI
amHI
coRV 0.95
ligest BamHI 
Blunt end
LIGATE
stEII
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Nrul 5.1
SV40PA
Digest Hdlll / BstEII
Blunt end
EcoRV EcoRV
EcoRV pMP
Digest EcoRV 
LIGATE
Nrul
EcoRI
OTCMOD PCR
pMOP
Figure 11. Formation of creatine kinase-OTC'Moo 
expression cassette.
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Figure 12 Restriction enzyme digestion map of creatine kinase-OTC^^^ 
expression cassette.
A) This is a restriction enzyme map of the creatine kinase-OTCM°° expression 
construct in plasmid pIC20H.
B) Diagnostic restriction enzyme digestions of the resultant creatine kinase- 
q j^ m o d  expression construct in pIC20H H:Hind III, B:BamH I, X;Xho I, 
EV:EcoR V, Bg:Bgl II, Hc:Hinc II, N:NruI,.
H RI N ,H
B B B X H X
Creatine Kinase promoter/enhancer
OTC cDNA
SV40 Polyadenylation/intron
1Kb
A. I
JD
-  EV B H B g H c X
Kb
4
3 ■
2 ■
1.5
1
0.5
B.
Figure 12. Restriction enzyme digestion map of creatine 
kinase-OTCMon expression construct.
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3.2 4.GENERATION OF TRANSGENIC MOUSE LINES BY 
PRONUCLEAR INJECTION
3 .2 .1  M i c r o - i n j e c t i o n  o f  e x p r e s s io n  c o n s t r u c t s
Standard micro-injection technique was employed as described in ‘Manipulating the 
mouse embryo’ by Hogan et al (Hogan, Costantini et a l 1986). The expression 
constructs were excised from the parental plasmid vector and purified by dialysis 
against injection buffer. The purified, linearised expression constructs were 
originally micro-injected at a concentration of 2 ng/pl. No transgenic pups were 
obtained after screening 25 resultant pups. Subsequently a concentration of 5 ng/juil 
of DNA was used in the micro-injection.
This table indicates the efficiency of the technique
Table 1. Efficiency of pronuclear injection after the technique was optimised.
Expression
Construct
Concentration 
Of DNA
Number of 
Pups bom
Number of
transgenic
mice
Efficiency
Albumin 
driven OTC
5 |ig/ml 40
(+5 dead)
3 7.5%
Creatine 
Kinase driven 
OTC
5 pg/ml 22 3 13.6%
Keratin V 
driven LacZ 
(see later)
5 pg/ml 13 3 23%
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3 .2 .2  5. A n a l y s i s  o f  i n t e g r a t i o n  s u g g e s t s  m o s t  l i n e s  h a v e
INSERTED MULTPLE COPIES OF THE TRANSGENE.
3 .2 .2 J  S o u t h e r n  B l o t  ANALYSIS
All founder mice resulting from pronuclear injection were screened for the presence 
of the transgene by Southern blot analysis performed on 5 pg of genomic DNA 
extracted from a tail tip biopsy (Fig 13). The DNA was digested overnight with 
Hindlll or BamHI, blotted overnight and the resultant blot probed using 
radioactively labelled 850 bp SV40 intron and polyadenylation sequence. This 
sequence is of viral origin and has no homology to any murine genomic sequence. 
Using this method three founder mice were identified from each expression 
construct. The albumin founder lines were termed the ‘K ’ lines and comprised KE, 
KD and KG, whilst the creatine kinase founder lines were deemed the ‘Q’ lines and 
comprised QA, QB and QE.
Southern blot analysis (Fig 13) shows proof of transgene integration. Unfortunately, 
no single restriction enzyme cut twice within either transgene to produce a constant 
size internal band. The Hindlll site 3’ to both expression constructs in the pIC 
20H/SV40 plasmid was lost when the expression cassettes were excised from the 
parental vector prior to pronuclear injection. However, as more than one copy of a 
transgene usually integrates in a ‘head to tail’array, the presence of a Hindlll site at 
the 5’end of the albumin-OTC^^^ expression construct should produce a constant
1.2 Kb band when the SV40 polyadenylation sequence is used as a probe, this band 
being diagnostic for tandem transgene integration. This constant band is seen in both 
the KD and KE line but not the KG line suggesting multiple transgene copies in KD 
and KE but not in KG lines.
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Figure 13. Southern blot analysis of albumin and creatine kinase-OTCM®*  ^
founder lines.
Southern blot analysis of all creatine kinase and albumin-OTC^°^ founder 
transgenic lines digested with BamHI or Hindlll. The SV40 polyadenylation 
sequence was radioactively labelled as the probe. KD and KE have an internal 1.2 
Kb band, which is absent in KG. This internal band is formed by ‘head to tail’ 
insertion of the transgenes at the point of integration and is therefore indicative of 
the integration of multiple transgenes. In addition, KD shows multiple bands of 
varying size suggestive of multiple chromosomal integration sites. Unfortunately in 
the creatine kinase-OTC^^^ transgenic lines, neither BamHI or Hindlll digestions 
give an internal constant band.
QE QB QA KD KG KE 
H B H B H B H B H B H B
Kb
6
5
4
2
1.5
B: BamH I H: Hind III
Figure 13. Southern blot analysis of albumin and creatine 
kinase-OTCMoo founder lines.
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Figure 13 also shows the presence of multiple bands in addition to the constant 1.2 
Kb band in the KD founder line, therefore additional Southern blot analysis was 
performed with a lesser amount of genomic DNA and a higher enzyme 
concentration in order to rule out the possibility that the additional bands were due 
to incomplete digestion of the genomic DNA (Fig 14).
This second Southern blot result gave identical results to the first. Thus, the 
additional bands could be due to gross rearrangements of the integrated transgene. 
Alternatively, it might suggest that the transgene had integrated into more than one 
chromosomal location. In order to address the latter question, transgene integration 
sites were visualised in the KD founder mouse using fluorescent in situ 
hybridisation (FISH).
3,2,2,2 F l u o r e s c e n c e  In  S i t u  H y b r i d i s a t i o n  (FISH) w a s  u s e d  t o
SHOW CHROMOSOMAL LOCALISATION OF THE TRANSGENES 
FISH provides a direct and powerful way to study the cytogenetic localisation of 
DNA sequences. In order to confirm the hypothesis that the KD founder mouse has 
multiple integration sites of the transgene, FISH was optimised using the entire 
albumin-OTC^^^ transgene construct as a probe (Fig 15). Murine metaphase 
chromosome spreads were obtained by a mixed splenic lymphocytic culture from 
two Fi progeny from both the KD and KE transgenic lines. The whole albumin- 
OTC^o° transgene was then labelled with a fluorescent epitope and used as a probe 
for the detection of the site of transgene integration. This technique confirmed the 
presence of one transgene integration site in the progeny of both these lines (Fig 15). 
Due to the fact that the majority of murine chromosomes are acrocentric and
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Figure 14. Southern blot analysis of aIbumin-OTCM®° founder lines KD and 
KE.
As previously shown (Fig 13), multiple bands were obtained in the Southern blot 
of KD after restriction enzyme digestion. These bands could have been an artefact 
due to incomplete digestion of the genomic DNA, and therefore a confirmatory 
Southern blot of KD and KE was performed using 5 jig genomic DNA from 
albumin-OTC^^° lines. Genomic DNA was digested with Hindlll and probed 
with 0.85Kb SV40 polyadenylation sequence. The KD line shows multiple bands 
suggestive of multiple chromosomal integration sites.
KE KE KD KD KD Kb
4
3
2
1.5
Figure 14. Southern blot analysis of albumin-OTC^OD 
founder lines KD and KE.
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Figure 15. Fluorescent in situ hybridisation of KE and KD line chromosome 
meta phase spreads.
Metaphase chromosome spreads were obtained from KE and KD transgenic lines. 
Fluorescent in situ hybridisation was performed using the entire albumin- 
ti'ansgene as probe. Both lines show a single chromosomal insertion site. 
Female mice were used in this assay to exclude integration into the ‘X ’ 
chromosome not being detected.
KD line
KE line
Figure 15. Fluorescent in situ hybridisation of KE and KD 
line chromosome metaphase spreads.
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because unique centromeric probes were not available, it was not possible to 
determine which chromosome the transgene had integrated into in both F i lines.
3.2 .3  DURING BREEDING THE PRESENCE OF THE TRANSGENE WAS 
DETECTED BY A PCR SCREENING REGIME
After confirmation of integration of the gene expression constructs by Southern Blot 
analysis of founder transgenic mice, a PCR based screening procedure was used to 
screen the progeny from subsequent breedings (Fig 16). The PCR used to detect 
transgene integration was designed to amplify only exogenous OTC^^^^ gene 
construct DNA, by selecting primers within exons that spanned a large intronic 
sequence. The endogenous genomic sequence OTC gene was thus unlikely to be 
amplified by PCR.
Total genomic DNA was extracted from tail tip biopsy and used as a template for 
the PCR reaction. The PCR product was 340 bp in positive transgenic mice (Fig 16). 
The same PCR was used to screen all the albumin-OTC^°^ and creatine kinase- 
OTC^OD j^- j^^sgenic lines. During optimisation of the OTC^*^^ cDNA PCR, a 
qualitative correlation was performed between PCR results and those obtained by 
Southern Blot analysis of the Fi mice from the ‘K’ founder lines of mice. The results 
were identical in all cases.
3 .2 .4  N o r t h e n  b l o t  a n a l y s i s  s h o w s  t h a t  t h e  i n t e g r a t e d
TRANSGENES ARE EXPRESSED
Although integration of the transgene had been shown by Southern and FISH 
technology, approximately 5% of integrated transgenes are not expressed. In order 
to confirm expression of the transgene, total mRNA was extracted from the relevant 
target tissue i.e. liver or skeletal muscle The 0.85 Kb SV40 polyadenylation/intron
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Figure 16. Detection of the recombinant transgene by PCR.
A PCR was optimised to screen for the presence of the transgene during breeding 
of the different transgenic and OTC deficient lines. Primers were designed in two 
adjacent exons of the endogenous OTC gene, thereby amplifying across an intron. 
The presence of the intron in the endogenous OTC gene would prevent a PCR 
product being formed, whilst the OTC^*^’^  cDNA, which contained no intron, 
produced a 340 bp PCR product which could be visualised on a 1.5% agarose gel. 
The template for the PCR reaction was genomic DNA extracted from a tail tip 
biopsy.
Kb 1 2 3 4 5 6 7 8
0.5
0.394
0.344
0.290
# #
Lanes 1. 1 Kb ladder
2. Negative for transgene
3. Negative for transgene
4. Negative for transgene
5. Negative for transgene
6. Positive for transgene
7. Positive for transgene
8. Negative for transgene
Figure 16. Detection of the recombinant 
transgene by PCR.
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viral sequence was used as a radioactive probe for Northern blot analysis. Figure 17 
shows a Northern blot result using 15 gg of total RNA for lines KE, KD, KG, QA, 
QB and QE. Northern blot analysis confirmed expression of the transgenes, with an 
expected mRNA of 1.8 Kb in all six of the albumin-OTC^^^ and creatine kinase- 
QTCMOD transgenic lines.
KE shows a doublet band at the expected 1.8 Kb mRNA size, whilst KD has only a 
faint band at the expected size with the majority of the transcript being much larger. 
This abnormal KD transcript size on Northern blot analysis taken together with the 
Southern blot and FISH data (Figs 13, 14 &15) strengthen the hypothesis that this 
line has rearranged the transgene on integration. KG shows the highest level of 
specific gene expression in the albumin promoter driven group, despite
Southern analysis results indicating that only one copy of the gene expression 
construct has integrated (Fig 13).
The Northern blot results of both hepatic and skeletal muscle recombinant OTC 
expression in the albumin and creatine kinase-OTC^°° transgenic lines indicates 
that in addition to the correct sized transcript of 1.8 Kb, there were multiple other 
transcripts from the OTC expression constructs (Fig 17). These multiple transcripts 
are unlikely to be due to expression from the endogenous gene as they are absent 
from control lanes and the SV40 probe has no homology to endogenous murine 
genomic sequences. Although these alternative transcripts may suggest 
rearrangement of the transgene at the genomic level, this phenomenon of multiple 
transcripts had been seen in other transgenic mouse lines produced in the research 
group which have also incorporated the same SV40 polyadenylation / intron 
sequence. It has been shown that the SV40 polyadenylation sequence can cause 
aberrant splicing events (Huang and Gorman 1990).
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Figure 17. Northern blot analysis of albumin and creatine kinase-OTC^®^ 
transgenic lines.
Northern blot analysis using total RNA from hepatic tissue in the albumin-OTC^°^ 
lines (KE, KD, KE) and total RNA from skeletal muscle from the creatine kinase- 
OTCN^od lines (QA, QB, QE). The SV40 polyadenylation sequence was 
radioactively labelled as a probe. KG and KE lines show reasonable expression of 
the correct 1.8 Kb transcript, although KE does appear to have a doublet band at 
this size. Although KD does have a 1.8 kb transcript, the majority of the KD 
transcript appears larger than this, which may suggest that the transgene may have 
rearranged during integration. QE shows the highest expression of OTC^^° 
transcription although in fact all the ‘Q’ lines show higher expression levels than 
the ‘K’ lines. The larger transcript sizes do appear constant in all the transgenic
lines.
I
n
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Figure 17. Northern blot analysis of albumin and creatine 
k i n a s e - t r a n s g e n i c  lines.
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3 .2 .5  T h e  e x p r e s s io n  p a t t e r n  o f  t h e  t r a n s g e n e  c o r r e l a t e d
WELL WITH THE REGULATORY SEQUENCES USED IN THE CONSTRUCT
The tissue-specific expression of the albumin and creatine kinase promoters was 
investigated. In one representative transgenic line for each gene construct, total 
RNA was extracted form multiple tissues from a KE (albumin-OTC^^^) and a QE 
(creatine kinase-OTC^°°) mouse, and Northern blot analysis was performed using 
the unique 0.85 Kb SV40/intron polyadenylation sequence as the hybridisation 
probe (Figs 18 and 19).
3 ,2.5 .1  CREA TINE KINASE PROMOTER
Northern blot analysis of the QE creatine kinase-OTC transgenic founder is shown 
in figure 18. Total RNA was extracted from liver, small intestine, brain, lung spleen, 
kidney, skeletal and cardiac muscle. A 1.8 Kb transcript can be seen, as expected, in 
skeletal muscle RNA as well as, to a lesser degree, cardiac muscle RNA. There is 
also a faint band of similar size present in the renal RNA sample. This result shows 
that the murine regulatory sequences from the creatine kinase gene used in this 
construct are capable of directing high levels of gene expression in skeletal, and to a 
lesser extent, in cardiac muscle. This pattern of creatine kinase promoter/enhancer 
regulated gene expression has been previously reported (Hoefler, Noehammer et al. 
1997). In the current study, the Northern result suggested there is additionally a very 
low level of recombinant OTC mRNA expression in renal tissue, not previously 
described.
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3,2,5,2 A l b u m in  PROMOTER d r iv e n  g e n e  e x p r e s s io n  c o n s t r u c t  
Total RNA was extracted from multiple tissues of the KE transgenic line and 
Northern analysis was performed using the 0.85 Kb SV40/intron polyadenylation 
sequence as the probe. This Northern blot result (Fig 19) indicates regulatory 
sequences from the murine albumin promoter and enhancer appear to drive tight 
hepatic-tissue specific gene expression. No illegitimate transcripts were seen in any 
of the tissue samples.
3.3 T h e  a b i l i t y  o f  e c t o p i c  r e c o m b i n a n t  OTC
EXPRESSION TO CORRECT THE PHENOTYPES OF OTC 
DEFICIENT MOUSE MODELS
Having established successful transgene integration and tissue specific expression of 
the albumin-OTC^^^ and creatine kinase-OTC constructs in transgenic 
founders, the aim of this study was to investigate whether exogenous expression of 
the recombinant OTC in skeletal muscle would correct the phenotype of the OTC 
deficient mouse models. This was achieved by breeding the creatine kinase- 
QTCMOd transgenic mice onto a Spf and Spf^^^ mutant background. As the OTC 
mutation is X-linked only male mice with both the transgene and OTC endogenous 
mutation were analysed. In addition, as a positive control, the albumin-OTC^°^ 
mice were also bred onto the OTC deficient backgrounds.
The effect of the transgenic tissue-specific expression of recombinant OTC on the 
OTC deficient mouse models was assessed by three criteria namely; 1) correction of 
the phenotype associated with endogenous OTC deficiency, 2) reduction in plasma 
ammonia levels, which are elevated in OTC deficiency and finally 3) direct in vitro 
assayed tissue- specific OTC activity
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Figure 18. Northern blot analysis indicating the tissue specificity of the creatine 
kinase-OTC’'^ °^ expression cassette.
Northern blot analysis showing tissue-specific expression of creatine kinase- 
OTC^od transgene (QE line) using the SV40 polyadenylation sequence as the probe. 
Total RNA was extracted from multiple tissues from a QE transgenic mouse. High 
QY^MOD expression levels are seen in skeletal muscle, moderate in cardiac tissue and 
low in renal tissue. In the skeletal muscle there is also a smaller transcript seen 
which was also present in Figure 17. The negative control is total RNA extracted 
from skeletal muscle from a non-transgenic mouse, indicating the transgene-specific 
nature of the SV40 probe.
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Figure 18. Northern blot analysis indicating the tissue 
specificity of the creatine kinase-OTC''^^^ 
expression cassette.
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Figure 19. Northern blot analysis showing tissue specific expression of the 
albumin-OTC^^*’ transgene.
Northern blot analysis showing tissue-specific expression of albumin-OTC^^^ 
transgene (KE line). The SV40 polyadenylation sequence was radioactively 
labelled as the probe. Total RNA was extracted from multiple tissues from a KE 
transgenic mouse. High expression of the transgene is seen in hepatic extract 
only.
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Figure 19. Northern blot analysis showing tissue specific 
expression of the albumin-OTC*'^®*  ^ transgene.
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3 .3 .1  B r e e d in g  o f  t r a n s g e n ic  l in e s
3 3 .1 .1  P h e n o t y p e  o f  a f f e c t e d  OTC d e f i c e n t m i c e
The phenotypes of the affected Spf and Spf^ ®^  ^male mice were scored at weaning. 
At this stage affected males showed considerable variation in phenotypes. The 
majority of the affected males were small and failing to thrive, with sparse to absent 
hair growth, whilst in about 5% of cases severe runting prevented weaning and 
necessitated culling (Fig 4). The affected males did grow but remained noticably 
smaller than their unaffected male littermates. The appearance of body fur was 
delayed by about 2 weeks and appeared in sparse irregular clumps, which slowly 
outgrew to cover the entire body. By 8 weeks the only phenotype detectable was 
low body weight and a 'waxy' appearance to the coat texture which appeared to be 
due to thinning of the fine down undercoat of fur. On the mixed (FVB) x (C57B1/6J) 
background, no phenotypic difference could be observed between the sparse fur and 
sparse fur^^^ mouse colonies. However, there was a difference in mortality rate 
between the sparse fur and the sparse fur"^^  ^mouse colonies with a higher mortality 
rate in the latter.
3 ,3 ,1 ,2  B r e e d in g  o f  t h e  r e c o m b in a n t  O T C  t r a n s g e n ic  m i c e  o n t o  a n
OTC DEFICIENT BACKGROUND
The C57B/6J (B6) transgenic founder mouse from each line was bred with both Spf 
and the Spf^^^ animals, which were both outbred with a mixture of (FVB) x 
(C57B1/6J) genetic background. The Fi females from an affected male X wildtype 
cross were obligate carriers of the mutant OTC allele and were further crossed with 
wildtype males to produce 50% affected Fz males. Unfortunately due to the higher 
mortality in the Spf^^^ colony, the number of surviving transgenic mice on this
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mutant background, was very low which compromised statistical analysis of this 
data. The data from the three albumin-OTC^^°/Spf^®^ lines was therefore pooled 
for statistical analysis. Similarly, the data from the creatine kinase-OTC^^^/Spf^^^ 
lines was pooled for statistical purposes.
As mentioned previously, a complicating factor was the large variation in 
expressivity within the 95% of affected Spf male mice that survived past weaning. 
This variability could be due to interactions between the OTC gene locus and other 
modifier genes, as has been suggested in the human clinical setting. Regardless of 
cause, this large variation in expressivity precluded a meaningful score of affected 
phenotypes when the Spf and Spf^^^ were bred onto transgenic backgrounds. To 
minimize subjectivity, mice that showed any feature of the Spf phenotype were 
classified as ‘affected’ and no intermediate phenotypic classification was attempted. 
At this juncture, transmission of the OTC transgene into Fi and F2 progeny was 
determined by PCR of the rat OTC cDNA. Due to the higher residual hepatic OTC 
activity present in the Spf than the Spf^®  ^ mice, it was expected that these mice 
would be more likely to show phenotypic correction by the transgene.
Unfortunately, despite the documented presence and expression of the transgene, no 
correction of either the sparse fur or sparse fur"^^  ^murine phenotype was noted after 
breeding with any of the transgenic founder lines, including, unexpectedly, the 
hepatocyte-specific transgenic K lines, KD, KE and KG.
Although the presence of Spf mutation could be assessed by phenotypic 
examination, in those mice with a mild phenotype the presence of the Spf mutation 
was confirmed at the genomic level by an amplification refractory mutation 
detection system (ARMS) reaction (Fig 20). This technique was also performed in 
those phenotypically affected transgenic mice from the K (hepato-specific) lines in 
order to confirm the presence of the sparse fur mutation and, thereby ruling out the
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Figure 20. Amplification refractory PCR (ARMS) assay for sparse fur 
mutation. This allows the molecular distinction of Spf and wildtype mice based on 
the single Spf point mutation in the endogenous OTC gene. PCR forward primers 
were designed in which the 3’ nucleotide of the oligonucleotide has high fidelity 
for either the Spf genomic mutation or the wildtype genomic sequence. The 
downstream reverse primer in both reactions was a common primer.
Common primer-5’ GGC ATT ATC TAA GGA GAA GCATCA TCT TCT C 
Wild type Primer 5’ AC A CCC TTC CTT TCT TCA CAC ACA AGA CAT G C
Spf primer 5’ ACA CCC TTC CTT TCT TCA CAC ACA AGA CAT GA'
The PCR conditions are optimised so that the Spf mutation primer will not prime 
off a wildtype sequence and the wildtype primer will not prime of a Spf mutation 
sequence. The presence of the OTC^°^ transgene was screened for using the PCR 
design-specific for the exogenous transgene (Figure 16.) PCR products amplified 
from genomic DNA using primers specific for A) Transgenic OTC cDNA, B) 
Wildtype endogenous OTC sequence (5’ end of exon 4 ~ amino acid 117), C) 
Endogenous Spf mutation (5’ end of exon 4 -amino acid 117.)
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T: transgene, E: endogenous OTC gene, P: unincorporated primers
Mouse 1. Female, Transgene on a wildtype OTC background 
( No PCR product specific to the sparse fur mutation) 
Mouse 2. Female,Transgene on a heterozygous background 
( PCR products specific to both the sparse fur and 
wild type OTC genomic alleles)
Mouse 3. Male , Transgene on a wildtype background
( No PCR product specific to the sparse fur mutation)
T
E
P
Figure 20. Amplification refractory PCR assay for the Spf mutation.
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possibility that the transgene may have a detrimental effect on normal OTC 
expression and funetion, and thus produce an affected phenotype. The possibility of 
this latter effect was also ruled out by the birth of phenotypieally normal male mice 
carrying the transgene. ARMS was also performed in unaffected transgenic males to 
assess the absence of the mutant OTC allele, thus excluding the possiblity that in 
these unaffected male mice the normal phenotype was due to eorrection of a mutant 
allele by the transgene. Unfortunately, the ARMS reaction for the Spf^^^ mutation 
could not be reliably optimised as it gave false positives with primers for the sparse 
fur^^^ mutation in wildtype DNA. This may have been due to the high GC content 
at the 3 ’ end of the Spf^^^ mutation specific primer. The last 5 3 ’ bases comprised 4 
G:C bonds in comparison to the Spf mutation spécifié primer which only contained 
2 G:C bond in the last 5 3’ nucleotides.
Due to the wide phenotypie variation seen within the breeding eolonies of both 
sparse fur and sparse fur^^^, it was felt that any attempt to correlate modulation of 
phenotypic severity with expression of transgenes bred into this colony was not 
possible, therefore biochemical analysis of the miee was undertaken.
3 .3 .2  P l a s m a  A  MMONiA l e v e l s  w e r e  e v a l u a t e d  t o  d e t e r m in e  
e f f ic a c y  o f  r e c o m b in a n t  O T C  e x p r e s s io n
The plasma ammonia level is a metabolie marker of a hypomorphic OTC allele used 
in clinical practice (normal range 10-35 p mol/1). Although by no means 
pathognomie, plasma ammonia is elevated when the urea cycle decompensates, and 
is therefore raised in cases of OTC deficiency. Plasma ammonia levels were 
investigated as a possible indicator of partial correction of the metabolic OTC defect 
in the Spf mice.
109
Ammonia levels (pmol/1) were assayed in plasma samples obtained by cardiac 
puncture. Only male mice were used in this assay and they were always sacrificed at 
the same time of day to allow for variation in NH4 levels due to dietary intake or 
physical activity. The plasma was isolated immediately.
As the data set collected was small (18, 12 and 29 mice in the wild type, Spf^®  ^and 
Spf control groups respectively, Table 2) a non parametrie statistical analysis was 
performed, namely the Mann-Whitney test, which compares two independent 
groups. This test was performed using the SPCC statistic programme.
The wildtype, sparse fiir and sparse fur^^^ backgrounds had median plasma 
ammonia levels of 33.0, 58.0 and 236.5 respectively. Figure 21 demonstrates the 
wide variation in NH4 levels in both the Spf and Spf^^^ mice compared to the wild 
types, as reflected earlier in the variable expressivity of the post-natal phenotypes. 
Nevertheless, non-parametric testing of the plasma ammonia (jumol/l) showed a 
statistical difference between the levels found in both the Spf and Spf^^^ compared 
to the wildtype mice (Table 2, Fig 21). This indicated that the plasma ammonia level 
was a reasonable metabolic index, which could differentiate between a group of 
miee with mutant OTC alleles from those with wildtype alleles.
3 3 ,2 ,1  Th e  p r e s e n c e  o f  t h e  a l b u m in -O T C ^ ^ ^  t r a n s g e n e
SIGNIFICANTLY REDUCED THE PLASMA AMMONIA LEVELS IN THE OTC 
DEFICIENT MOUSE MODELS
Plasma ammonia levels were measured in the albumin-OTC^^^ transgenic mice 
bred with the sparse fur mutant mice. Due to the X-linked inheritance of the 
endogenous OTC gene, only male mice were assayed. Each of the albumin-OTC’^ ®^  
lines was analysed separately. The results are depicted in figure 22 and tabulated in
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Table 3. The KG and KE lines bred onto a Spf background had median plasma 
ammonia levels of 41 and 34 respeetively and showed a statistically significant 
improvement in ammonia levels compared to non-transgenic Spf background 
(p=0.009 and p=0.01 respectively) (Table 3). In addition, they showed no significant 
difference in plasma ammonia values from the wildtype OTC background (p=0.258 
and p=0.759) (Table 3). However, the number of animals analysed for the KD 
transgenic line was insufficient to show a statistically significant difference from 
Spf (p=0.071). Nevertheless, it is clear that the data from the KD transgenie line was 
following the same trend as in KG and KE lines (Fig 22), despite the low level of 
QTCMOd transcript seen in the Northern Blot analysis (Fig 17). By pooling the data 
from the three albumin-OTC’^ ®  ^ lines, there was a highly signifieant improvement 
in plasma ammonia levels compared to Spf background (p=0.001) and no significant 
difference compared to the wildtype background (p=0.380) (Table 3). It should also 
be noted that the large variation in plasma ammonia seen in the Spf mice is virtually 
eliminated in the three transgenic lines, with the exception of one KG mouse (Fig 
22).
Unfortunately due to the higher mortality found in the Spf^^^ mice, it was not 
possible to analyse the albumin transgenic lines separately on this background and 
therefore results from all the albumin transgenic lines were amalgamated (Fig23, 
table 4). The results show a significant improvement in the plasma ammonia levels 
in the albumin-OTC‘^ ^° transgenic mice on the Spf^^^ baekground compared to the 
SpfASH background alone (68 compared to 236.5p,mol/l, p=0.028) but the ammonia 
level was still significantly different from those found in the wildtype mice 
(p=0.003) (Table 4). This is most likely because of the small sample size analysed 
for the K lines (N~7). The ‘K’ line plasma ammonia data show a tight distribution
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with little variation in ammonia levels measured (Fig 23), which is similar to the 
spread of values obtained in the wildtype control group and distinct from the larger 
variation in values seen in the Spf^®  ^group (Fig 21).
3 3 ,2 ,2  Th e  p r e s e n c e  o f  t h e  c r e a t in e  k in a s e -O T C ^ ^ ^  t r a n s g e n e  h a d
NO EFFECT ON PLASMA AMMONIA LEVELS IN THE O T C  DEFICIENT MOUSE 
MODELS
Due to low numbers of mice available, data from the creatine kinase-OTC^^^ lines 
was pooled together on both the Spf and Spf^^^ backgrounds (Figs. 24 and 25, table 
5A and B) In neither case was the plasma ammonia in the ‘Q’ lines signifieantly 
lower than in the mutant OTC allele mice alone (p=0.152 on the Spf background 
and p=0.057 on the Spf^^^ background) (table 5). Indeed on the Spf background the 
median plasma ammonia level was higher than on the Spf^^^ background (Fig. 24 
and 25, table 5). Closer examination of the original data (Table 5A) suggests that on 
the Spf background the ammonia levels are widely spread with the majority (5/9) of 
the levels being outwith the normal values. However, on the Spf^^^ background, the 
majority of the values are within normal values. If the QA line is analysed alone all 
the ammonia values are within then normal range and have a much smaller spread 
than that seen in the QE line suggesting that there may have been a lowering of the 
ammonia concentration in the QA line, however inadequate mouse numbers 
precluded statistical analysis.
In addition, creatine kinase-OTC^°^ lines show a wide variation in plasma ammonia 
level on both a Spf and Spf^^^ background similar to the results obtained from the 
mutant OTC allele background alone (Figs 24 ,25 & 21),
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Figure 21. Plasma ammonia levels in wildtype, and affected male Spf and 
SpF^ "^ mice.
Plasma ammonia levels were measured in blood obtained by cardiac puncture from 
male wild type, and affected Spf and Spf^^^’’ mice. Each data point represent the 
result obtained from an individual mouse. There is a statistical difference values 
between the three groups. In addition, there appears to be a wider spread of values 
in the two OTC deficient groups. This variation in plasma ammonia levels seen in 
the Spf and Spf^^" mice is mirrored by the wide variation in severity of affected 
phenotypes seen in the males.
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Figure 22. Plasma ammonia levels in albumin-OTC^^° transgenic mice bred 
onto a Spf background.
Plasma ammonia values (pMol/L) were assayed in male mice from the indicated 
albumin-OTC^°'^ transgenic lines were bred onto a Spf background. KG and KE 
show a statistically significant improvement in plasma ammonia levels eompared to 
the non-transgenic Spf background alone. In addition, the spread in plasma ammonia 
levels is less than that seen in the Spf group, more in keeping with the wildtype 
ammonia values. The KD group, containing the smallest number of animals, does 
not show a statistically significant amelioration of ammonia values, although there is 
not the spread of values seen in the Spf group.
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Figure 23, Plasma ammonia levels assayed in albumin-OTC''^^^ transgenic 
lines bred onto a sparse OTC deficient background.
Plasma ammonia levels were assayed in male albumin-OTC^^^transgeniclines 
bred onto a background. Each point represents the data from an individual
mouse.
Due to low numbers of animals examined for each construct, the data from all the 
different albumin-OTC^°° transgenic lines were pooled and analysed together. 
There is a statistically significant improvement in plasma ammonia levels in the 
presence of the albumin-OTC'^^° transgene compared to the non-transgenic OTC 
deficient group alone.
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Figure 24. Plasma ammonia levels assayed in creatine kinase-OTC^^*^ 
transgenic lines bred onto a Spf OTC deficient background.
Plasma ammonia values were assayed in male mice from the indicated creatine- 
q j q Mod i^-gj^sgenic lines were bred onto a Spf background. Each point represents 
an individual mouse. There is no statistically significant improvement in ammonia 
values in the transgenic group compared to the non-transgenic OTC deficient 
group. In addition, the transgenic group shows the same wide spread distribution in 
values noted in the non-transgenic Spf group.
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Figure 25. Plasma ammonia levels assayed in creatine kinase-OTC^^^ 
transgenic lines bred onto a Spf^^^OTC deficient background.
Plasma ammonia levels were assayed in male creatine kinase-OTC’^ ^^ transgenic 
lines bred onto a SPF^^^ background. Each point represents the data from an 
individual mouse. Due to low numbers of animals examined for each construct, the 
data from all the different creatine kinase-OTC^^° transgenic lines were pooled 
and analysed together. There is no statistically significant improvement in plasma 
ammonia levels in the presence of the albumin-OTC^^^ transgene compared to the 
non-transgenic OTC deficient group alone.
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Table 6 Hepatic OTC activity (OD49o/mg protein) on sparse fur, sparse fur^ ®“ 
and wildtype background
All assays were performed in triplicate and the average of the results was taken.
Wildtype 
(No 9)
Sparse fur 
(No 18)
Sparse 
furASH 
(No 8)
Median OTC 7.6 1.2 0.44
Wildtype PVO.OOOl P*<0.0001
Table 7 Hepatic OTC activity (GD49o/mgprotein) levels in the albumin -OTC^^^ 
lines on a sparse fur background.
Wildtype 
(No 9)
Sparse
fur
(No 18)
KD 
(No 9)
KE
(No 10)
KG
(No 15)
All ‘K’ Line
Median OTC 7.6 1.2 1.44 1.37 1.65
Wildtype P*=0.0001 P*<0.0001 P*<0.0001 P*=0<0001
Sparse fur P=0.145 P=0.089 P=0.006 P*=0.007
Table 8 Hepatic OTC activity (OD49o/mgprotein) in the albumin -OTC^^^ lines
on a sparse fur^^  ^background.
Wildtype Sparse FurASH All ‘KTines
(No.9) (No 8) (No 8)
Median OTC 7.6 0.44 0.61
Wildtype P*<0.0001
Sparse fur'^^^ P-0.161
statistical significance in comparison to wildtype data by Mann Whitney test
Table 9 Skeletal Muscle OTC activity (OD49o/mgprotein) in normal mice and in
the creatine kinase -OTC^^^ lines.
Baseline 
(No 13)
QA
(No 11)
QB
(No 5)
QE 
(No 8)
All “Q”lines
Median OTC 0.73 5.4 1.7 17.2
Baseline P*<0.0001 P*=0.014 PVO.OOOl P'<0.0001
Hepatic OTC activity (OD49o/mgprotein) leve 
sparse fur background.
s in the albumin -OTC*^^^ lines on a
118
Table 5 Plasma ammonia levels (pmol/1) in creatine-kinase lines.
Due to low numbers of mice examined, the QA, QB and QE data was pooled and 
analysed together.
Table 5A indicates the raw data in each founder creatine-kinase OTC^°^ founder line, 
whilst table 5B is the pooled data analysed.
Table 5A
creatine-kinase OTC line NH3 levels on sparse fur 
background
NH 3 levels on sparse fur^^ 
background
QA 19 27, 50, 29, 24,
QB 185, 55,104
QE 27, 60, 131,280,309 145,314,31,392
Table 5B
Wildtype Sparse
fur
(No 28)
Sparse furASH 
(Nol2)
All “Q’ lines 
on sparse fur 
B/G (No 9)
All ‘Q’ lines 
on sparse
(No 8)
Median
Ammonia
33.0 58 236.0 104.0 40.5
Wildtype P=0.012 P=0.338
Sparse fur P=0.152
Sparse fur ASH P=0.057
p*= statistical significance in comparison to wild type data by Mann Whitney test
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3 .3 .3  TOTAL ORNITHINE TRANSCARBAMYLASE ACTIVITY WAS ASSESSED 
IN THE TRANSGENIC LINES
Direct measurement of OTC activity was undertaken in the different transgenic 
groups on both the Spf and Spff^®^ backgrounds. An in vitro assay was optimised to 
measure OTC activity in total tissue from liver and skeletal muscle. The estimate of 
OTC activity was then standardised against the protein content of the individual 
tissue. An arbitrary unit of OTC activity was used to compare the different sample 
populations, namely OD49o/mg protein. Due to the X-linked inheritance pattern of 
OTC deficiency, this assay was only performed on male mice.
Baseline hepatic OTC activity was measured in the normal, Spf and Spf^®  ^mouse 
populations and gave results of 7.6, 1.2 and 0.44 OD49o/mg protein respectively (Fig 
26, Table 6). The results confirm a significant difference in hepatic OTC activity 
between the different OTC mutant alleles and the wildtype hepatic activity. 
Compared to the wildtype mice, the Spf and Spf^^^ mice had a hepatic enzyme 
activity of 16% and 5%, which is in keeping with relative OTC activities reported 
originally in the mutant OTC mice (Qureshi, Letarte et al. 1979; Hodges and 
Rosenberg1989).
In comparison with the plasma ammonia levels observed in these mice (Fig 21), 
hepatic OTC activités showed a smaller variation in values within each group, with 
wild type mice having the largest spread (Fig 26). However, as it was not possible to 
prove normal distribution to the values obtained within a group, the results were 
analysed using non-parametric statistics, namely Mann-Whitney.
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3,33A HEPATIC OTC ACTIVITY IN ALBUMIN TRANSGENIC LINES ON A 
SPARSE FUR OR SPARSE FUR^^^BACKGROUND
Each albumin transgenic line was analysed independently (Fig 27, Table 7). The KD 
and KE lines showed no significant increase in hepatic OTC activity compared to 
the Spf background alone (1.44 and 1.37 OD49o/mg protein, p=0.145 and p=0.089 
respectively) (Table 7). However, the KG line showed a significant increase in OTC 
activity compared to the Spf (1.65 compared to 1.2 OD49o/mg protein, p=0.006), but 
it was still significantly lower than wildtype hepatic OTC levels (p<0.0001) (Table
7). If data from the ‘K’ line mice were pooled, there was a significant elevation in 
hepatic OTC activity in this group compared to the Spf group (p=0.007) but OTC 
levels were still significantly lower than in the wildtype group (p<0.0001)(Table 7). 
On a Spf^^^ background there were not enough mice to analyse each albumin 
transgenic line separately and therefore, they were grouped together (Fig 28 Table
8). The albumin transgenic mice on a Spf^ ^*^  mice background showed no 
improvement in OTC activity compared to the Spf^®  ^mice alone (0.61 compared to 
0.442 OD49o/mg, p==0.161) (Table 8). The transgenic group had a significantly lower 
hepatic OTC activity than the wildtype mice did (p<0.0001)(Table 8).
3,33,2 SKELETAL MUSCLE OTC ACTIVITY IN THE CREATINE KINASE 
TRANSGENIC LINES
As neither the Spf nor the Spf^^^ mice have skeletal muscle OTC activity, the 
creatine kinase transgenic OTC activity was not measured on either of these 
backgrounds. Each transgenic line was analysed separately (Fig. 29, Table 9). All 
the creatine kinase transgenic lines had significantly higher levels of OTC activity 
than was found in baseline skeletal muscle with QA, QB and QE skeletal muscle
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activity being 5.4, 1.7 and 17.22 OD49o/mg: p<0.0001, p=0.014 and p<0.0001 
respectively) (Table 9). Line QE had an OTC activity that was three times higher 
than was found in normal hepatic tissue (Tables 6 and 9). This result correlated with 
the Northern Blot analysis of the mRNA levels which also indicated a higher 
transcript level in skeletal muscle in QE, than in the hepatic tissue of any of the K 
lines (Fig. 17)
Interestingly, when comparing with the plasma ammonia levels, the QE line has the 
higher values compared to those seen in the QA line despite a markedly higher level 
of skeletal OTC activity (Table 5 A).
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Figure 26. OTC activity assayed in wild type, Spf and Spf^^^ hepatic 
extracts.
OTC levels were assayed in male liver extracts wild type, Spf and Spf^^^ 
liver extracts. Each data point represents the mean of triplicate 
measurements from one animal. There is a statistically significant 
difference in OTC activity between the three groups.
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Figure 27. Hepatic OTC levels in albumin-OTC^^^ transgenic mice bred onto 
Spf background.
OTC levels were assayed in male liver extracts from the albumin-OTC^^^ 
transgenic lines bred onto mice carrying the SPF mutation. Each data point 
represents the mean of triplicate measurements from one animal. KG showed a 
statistically significant increase in OTC activity above that seen in the non­
transgen ic Spf liver.
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Figure 28. Hepatic OTC levels in albumin-GTC’'^ ^^  transgenic mice bred onto 
background.
OTC levels were assayed in male liver extracts from the albumin-OTC^^^ 
transgenic lines bred onto mice carrying the mutation. Each data point
represents the mean of triplicate measurements from one animal. The transgene gave 
no statistically significant alteration in OTC level compared to non-transgenic 
mice.
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Figure 29. Skeletal muscle OTC levels in creatine kinase-OTC^^^ transgenic 
mice.
OTC levels were assayed in male skeletal muscle extracts from the creatine kinase- 
QY^MOD 1^2'ansgenic lines. Each data point represents the mean of triplicate 
measurements from one animal. The transgene gave a statistically significant 
increase in skeletal OTC level compared to non-transgenic mice.
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T able 6 Hepatic OTC activity (OD4 9 o/mg protein) on sparse fur, sparse fnr"^ ^^  
and wildtype background
All assays were performed in triplicate and the average of the results was taken.
Wildtype 
(No 9)
Sparse fur 
(No 18)
Sparse 
furASH 
(No 8)
Median OTC 7.6 1.2 0.44
Wildtype P*<0.0001 P*<0.0001
T able 7 Hepatic OTC activity (OD4 9o/mgprotein) levels in the albumin -OTC^^^ 
lines on a sparse fur background.
Wildtype 
(No 9)
Sparse
fur
(No 18)
KD 
(No 9)
KE
(No 10)
KG
(No 15)
All ‘K’ Line
Median OTC 7.6 1.2 1.44 1.37 1.65
Wildtype P =0.0001 P*<0.0001 P'<0.0001 F^=0<0001
Sparse fur P=0.145 P=0.089 P*=0.006 P'=0.007
Table 8 Hepatic OTC activity (OD4 9o/mgprotein) in the albumin -OTC^^^ lines 
on a sparse fur"^ ®^  background.
Wildtype
(No.9)
Sparse FurASH 
(No 8)
All ‘KTines 
(No 8)
Median OTC 7.6 0.44 0.61
Wildtype P*<0.0001
Sparse fur^^’^ P=0.161
p^= statistical significance in comparison to wildtype data by Mann Whitney test
Table 9 Skeletal Muscle OTC activity (OD4 9o/mgprotein) in normal mice and in
the creatine kinase -OTC M O D lines.
Baseline 
(No 13)
QA
(No 11)
QB 
(No 5)
QE
(No 8)
All “Q”lines
Median OTC 0.73 5.4 1.7 17.2
Baseline P*<0.0001 P'=0.014 P*<0.0001 P*<0.0001
Hepatic OTC activity ( O D 4 9 0 / mgprotein) levels in the albumin -OTC lines on a 
sparse fur background.
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3.4 In v e s t ig a t io n  o f  t h e  e p id e r m is  a s  a  p o s s ib l e
TARGET ORGAN FOR RECOMBINANT GENE EXPRESSION
The first section of this project, to investigate the effect of exogenous OTC 
expression on OTC deficient mouse models, was only possible because the tissue- 
specific promoters employed, namely the albumin and creatine kinase regulatory 
sequences had already been well characterised and shown to be capable of directing 
gene expression to the relevant target tissues.
With the long term goal of developing epidermal specific expression constructs 
work was also undertaken to assess the ability of a novel bovine keratin 5 mini gene 
construct to drive expression of recombinant genes to the epidermis.
The epidermis is a highly attractive tissue in which to express many exogenous 
genes as it is easily accessible allowing the optimisation of non-invasive techniques 
such as liposomes for gene delivery. In addition, in vitro culture and transplantation 
of skin is well established in clinical practice. The skin has the additional benefit of 
being easily monitored after gene delivery (review Trainer and Alexander 1997). As 
the epidermis forms the outer layer of the skin, it provides the body’s first line of 
defence and as such has attracted much attention as a target for tissue-specific 
promoters. However, regulation of gene expression in the epidermis is very 
complex, as there are both temporal and cell type-specific controls of different gene 
promoters. Thus, in order to investigate the bovine keratin 5 gene expression profile 
both in adult mouse and during embryogenesis, a reporter gene construct comprising 
a Keratin 5 expression cassette and the E.coli (3 galactosidase (Lac Z) reporter gene 
cDNA was formed.
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3 .4 .1  F o r m a t io n  o f  a  k e r a t in  5 d r iv e n  L a c Z  r e p o r t e r
CONSTRUCT
A plasmid containing a bovine keratin 5 and 6 ‘minigene’ expression cassette was 
obtained from Manfred Blessing (Blessing, Nanney et al. 1993). This plasmid had 
been generated by cloning the bovine genomic sequence containing the contigous 
keratin 5 and 6 genes and then deleting from this genomic sequene, the keratin 5 and 
keratin 6 translated sequences. In the case of the keratin 5 gene all that remains is 
5.5 Kb of the 5' regulatory sequence including the first 30 bp of the 5' untranslated 
sequence, and the last intron, non-translated exon and endogenous poly adénylation 
sequence, at the 3 ’ end. Between these two K5 gene elements was a unique Sail site 
for insertion of cDNAs.
The strategy for formation of the Keratin 5 driven lacZ reporter construct is 
summarised in figure 30. In brief, the keratin 5 minigene regulatory sequence were 
separated from the keratin 6 minigene using a Kpnl digest. This was then ligated 
into the plasmid pIC20R, in which the endogenous Sail site had been destroyed by 
restriction enzyme digestion, end filling of over hanging termini and then ligation of 
the ‘flush’ ends. The entire E.coli |3- lactamase coding sequence (Lac Z) cDNA 
including an ‘ATG’ translation initiation sequence to a ‘STOP’ codon was then 
amplified by means of PGR, incorporating Sail restriction enzyme sites into the 5 ’ 
ends of the amplicon primers. This was ligated into the keratin 5 minigene construct 
downstream from the promoter sequences and upstream from the endogenous 
polyadenylation sequences using its unique Sail site (Fig 31 A).
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Figure 30. Formation of Keratin 5-LacZ expression cassette.
130
Figure 31. Sou thern  b lo t analysis of K era tin  5-Lac Z  founder
C. A restriction enzyme digestion map of the Keratin 5-LacZ expression construct 
in pIC20H
D. Southern blot analysis of 10 p.g genomic DNA extracted from the Keratin V- 
Lac Z transgenic founders lines (WA, WB, WD). The DNA was digested with 
BamHI and the 3Kb Lae Z cDNA was radioactively labelled as the probe. The 
Southern blot shows the expected 3 Kb transcript in all three founder lines.
B, s  B, S K
B
Keratin V 5’regulatory sequences 
Lac Z cDNA
Keratin 5 3’ regulatory sequences 
B: BamHI, S: Sail, K: Kpnl
2 Kb
B.
3 Kb
Figure 31.Southern blot analysis of Keratin 5-Lac Z founder lines.
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3.4.2 C o n f ir m a t io n  o f  t h e  r e p o r t e r  a c t i v i t y  o f  k e r a t in  5
CONSTRUCT BY TRANSIENT IN VITRO TRANSFECTION.
In order to confirm the functional capacity of the expression construct, the resultant 
Keratin 5 driven lac Z and empty pK5 vector plasmids were separately transiently 
transfected into a squamous
carcinoma cell line SN161 which is known to express the keratin 5 gene. 48 hours 
post transfection the in vitro cell culture was stained with X-Gal, the substrate for p 
galactosidase activity. The resultant blue-staining cells confirmed p-Galactosidase 
expression and protein activity (Fig 32) in the pK5-acZ activity. The control 
trasnfection with the empty pK5 vector remained negative (data not shown). The 
low number of stained cells was mostly likely due to a low level of transfection 
efficiency.
3.4.3 F o r m a t io n  o f  t r a n s g e n ic  l in e s
The K5-LacZ transgene was excised from the parental vector by a Kpnl restriction 
enzyme digestion and used for pronuclear injection as described in material and 
methods previously. Three transgenic founder mice (WA, WB, WD) were obtained 
(see section 3.2.1.).
Integration of the transgene was confirmed by Southern Blot analysis. Genomic 
DNA was digested with BamHI and then the filter was probed with the entire 3 Kb 
lacZ cDNA. This should produce a 3 Kb internal band on Southern Blot analysis as 
shown in figure 3 IB. The founder transgenic mice were each bred onto a NIH 
background. Screening for the transgene in the founder mice progeny was 
performed by direct staining of the tail tip biopsies with X-Gal.
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Figure 32. Expression of k e ra tin  5-Lac Z  expression con stru c t in SN161 cell 
line.
In order to assess the integrity of the K5-Lac Z expression cassette. The construct 
was transfected using a liposome-mediated method into SN161 carcinoma cell 
line, which is known to express the keratin 5 gene. The cells were then fixed and 
stained for p galactosidase expression. Blue staining cells indicate Lac Z 
expression. The low number of cells expressing the K5-Lac Z construct is due to 
the transient nature of the transfection and poor transfection efficiency.
ê20|liM
Figure 32. Expression of keratin 5-Lac Z expression 
construct in SN161 cell line.
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3 .4 .4  T h e  E x p r e s s io n  p a t t e r n  o f  K e r a t in  5 -L a c  Z  c o n st r u c t  in
ADULT MOUSE TISSUE CORRELATES WELL WITH THE EXPRESSION OF 
THE ENDOGENOUS KERATIN 5 GENE.
Transgenic mice were sacrificed by cervical dislocation and fresh tissues were fixed 
and stained for p-Galactosidase activity. The tissues were then embedded in 
paraffin and 7 pM sections cut. The slides were counter-stained with eosin. In the 
case of the orbital eye sections, after the tissue was stained they were sectioned by 
Dr B Clarke in the Dept, of Ophthalmopathology, Western Infirmary.
The results discussed here are from two out of the three mouse lines studied namely, 
WB and WD.
The epidermis (Fig 33) shows high levels of Lac Z expression. In the section 
shown, the staining appears to be mainly confined to the basal epidermal layer as 
expected (Lersch and Fuchs 1988), although there is some staining in the suprabasal 
layers which could be due to leeching out of the cells of the Lac Z gene product or 
the X-Gal cleavage product. The skin section also shows high levels of expression in 
the bulbs of the hair follicles found deep in the dermis, but which are also epithelial 
in nature and known to express K5. The Lac Z staining pattern seen in the tongue 
(Fig 33) correlates with endogenous keratin 5 gene expression (Dhouailly, Xu et al.
1989). B galactosidase activity is seen in both the basal and parabasal layers of the 
two distinct epithelia making up the filliform papillae found on the upper surface of 
the tongue. From the oral cavity the keratin 5 expression is then seen to continue in 
the basal layers of the epithelium covering the oesophagus continuing down into the 
basal layers of the forestomach (fig 34). This is the expected pattern of the keratin 
gene associated with the basal layer of stratified and pseudostratified epithelium 
(Moll, Dhouailly et al. 1989). Both the control and the keratin 5 transgenic mice
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Figure 33. Expression of keratin 5-Lac Z transgene in skin and tongue.
A) Section of transgenic skin stained with X-Gal and eosin. The X-gal staining of 
the skin from a keratin 5-Lac Z transgenic mouse shows expression in the basal 
layer of the epidermis and hair follicle e) epidermis f) hair follicle. There appears 
to be a quantitative difference in staining within the epidermal section as shown 
with the more intense Lac Z staining in the basal layers being associated with 
staining in the suprabasal compartment. This suprabasal staining pattern could be 
due to diffusion of the gene product or the cleavage product of X-Gal. 
Alternatively it could be produced by residual Lac Z protein activity in 
differentiated keratinoeytes. B) X-gal, haematoxylin and eosin stained epidermis 
from a non-transgenic mouse shows no Lac Z staining.
C) Lac-Z staining of the tongue showing expression in the anterior surface papillae 
(p) and basal layer of the epithelium papilla compared to control tissue (D). This 
Lac Z staining pattern obtained from the transgene expression mirrors the 
expression pattern of the endogenous keratin 5 gene in these tissues.
200|xM B 200nM
D
200nM
200nM
Figure 33. Expression of keratin 5-Lac Z transgene in
skin and tongue.
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Figure 34. E xpression o f K era tin  5-Lac Z  transgene in the  eye and  
gastro in testinal trac t.
A) Histological section of oesophagus and stomach from a keratin 5-Lac Z 
transgenic mouse stained with Lac Z and eosin. Lac Z staining shows 
expression in the basal layer of the epithelium in the oesophagus (o) and 
forestomach (s) compared to a non-transgenic control mouse stained with 
haematoxylin and eosin (B).
B) Histological section of the orbit of the eye (This section was kindly prepared by 
Dr B. Clarke, Dept of Ophthalmopathology, Western Infirmary, Glasgow.) Lac 
Z staining is clearly seen in the proliferative limbic area of the eye. The limbic 
area (La) is found at the junction of the iris (i) and cornea (c): and is thought to 
contain the corneal stem cells. The corneal cells downregulate K5 and K14 as 
they mature and form the avascular cornea, which covers the iris. The mouse 
was brown agouti in colouring, which accounts for the normal dark pigment 
granules seen in the iris. Retina; (r), lens; (1).
A
200pM
C
200pM
B
Figure 34. Expression of Keratin 5-Lac Z transgene in the eye
and gastrointestinal tract.
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F igure  35, E xpression  o f K era tin  5 -L ac Z  tran sg en e  in ep ithe lium  o f sm all 
intestine.
A) Paraffin-embedded histological section of intestinal tissue from K5-Lac Z 
mouse stained with Lac Z. This section shows generalised staining of epithelium in 
all villi (v) including the Peyers Patches. This result may be a staining artefact due 
to the presence of Lac Z-expressing bacteria in the intestine. Therefore, the staining 
was repeated on a whole-mount intestine preparation after removal of intestinal 
bacteria (B). This staining results still indicates Lac Z expression in the epithelial 
lining of the villi. This staining pattern was not seen in the control, non-transgenic 
mouse (C). There is no endogenous keratin 5 expression in this tissue as the 
intestine is lined with simple columnar epithelium.
A. 200 pM
C.
0.5 mm B.
0.5 mm
Figure 35. Expression of Keratin 5 -Lac Z transgene in 
epithelium of small intestine.
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showed Lac Z staining in the hindstomach (data not shown) so no comment could be 
made as to keratin 5 expression pattern in that particular tissue.
In the small and large intestine, there appears to be expression of the keratin 5-Lac Z 
construct in the basal layers of epithelium in these tissue. Although the original 
results were obtained by staining of whole intestine preparations and therefore may 
have included false positive staining from bacterial Lac Z expression in the lining of 
the intestine (Fig 35), the same results were obtained when the intestine was fixed as 
a wholemount and treated with mucin and bacteria removing agent prior to staining 
(Fig 35). The intestinal Lac Z staining pattern was was seen in both transgenic lines 
investigated and are therefore not due to a chromosomal positional effect secondary 
to the site of integration of the transgene but must be due to the absence of the 
regulatory sequences governing cell specific control of gene expression in this 
tissue. The expression pattern appears to be in the simple columnar epithelium 
lining the intestine. The control murine gastrointestinal tract did not show this lac Z 
expression on wholemount staining (Fig 35).
The keratin 5 driven transgene also showed very specific cellular expression in the 
proliferative region of the cornea as expected from the expression pattern of the 
endogenous keratin 5 gene (Fig 34). Other tissue, such as liver, lung, spleen and 
brain were also stained for Lac Z but none was observed.
In conclusion, with the exception of the intestinal staining, the expression of the 
transgene correlated well with the documented endogenous keratin 5 expression 
pattern.
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Figure 36. Expression p a tte rn  of keratin  5 -Lac Z transgene a t d9.5 and  dlO.5 
d u ring  em bryonic developm ent.
A.) d9.5 embryo with first noticeable gene expression as shown by low level |3 
galactosidase staining on the lateral aspect, indicated by the aiTow
B.) dlO.5 transgenic embryo showing K5 expression in first branchial arch (BA), 
nasal pit (NP) and over the developing somites. There is goes expression the 
forelimb (VL). There is a cranial to caudal diminution of gene expression, in 
keeping with the normal embryo developmental gradient C .) K5 expression is 
higher in the ectoderm directly overlying an individual somite compared to 
intervening tissue.
n
1 mm 1 mm
U Somites
Posterior aspect of 
fore limb bud
Figure 36. Expression pattern of keratin 5 -Lac Z transgene
at d9.5 and dlO.5 during embryonic development,
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3 .4 .5  E m b r y o n ic  e x p r e s s io n  o f  k e r a t in  5 -L a c  Z  r e p o r t e r
CONSTRUCT
In addition to examining the keratin 5-Lac Z expression pattern in adult tissue, the 
expression pattern during embryonic development was also documented. Embryos 
from d8 to dl4 postcoitum matings on a mixed (FVB) x (C57B1/6J) genetic 
background were harvested, fixed and stained for Lac Z activity as described 
previously. Initial expression could be detected over the caudal aspect of the lateral 
ridge from d9.5 (Fig 36). The staining was very weak and difficult to photograph but 
was reproducible. No staining was observed prior to this. By dlO.5 the expression 
pattern increased in the ectoderm covering the lateral aspect of the embryo with 
relative sparing of the cranial vault, dorsal and ventral aspects. Marked staining was 
observed over the somites with strong cranial somite staining with dissipation of 
staining occurring in the more caudal somites. This staining is very specific to the 
individual somites and not the intervening cells. Gene expression was easily visible 
in the first branchial arch. In particular, there is strong expression in the mandibular 
branch with weaker staining detectable in the maxillary branch of the first branchial 
arch. There was also a strong focus of expression in the nasal pit. At dlO.5 there was 
also initiation of gene expression at a focus in the proximal central position on the 
fore limb bud (Fig 36).
LacZ expression increased in intensity over the next 24 hours and at d l l .5 the 
expression pattern increased over the lateral aspect of the embryo in a more ventral 
direction, although there was still marked sparing of the dorsal and cranial vault 
regions. The individual somites could still be clearly visualised but there was less 
distinction between somatic and intersomatic regions. The eye and branchial arch 
show increased staining. In addition, the staining in the proximal limb extended 
more distally whilst expression in the proximal aspect of the hind limb bud was
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Figure 37. Expression pattern of Keratin 5-Lac Z transgene at d ll .5  during 
embryonic development.
Two dl 1.5 embryos stained for p galactosidase activity (A) Negative control from 
wildtype litter. (B) K5-Lac Z transgenic embryo showing expression in the first 
branchial arch, somites and in the periphery of the limb buds. The staining was 
more intense in the proximal fore- rather than hind limb. This is not unexpected as 
the fore limb develops earlier and therefore is more advanced developmentally than 
the hind limb. There is also a diminution of Lac Z expression over the anterior and 
posterior aspects of the embryos. The P galactosidase staining in the brain was not 
reproducible within and between the two transgenic lines and may be due to 
retention of the Lac Z gene product or the staining product. Wildtype embryos 
showed no p-galactosidase staining at any point studied during embryogenesis.
Non reproducible staining in brain
1 mm
B
Figure 37. Expression pattern of Keratin 5-Lac Z transgene 
at d ll.5  during embryonic development.
141
Figure 38. Expression pattern of keratin 5-Lac Z transgene at dl2,5 during 
embryonic development.
Transgenic dl2.5 embiyo showing increased gene expression in the maxillary area 
as well as over the fronto-lateral aspect of the embryo. The staining pattern over 
the limbs has increased and extends more distally, although the hind-limb still 
shows delayed expression pattern compared to the fore limbs (A). There is 
noticeable sparing of staining overlying the dorsal and cranial tissue (B) forming a 
sharp demarcation line (D). Staining is marked in the developing maxillaiy hair 
follicles, supra orbital fibrillae and limbic area of the eye (C).
A. B.
ü
1 mm 1 mm
1 mm 1 mm
Figure 38. Expression pattern of keratin 5-Lac Z 
transgene at dl2.5 during embryonic development.
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clearly visible. In the day 11.5 embryo there was also marked staining in the brain. 
This staining pattern was not reproducible and was found intermittently in differing 
embryonic stages in the different founder transgenic lines. Therefore, it is likely that 
this is a staining artefact. As can be seen in the d ll.5  negative control, staining in 
the brain was not seen when lac Z expression was totally absent and it may therefore 
result from trapping of Lac Z in the brain vesicles (Fig 37). The staining in the brain 
may represent trapping of the b-galactosidase gene product or the X-Gal cleavage 
product.
By day 12.5 (Fig 38) there is strong expression over the lateral and anterior aspects 
of the embryo with continued sparing of the areas over the developing central 
nervous system; namely the cranial vault and spinal column.
The maxillary and mandibular regions are highly stained with the whisker follicles 
showing increased K5 expression before the rest of the pelage hair follicles. In 
particular the primordia of the two prominent tactile hair follicles in the supraorbital 
region are clearly defined as well as their two counterparts in the infraorbital region. 
The K5 expression pattern has moved distally along the both limb buds with the 
proximal limb remaining more advanced. Histological sections of the embryo at this 
stage indicate that the Lac Z staining is not limited to the ectodermal tissue but in 
some instances appears to extend into the underlying mesoderm (Fig 39 A, B, C, D). 
In figure 39 marked Lac Z staining can be seen in A) the ectodermal tissue in the 
maxillary area, and the developing whisker hair follicles. Weaker staining due to 
diffusion can be seen in the mesoderm underlying the ectoderm. This does not 
appear to be cellular and may represent a staining artefact ; B) in all the layers of the 
ectodermal tissues in the nasal pit; (C) There is also expression in a distinct region 
of mesoderm near the optic nerve underlying the area adjoining the developing eye, 
in addition to the epithelium coating the posterior aspect of the eye. In particular,
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Figure 39. Histological sections through a stained keratin 5 -Lac Z transgenic 
dI2.5 embryo.
Histological sections through a stained transgenic dl2.5 embryo. There is 
ectodermal expression of the transgene in the nasal epithelium in keeping with the 
adult Keratin 5 endogenous expression pattern (A). In addition, there is expression 
in the maxillary hair follicles and interfollicular ectoderm (D). However, 
expression is not restricted to the ectoderm in the developing skin and Lac Z 
staining is also noted in the underlying mesoderm (B). It is difficult to determine 
whether this mesodermally staining is specific or due to diffusion of the very high 
level of staining seen in the overlying ectoderm. In the developing eye, there also 
appears to be mesoderm expression which appears to be site specific rather than 
due to a staining artefact. (C).
l^asal pit epithelium showing discrete Lac Z staining.
200 uM
200 pM
200 \iM
Very high levels of Lac Z 
staining in the ectoderm.
Presence of low levels of Lac Z 
staining in the underlying 
mesoderm.
Lac Z staining in mesoderm 
surrounding optic stalk.
High levels of Lac Z 
expression in ectoderm and 
developing whisker follicles.
D . 200 m
Figure 39. Histological sections through a stained 
keratin 5 -Lac Z transgenic dl2.5 embryo.
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Figure 40. Expression pattern of Keratin 5-Lac Z transgene at d l3.5 in 
embryonic development.
dl3.5 transgenic embryo showing marked K5 expression over almost entire 
embryonic epidermis with noted sparing of the distal aspects of the developing hind 
limbs and tail There is a high level of gene expression in the pelage hair follicles. 
The epidermis at this juncture is friable and if damaged there is no expression in the 
underlying mesoderm. This suggests that previously described mesodermal Lac-Z 
staining could be due to diffusion of either |3-galactosidase gene product or X-Gal 
cleavage product.
/1 mm
Hind limbs
B 1 mm
Figure 40. Expression pattern of Keratin 5-Lac Z 
transgene at dl3.5 in embryonic development.
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this section would suggest that the K5 expression pattern visualised is specific as the 
staining pattern seems too localised for it to be attributable to leeching out of the lac 
Z gene products causing a staining artifact; (D) Lastly, marked lac Z staining can be 
seen in the mesoderm underlying the main body ectodermal covering at dl2.5. It 
should be noted that although the Lac Z staining is of a much higher intensity in the 
ectoderm, there does appear to be cell specific Lac Z expression in the underlying 
meosderm cells. By day 13.5 (Fig 40) the body is almost completely covered with 
an epithelium expressing keratin 5. However, there is still a noticable diminution of 
Lac Z staining in the caudal region. The pelage hair follicles now express high 
levels of keratin 5 and the skin has become more friable during handling.
By day 14.5 there is generalised expression of K5 over the entire embryonic surface. 
The epithelium is as this juncture very friable and in areas where it has become 
detached there is no underlying Lac Z expression seen. This suggests that the 
underlying mesodermally staining described previously may indeed be due to 
diffusion of transgene product or stain into the lower tissues.
146
4. DISCUSSION
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4.1 DESIGN OF EXPRESSION CONSTRUCTS
4.1.1 MODIFICATION OF RAT OTC cDNA
The ornithine transcarbamylase protein has been highly conserved in evolution, 
especially within its catalytic sites. The human OTC cDNA has 95% amino acid and 
90% DNA sequence identity to the rat OTC. In addition, the rat OTC cDNA 
(Genbank accession No. Ml 1266) used in the current study (Nguyen, Argan et al. 
1986), has 98% homology with the mouse OTC gene. Previous work (Cavard, 
Grimber et al. 1988; Shimada, Noda et al. 1991) has shown that hepatic expression 
of the rat OTC cDNA produces a protein capable of substituting for and correcting 
the enzyme defect in the Spf and OTC deficient mouse models.
Initiation of translation in multicellular eukaryotes has been shown to be influenced 
by five elements in mRNA structure namely 1) the 5’ m7G cap; 2) the primary 
sequences surrounding the AUG codon; 3) the position of the AUG codon; 4) the 
leader sequence, and finally 5) the secondary RNA structure surrounding the AUG 
codon (Kozak 1996). In the rat OTC cDNA the largest open reading frame is 
commensurate with a translation initiation codon at nucleotide position 101 of the 
cDNA present in the surrounding context of G A A G AUG C T G T C T.
Sequence data compilation from 699 vertebral mRNAs (Kozak 1987), and 
experimentally-derived sequences (Kozak 1986; Kozak 1989) suggests that the 
optimum translation consensus sequence surrounding the AUG codon which ensures 
fidelity and efficiency of translation initiation is G C C A/G C C AUG G. In this 
motif the two base pair positions most critical for optimum high level translation are 
the 'A' at position -3 and 'G' at position +4. Their importance is emphasised by their 
highly conserved nature within different genes (Kozak 1986). As shown previously, 
although the OTC cDNA conformed to the consensus optimum Kozak sequence at -
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3 base position, the nucleotide at +4 position was a cytidine. Therefore, site-directed 
mutagenesis was used to convert the nucleotide at position +4 to a ‘G’, in an attempt 
to increase the translational efficiency of the rat OTC cDNA from an ectopic 
promoter. However, a more recent study (Kozak 1997) called into question the 
effect of including this transversion event, suggesting that the enhancement in 
translation conferred by a 'G' at position +4 is lost when the subsequent base is a 'U'. 
Unfortunately this is indeed the case in the rat OTC cDNA and thus this 
modification may indeed be neutral if not detrimental to translational efficiency.
This alteration in nucleotide sequence at position +4 has the effect of changing the 
second amino acid in the leader sequence of the OTC protein from a leucine to a 
valine. The evidence that this amino acid substitution is not detrimental to enzymic 
activity is seen most clearly in the creatine kinase transgenic mouse lines, where 
high levels of muscular OTC activity were assayed compared to background levels 
found in non-transgenic skeletal muscle. Since the enzyme produced in the 
transgenic skeletal muscle cells, which can only have originated from the transgene, 
was capable of OTC, it can be assumed that the recombinant polypeptide is able to 
form the normal active OTC homotrimeric configuration required.
It is difficult to access whether truncation of the 5’ and 3’ untranslated sequences in 
the OTC^^^ gene construct had any beneficial or detrimental effect on resultant 
OTC production in the transgenic animals since expression constructs containing the 
full-length sequences were not made. The rationale for shortening the 5’ 
untranslated region from the OTC cDNA was based on the observation of an 
inhibitory effect on translation due to secondary structure formation in the long 
5’UTRs of other genes (Kozak 1986; Manzella, Rychlik et al. 1991; Yukht, Davis et 
al. 1995). Although the 3’ UTR of certain genes has been associated with a
translational enhancer effect (Lorenzini and Scheffler 1997; Wang, Browning et al.
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1997), in many genes this region may contain tissue-specific translational inhibitory 
motifs for mRNA degradation (Lai and Posakony 1997). The 3’ UTR of the OTC 
gene construct was therefore limited to 8 bp following the OTC translation 
termination codon plus either the SV40 3 ’ non-coding region or, in the case of the 
keratinocyte -specific construct, the endogenous K5 3’UTR. Once again both the 
results obtained from the Northern blot as well as in the direct OTC activity seen in 
the creatine kinase and albumin-OTC^^° transgenic mice would suggest that neither 
of these alterations had an adverse effect either on transcription or translation of the 
rat OTC cDNA in hepatic or skeletal muscle, although this was not directly 
investigated.
4. L 1.1 CREA TINE KINASE DRIVEN O T C  EXPRESSION CASSETTE 
The targeting of somatic gene therapy to muscle cells has been under investigation 
for almost a decade, since it was first noted that direct intramuscular injection of 
naked DNA resulted in plasmid uptake and gene expression (Wolff, Malone et al.
1990). Due to the long survival and low replicative index of muscle cells, this 
ectopic gene expression could persist with no requirement for vector replication for 
up to 19 months despite being targeted to a post-mitotic cell (Wolff, Ludtke et al. 
1992). The classical example of muscle cell targeted gene expression has been the 
use of human dystrophin to supplement a mouse dystrophin deficient model 
(Acsadi, Dickson et al. 1991), or the expression of utrophin to counter the effect of 
dystrophin deficiency in a similar murine model (Rafael, Tinsley et al. 1998; 
Tinsley, Deconinck et al. 1998). Both the utrophin and dystrophin gene products are 
normally expressed in skeletal muscle and thus it can assumed a priori that the 
machinery required for expression and translation of the recombinant forms of these
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proteins is present in muscle fibres. This is especially pertinent as this study 
involved the expression of recombinant protein not normally expressed in muscle 
cells. A recent study combined both fluorescence in situ hybridisation and 
immunohisto chemistry in monitoring the presence of introduced genes and the 
expression of their gene products (Gussoni, Wang et al. 1996). Their results 
suggested that the efficiency of gene transfer is affected not only by gene delivery 
but also by cellular controls on gene expression.
Proof of principle that dystrophin deficient muscular phenotypes can be ameliorated 
by expression of utrophin was established using transgenic technology. More 
recently, targeting of expression vectors has utilised adenoviruses injected directly 
into muscle as a means of increasing transfection efficencies. This approach has 
shown good results in expressing genes whose products supplement and correct an 
abnormal muscular phenotype (Gilbert, Nalbanoglu et al. 1998; Greelish, Su et al. 
1999). In addition, an intra-muscular adenovirus approach has successfully been 
used in the treatment of canine Haemophilia B (Herzog, Yang et al. 1999). A series 
of intramuscular injections caused partial correction of the whole blood clotting time 
in a canine model for Christmas disease.
An alternative method for the investigation of muscle-directed gene therapy is the
culture and transfection of myoblasts in vitro followed by their injection into adult
muscle. Following myoblast transplantation the donor nuclei appear to be either
surrounded by host nuclei or they fuse into the preexisting multinucleated myofibers
that are vascularised and innervated (Gussoni, Wang et al. 1996). This method of
myoblast transplantation has been shown to be amenable for the expression of both
endogenous mucle proteins such as dystrophin (Gussoni, Pavlath et al. 1992) as well
as exogenous recombinant protein such as growth hormone (Dhawan, Fan et al.
1991), and may well form a reliable vehicle for the systemic delivery of
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recombinant proteins. One major drawback to this method of gene transfer is that 
myogenic cells have a limited life span in vitro and, in comparison to skin 
fibroblasts, this limits their clinical application in cell replacement. Interestingly one 
group recently immortalised primary myogenic cells using SV40 large -T  antigen, 
which could be excised by means of the Cre-lox recombination system (Berghella, 
De Angelis et al. 1999). Although using a xenotransplantation model, no tumour 
formation was seen after transplantion of the floxed myogenic cells, they did only 
report >90% efficiency of excision of the large T antigen after application of Cre 
protein which would make transformation of the cells a plausible and worrying 
proposition.
In the current study the muscle-directed gene product was not normally expressed at 
this site and therefore it was of interest that muscle cells contain the post 
translational machinary necessary for formation of a catalytically active ornithine 
transcarbamylase homotrimer. In fact, the QE founder line produced a higher OTC 
activity in muscle than was normally found in hepatic tissue and it is worthy of note 
that this over-expression had no overt pathological sequelae for the mouse.
Despite the high level of recombinant OTC activity detected in vitro from skeletal 
tissue, no correction of the Spf or phenotype was observed when the
transgenic mice were bred onto these OTC deficient backgrounds. In addition, there 
was no statisitical amelioration of the plasma ammonia level noted in these OTC 
deficient/transgenic mouse crosses. Taken together, these results suggest that the 
OTC enzyme activity present in the skeletal muscle was not accessible to the urea 
cycle.
It is difficult to explain the finding that the ‘Q’ lines on a Spf background should
have a higher plasma ammonia level than the same transgene on a sparse fur^^^
background. In addition, there appears to be a reduction of plasma ammonia levels
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in the QA line compared to the QE line despite a lower level of OTC activity in QA 
skeletal muscle. This could indicate that the plasma ammonia level is not a reliable 
metabolic indicator of OTC activity, although in all other respects the plasma 
ammonia levels correlated well with hepatic OTC activity.
The results from the ammonia levels in the individual mice in the Spf^^^ group 
indicate that only three out of the eight mice had an elevation in plasma ammonia 
levels outwith the range found in the wildtype mice. The number of mice analysed is 
each group was small especially as the plasma ammonia levels showed an overlap in 
values between the control wildtype and affected groups. If more creatine kinase- 
OTCMOd mice had been analysed, it would have been easier to clarify whether there 
was no real improvement in ammonia levels or whether there was an occult 
improvement masked in statistical terms by the overlap in ammonia values.
It should be noted that the OTC enzyme assay used was a whole tissue in vitro 
assay, and therefore it does not rule out the possibility that the OTC peptide in the 
myocyte was not being correctly targeted to the mitochondrial membrane in vivo. 
Thus, there is the possibility that although the OTC enzyme is catalytically active it 
is sequestered in the wrong sub-cellular compartment due to the intentional leucine 
to valine missense mutation engineered into the recombinant OTC^^° protein. This 
argument could account for the lack of phenotypic or metabolic correction of the 
Spf and Spf^^^ mice seen despite the presence of high OTC activity in skeletal 
muscle.
Evidence refuting defective peptide targeting as a possible explanation of the
inability of OTC activity in the muscle cells to correct the OTC deficient phenotype,
comes from two distinct sources. Firstly from sequence data which indicates that the
first amino acid in the leader peptide is not highly conserved between species and
indeed valine, the amino acid formed through the site-directed mutagenesis, is
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actually a normal polymorphic amino acid variant at this site in the leader peptide 
(Tuchman, Morizono et al. 1995). Secondly, evidence from deletion studies 
highlight the mid portion of the leader sequence and in particular the presence of 3 
highly conserved arginine residues as being the essential region for the targeting and 
transportation of polypeptide into the mitochondrial matrix rather than the amino 
terminal amino acids (Horwich, Fenton et al. 1984; Horwich, Fenton et al. 1985; 
Horwich, Kalousek et al. 1986)].
A more likely explanation for the inability of high levels of skeletal muscle targeted 
OTC activity to correct the metabolic and phenotypic abnormalities in Spf and 
Spf^^^ mice is the absence of one of the substrates for the catalytic reaction to 
occur. There is little evidence that CPS I is expressed in skeletal muscle cells. If this 
is indeed the case, then despite ammonia being a highly diffusible substrate, no 
carbamyl phosphate would be produced in skeletal muscle. Carbamyl phosphate, as 
mentioned previously, is a substrate for OTC which is normally produced within the 
mitochondrion and it is highly likely that it will not diffuse over large distances. In 
the liver any excess carbamyl phosphate which leaves the mitochondrion is quickly 
metabolised in the pyrimidine pathway. If carbamyl phosphate was absent in 
myocytes even in the presence of high levels of OTC there would be little effect in 
lowering plasma ammonia levels in the mice as the substrate for ornithine 
transcarbamylase activity would be absent. This is certainly appears to be the case in 
all the creatine kinase driven transgenic lines; despite high levels of gene expression 
and OTC activity in skeletal muscle of transgenic animals, there is no difference in 
the plasma ammonia levels from the control, non- transgenic sparse fur and sparse
f ^ r ^ s H
Although at first glance, muscle cells are an unlikely target for the expression of
hepatic metabolic enzymes, and despite the failure of OTC^^° recombinant protein
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expressed in skeletal muscle to correct the OTC deficiency in Spf mice, the 
underlying hypothesis has been proven recently. Harding et al (Harding, Wild et al.
1998) produced transgenic mice in which the phenylalanine hydroxylase gene 
(PAH) was targeted to skeletal muscle under the transcriptional control of the 
creatine kinase promoter. The transgenic mice were then bred to PAH hepatic- 
deficient mice. The resulting mice, which had no endogenous hepatic PAH activity 
but did have exogenous skeletal muscle-specific PAH activity, showed an 
underlying basal hyperphenylalaninaemia. The serum phenylalaninaemia in these 
mice showed a marked decrease when further supplemented in the diet with 
tetrahydrobiopterin (BH4) a required cofactor for PAH. In this system, compared to 
the OTC metabolic pathway, the substrate for PAH namely phenylalanine is highly 
diffusible in plasma and is indeed the direct cause of the clinical pathology found in 
PAH deficient patients. It is through monitoring plasma levels of phenylalanine that 
the clinical diagnosis is made.
It could well be envisaged that in order for creatine kinase-OTC^^^ mice to utilize 
the skeletal OTC activity effectively a double transgenic with the CPS I gene also 
under the control of the creatine kinase promoter would be required. It is certainly 
within the realms of possiblity to foresee the use of plasmid or viral vectors with 
both transcriptional units as a method of delivery for both recombinant proteins. In 
addition, it would also be possible to express both recombinant proteins in 
myoblasts in vitro to check for their catalytic activity, and to subsequently transplant 
the myoblasts in adult muscle. These are certainly avenues worthy of future 
consideration.
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4 .1 .L 2  Th e  l iv e r  is  a  w ell  r e s e a r c h e d  t a r g e t  o r g a n  f o r
SUPPLEMENTIVE ENDOGENOUS GENE EXPRESSION
The fact that the liver is a major target organ for supplementive gene therapy lies 
both in the number of clinical disorders attributable to hepatic pathology, and in the 
hepatotrophic affinity of the viral gene expression vectors used in gene therapy 
studies. For these reasons, models involving gene expression studies in the liver 
have concentrated on supplementation of endogenous hepatic genes rather than the 
expression of exogenous genes as in the case of muscle or skin targeted gene 
expression. Due to the natural hepatic affinity of adenoviruses, recombinant forms 
of these viruses, when injected intravenously, can cause high levels of hepatocyte 
transfection and gene expression, allowing the potential treatment of a large number 
of gene disorders (Patijn and Kay 1999). The recent advances in modifying 
recombinant adenoviral vectors (Mortal, Parks et al. 1998), so that they are devoid 
of all viral encoding sequences, are hoped to decrease the inflammatory responses 
induced by classical adenoviruses which limit the duration of their gene expresion 
and thus their clinical potential. However, there may also be an immune response 
dependent on the recombinant protein expressed (Mortal, Parks et al. 1998). The 
power of the intravenous injection route is that it lends itself directly to clinical 
application. Evidence that even the application of a single intravenous injection can 
have a benefical effect on a murine model for glycogen storage disease type II is 
potentially very exciting (Amalfitano, McVie-Wylie et al. 1999). Similarly, 
although surgically invasive, high levels of hepatic gene expression can also be 
achieved by portal vein infusion of either retroviral or adenoviral recombinant 
vectors (Patijn, Terpstra et al. 1998). This method of intra-biliary administration 
(Peeters, Patijn et al. 1996) has the advantage of reducing the transfection of non-
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hepatic cells, which also occur with recombinant viral administration by the intra 
venous route. Even when administered by intramuscular injection in an attempt to 
target muscle cells, recombinant adeno-associated virus was found to be expressed 
and have a therapeutic effect in the liver due to dissemination of the virus in the 
blood (Daly, Okuyama et al. 1999). This study also highlights a danger in that it 
indicates that although the route of administration was designed to be 
muscle-specific, the hepatic affinity of the expression vector changed the target 
organ, which could have potentially hazardous implications.
An alternative means of targeting recombinant protein to liver is by culture and 
transfection of the hepatocytes ex vivo and then seeding of the genetically-modified 
hepatocytes back into the patient. This has been successfully achieved in the clinical 
setting for hypercholesterolaemia (Grossman, Raper et al. 1994; Grossman, Rader et 
al. 1995) and well as murine model systems (Overturf, Al-Dhalimy et al. 1996; 
Overturf, Al-Dhalimy et al. 1998). Although the use of autologous hepatocytes in 
these studies circumvents problems with immune rejection, the culture of any cell 
type in vitro can induce deleterious genetic cellular changes, which have detrimental 
consequences after the hepatocytes have re-populated the liver.
In the current study the albumin driven-OTC^°^ transgene was initially devised as a 
positive control for expression of the rat OTC^°° cDNA in the endogenous hepatic 
tissue. Therefore, it was counterintuitive to find that expression of the albumin 
driven expression construct did not correct the phenotype of either the Spf or the 
gpfASH QYQ deficient mice.
4 .1 .2  P a r t ia l  m e t a b o l ic  c o r r e c t io n  o f  t h e  sp a r se  f u r
PHENOTYPE BY THE ALBUMIN DRIVEN RAT OTC CDNA TRANSGENE.
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Although the albumin transgenic lines did not correct the phenotype of the Spf and 
SpfASH there does appear to be a slight improvement in OTC metabolism as 
measured by plasma ammonia levels. Using plasma ammonia as an intermediate 
metabolic index for OTC supplementation, transgenic lines KG and KE showed a 
significant decrease in plasma ammonia levels on a Spf background. Furthermore, 
the ammonia levels in these lines could not be differentiated from those in the 
wildtype mice. Although, the KD line was not found to have a statistically 
significantly lower plasma ammonia level, the plasma ammonia values appeared to 
be following the trend of the other two transgenic lines in having a lower and 
smaller spread of values. This trend was further highlighted if all the ‘K’ line mice 
were grouped together, as a significant difference in ammonia levels was found not 
only on the Spf but also the Spf^^^ background. The KD group contained the fewest 
mice and it is probable that if this group was expanded the difference in plasma 
ammonia levels may have reached a higher statistical significance. The small 
number of animals in this group particularly weakens the statistical significance, as 
there is a marked overlap in plasma ammonia levels between the control wildtype 
and OTC deficient groups of mice. This overlap necessitates a higher statistical 
power to separate these two sets of data into two statistically significant groups, 
which would in turn translate into large numbers of animals in each group. 
Alternatively, as opposed to plasma ammonia levels, it could be argued that a better 
index of metabolic correction would have been urinary orotic acid levels as this has 
been found both in the clinical setting and in other murine studies to correlate well 
with hepatic OTC activity. However, due to technical difficulties in collecting and 
analysing 24 hour murine urine samples it was not possible to undertake this 
analysis. Although, it would have been interesting to compare the results obtained 
from both the orotic acid urine and plasma ammonia levels.
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Having obtained results suggesting a partial metabolic correction of both OTC 
deficient mouse models, it was hoped that an increase in direct OTC hepatic activity 
would correlate with the improvement in plasma ammonia levels. Unfortunately 
when the OTC activity was measured in hepatic tissue only the KG transgenic line 
showed a significantly increased OTC activity when bred onto a Spf background, 
compared to the endogenous hepatic Spf OTC activity. This increase in the KG line 
was equivalent of a 6% increase in total hepatic OTC activity, bringing the total 
activity to 21% of wildtype. However, when all the ‘K ’ line mice on a Spf 
background were pooled they showed a significantly increased OTC activity 
compared to endogenous Spf OTC activity. Studies (Cavard, Grimber et al. 1988; 
Stratford-Perricaudet, Levrero et al. 1990) have suggested that the hepatic OTC 
activity must be in the region of 50-80% of normal to correct the phenotype of the 
Spf mice. As the hepatic OTC activity in the albumin-OTC^^^ mice was still well 
below this value, it is not surprising that the transgene failed to correct the mouse 
OTC deficient phenotype.
On the Spf^®  ^background the ‘K’ lines did not show a significant increase in OTC 
activity. The median activity rose from 5 to 8% of the wildtype hepatic value. 
Interestingly, although one group found an increase of hepatic OTC activity to only 
12% of normal was sufficient to correct the Spf^^^. phenotype, this transgenic line 
was also found to increase in intestinal OTC activity to 27% normal (Murakami, 
Takiguchi et al. 1989). It is difficult therefore to determine if it was the increase in 
OTC activity in the liver or the small intestine that had most influence on the 
correction of the Spf^ ®^  ^ phenotype. It may well be that the small intestine OTC 
activity would counter the low hepatic activity in correcting the Spf^®  ^phenotype. 
The Northern blot results from one of the current albumin-OTC^°^ transgenic lines 
showed a reasonable level of expression of the transgenic rat OTC transcript which
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was as expected hepatocyte-specifîc and therefore this transgene would have no 
effect on intestinal OTC activity.
Although the recombinant OTC^°° protein produced high levels of OTC activity in 
skeletal muscle cells, the increase in hepatic OTC activity was marginal. The use of 
the identical OTC^^° cDNA in the formation of both the creatine kinase and 
albumin-OTC^°° constructs eliminates the possibility of a PCR-induced mutation 
in the OTC^*^° cDNA accounting for this low enzyme activity in the liver. 
However, from the data given, it is not possible to exclude the possibility that the 
recombinant OTC^°^ protein has an intrinsically lower catalytic activity compared 
to the endogenous hepatic protein, as the levels of mRNA were also higher in the 
creatine kinase OTC^^^ transgenic lines. In addition, the information from the 
creatine kinase transgenic mice also precludes the alteration of the first amino acid 
of the leader peptide sequence affecting OTC activity.
The first possible hypothesis to account for this difference in OTC activity between 
the hepatic and muscle transgenic mice could be that the albumin promoter/enhancer 
is a relatively weaker promoter compared to the creatine kinase promoter. From the 
Northern data there does appear to be a lower quantity of transcript in the liver of 
the hepatic driven transgenic mice than in the skeletal muscle of the creatine kinase 
driven transgenic mice. However, albumin is one of the most predominant proteins 
in plasma and the gene shows a high level of transcriptional control in gene 
expression. It has been used to drive high expression of growth hormone in another 
transgenic mouse model (Pinkert, Omitz et al. 1987) and therefore it would be 
surprising, but not implausible, for the albumin to be the weaker promoter. 
However, it is more plausible that all the endogenous regulatory elements, which 
allow high transcription level in vivo may be absent from the 2.3 Kb promoter/ 
enhancer elements present in the albumin-OTC*^*^^ expression construct.
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A more technically based explanation is that the creatine kinase driven OTC 
transgenic mice may have integrated a higher number of copies of the OTC 
transgenes. There is no data comparing the transgene copy number in the different 
transgenic lines. The number of transgenes integrating into the genome during 
pronuclear injection can vary greatly from one to thousands of copies of the 
transgene and an increase in transcription levels in the creatine kinase-OTC'^^^ 
transgenic mice may be due to the presence of a high number of the transgene 
integrations. Future work must include a Southern blot to estimate the copy numbers 
in all the transgenic lines produced.
Another plausible explanation could be that the albumin promoter is directing 
recombinant OTC^^*^ gene expression to the subset of hepatocytes that are not 
intricately involved in the urea cycle pathway. The urea cycle predominately occurs 
in the periportal and not in the perivenule areas of the hepatic lobule. Again 
although a plausible explanation to account for the lack of murine phenotypic 
correction in vivo, the OTC assay employed measured total OTC activity from 
whole hepatic tissue and therefore would have detected OTC activity in both the 
hepatic compartments, periportal and perivenule. The lack of an increase in total 
hepatic OTC activity would suggest that in vivo there is no pool of sequestered 
recombinant OTC^°^ that is not accessible to the urea cycle. The use of tissue in 
situ hybridisation studies using the SV40 polyadenylation sequence as the probe 
could determine the expression pattern of the albumin-OTC^^^ transgene at a 
cellular level.
One further theory, which may have important implications despite many published
examples of correction of the OTC deficient mouse models, is the possibility that
endogenous mutant polypeptides produced in the heptocytes of Spf or Spf^^^
animals may have a dominant negative effect via a protein-protein interaction with
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the recombinant polypeptide. As discussed in the introduction, ornithine
transcarbamylase functions as a homotrimer. The translated OTC polypeptides are
transported into the mitochondrion where the leader peptide is cleaved off and the
peptides are joined to form the enzymatically active OTC homotrimer. In both OTC
deficient mouse models, endogenous OTC mRNA is produced, although in the
Spf^^^ hepatocytes the level is 10% that of wildtype OTC mRNA. Thus, in both the
Spf and Spf^®  ^ mice OTC polypeptides with a missense mutation are being
produced. When the albumin-OTC^^° transgene is bred onto these mutant OTC
lines, two populations of OTC polypeptides will be present within the same
hepatocyte, namely the recombinant OTC^^^ polypeptide and a mutant form from
the endogenous gene. Therefore, it is possible to postulate that the endogenous
mutant OTC polypeptides may have a dominant negative effect by forming a
homotrimer with the transgenic wild type OTC polypeptides and thereby decrease
the formation of functional OTC protein. This is never a normal physiological
possibility as in female heterozygotes, due to X chromosome inactivation, each
hepatocyte expresses either the normal or the mutant but not both forms of the OTC
polypeptide. This possible dominant negative effect could account for the small
increase in OTC activity despite the presence of high levels of transgenic mRNA.
Evidence that this is a real possibility and not just supposition, was provided in a
recent study (Morsy, Zhao et al. 1996) in which higher levels of adenoviral driven
OTC expression was required for a lower OTC activity in cell lines with
endogenous aberrant OTC production than cell lines with no endogenous aberrant
OTC activity. Western blotting confirmed the presence of equal amounts of OTC
protein formation but lower OTC activity in a hepatocyte cell lines derived from Spf
mice compared to a OTC non-expressing Cos cell line. In addition, this group
studied hepatocytes from two patients with OTC deficiency, one had a missense
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mutation in exon 3, which did not affect protein expression but totally abolished
protein activity, whilst the other patient had no protein on Western blot which
correlated with no enzymatic activity (mutation unknown). Morsey et al (Morsy,
Zhao et al. 1996) found that despite equal levels of adenoviral mediated
recombinant OTC expression in both these cell lines, the OTC activity was
substantially inhibited in the hepatocyte cell expressing a mutant form of OTC.
Although a valid possible explanation, the results from the Spf^®^ mice in this study
would suggest that this is not the total answer. The Spf^^^ hepatocytes have been
shown to have only 10% of normal OTC mRNA levels in keeping with 5% of
normal OTC activity. Therefore, assuming this level of OTC mRNA is translated at
the same level as wildtype, there should be less aberrant OTC polypeptide available
in the Spf^^^ hepatocyte compared to the sparse fur hepatocyte to form a dominant
negative effect. The result of this would be that the albumin-OTC^*^^ transgene
should increase the level of hepatic OTC activity in the Spf^^^ hepatocyte
proportionately higher than the Spf hepatocyte. This was not seen in this study
although the numbers of mice for the Spf^^^ / transgenic crosses were low.
If, however, this dominant negative effect of diminution of exogenous OTC activity
in the presence of endogenous aberrant protein formation holds true, it could be
clinically important. It would suggest that hepatocyte-targeted OTC gene therapy
might be most relevant only for a subset of patients with mutations causing an
effective null allele and therefore producing no endogenous protein. In the human
disease about 74% of all mutations found to date are nucleotide substitutions
causing missense or nonsense alterations, causing a diminution in OTC protein
activity but most patients do conserve some residual OTC activity suggesting the
presence of mutant protein. Therefore, it is conceivable that the majority of patients
with OTC may not be suitable for a direct hepatic OTC replacement approach unless
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high levels of the normal protein could be achieved. In addition, it would also 
highlight the importance of pursuing means of expressing ectopic OTC in tissues, 
other than liver, in which endogenous aberrant OTC protein is absent.
4.1 .3  P a t h o p h y s io l o g y  o f  t h e  S p a r se  f u r  a n d  s p a r se  f u r "^®**
MOUSE MODELS
It is of interest that the phenotype of the naturally occurring OTC deficient mice 
predominantly involves ectodermal tissue, as is highlighted by the terms used to 
describe them namely, sparse fur (Spf) and sparse fur and abnormal skin and hair 
(Spf^®^). Although these mice have been shown to have allelic mutations in the X- 
linked OTC gene identical to that describe in the equivalent human condition, the 
ectodermal phenotype found in the OTC deficient mice has not been described as a 
manifestation of the human presentation of OTC deficiency. The skin and hair in 
either OTC deficient males or obligate female carriers is normal, although the 
biochemical abnormalities are indeed identical to those described in the mouse 
models.
Argininosuccinicaciduria is caused by a defect in a urea cycle enzyme, 
arginosuccinase. Clinical manifestations include sparse hair and skin lesions, in 
association with other phenotypic changes such as mental and physical retardation 
and liver enlargement. This condition is due to the deficiency in argininosuccinase 
(Omin *207900), the cytosolic enzyme preceding OTC in the urea cycle and 
responsible for the production of arginine. The degree of ectodermal involvement 
appears to depend on the total protein intake of the patient (Coryell, Hall et al. 
1964), ‘Normalisation’ of the hair shafts has been shown with the commencement 
of a low protein, arginine supplemented diet (Batshaw, Roan et al. 1980). This
evidence associating low arginine levels with pathological ectodermal features, and
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the correction of these features with supplementation of arginine, suggest that sparse 
hair and skin lesions can result directly from low levels of arginine.
In the Spf and Spf^^^ OTC deficient mouse models, the characteristic phenotype 
may result indirectly from an arginine deficiency rather than directly as a result of 
OTC deficiency. Although this possibility certainly does not preclude the use of 
phenotypic scoring of the OTC deficient mouse as a correlate of OTC deficiency, it 
would however temper caution on relying on this solely as a direct correlate of 
hepatic OTC values as it may be more highly influenced by small intestine OTC 
activity. Evidence for this can also be seen in the study by Jones et al (Jones, 
Grompe et al. 1990) in which an increase in OTC activity in the small intestine 
alone was sufficient to correct the phenotype of Spf mice. The OTC activity in the 
small intestine is thought to metabolise excess nitrogen and the citrulline produced, 
when transported to the kidneys, is important in the de novo production of arginine. 
Previous transgenic studies (Cavard, Grimber et al. 1988; Jones, Grompe et al. 
1990) using the enodgenous OTC promoter would have increased the small 
intestinal as well as the hepatic OTC activity although small intestinal OTC activity 
is less commonly commented on. In the current study the albumin-OTC^^^ 
construct is hepato-specific and would have no effect on intestinal OTC activity, 
which may also have contributed to the lack phenotypic correction if this theory is 
true.
4.2 THE SKIN IS AN EXCELLENT TARGET ORGAN FOR 
EXOGENOUS RECOMBINANT PROTEIN EXPRESSION
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The skin is an excellent tissue as a target for gene therapy and as an organ for basic 
research studies on gene transfer and expression. It is easily accessible, monitored, 
has a good blood supply and has been shown to have the post translational 
machinery required to express many exogenous genes (Trainer and Alexander 
1997). Unlike the two other important tissues already discussed namely muscle and 
liver, the skin has been used primarily as an organ in which to express recombinant 
protein which has a more widespread function rather than the supplementation of an 
protein defective in the skin itself. The major limitation in treatment of intrinsic skin 
pathologies is their generalised nature, necessitating treatment of the entire skin. In 
addition, the keratin mutations causing epidermolysis bullose simplex (Korge and 
Krieg 1996) and epidermolytic hyperkeratosis (Bickenbach, Longley et al. 1996) 
tend to be dominant and therefore difficult to rectify by supplementive gene therapy 
due to the possibility of a dominant negative effect. However, the epidermis has 
been used to express gene products important in many differing fields. Applications 
have included the expression of insulin-like growth factors (Bickenbach, Longley et 
al. 1996) and epidermal growth factors (Bickenbach, Longley et al. 1996) to 
promote wound healing; the expression of coagulation cascade factor IX 
(Bickenbach, Longley et al. 1996) and growth hormone (Wang, Zinkel et al. 1997) 
in systemic disorders; antigenic epitopes (Raz, Carson et al. 1994) or active 
immunological gene products as genetic vaccines or to ellict a immunomodulatory 
effect towards neoplasm (O'Malley, Chen et al. 1995; Chong, Hutchinson et al. 
1996).
Kératinocytes can be classified into three types with respect to their clonal
proliferative capacity: (i) holoclones or stem cells with extensive growth capacity:
(ii) differentiated paraclones with a limited growth capacity; and (iii) intermediate
meroclones which are thought to constitute long lived progenitor cells in vivo
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(Barrandon and Green 1987). Ideally, epidermal gene targeting would involve 
integration of an exogenous gene into the genome of holoclone kératinocytes, whose 
progeny form both a self-renewing population of stem cells allowing long-term 
expression, and a more differentiated suprabasal population of kératinocytes. It is 
for this reason that it is the regulatory sequences from the basally expressed keratins, 
namely keratin 5 and 14 have been focused on to drive expression of exogenous 
gene products. In particular, the regulatory elements of the keratin 14 gene has been 
used extensively for delivery of many growth control molecules (Wysolmerski, 
Broadus et al. 1994; Wang, Zinkel et al. 1997).
It was due to this potential for both basic and preclinical studies in the skin that the 
bovine keratin 5 regulatory sequences (obtained from Manfred Blessing (Blessing, 
Nanney et al. 1993) were chosen for study in the current work. The keratin 5 gene 
was examined for its ability to regulate exogenous gene expression in both a tissue 
and cell specific manner. This was done means of linking the regulatory sequences 
to a reporter p galactosidase gene.
4.2 .1  KERATIN 5 MINIGENE EXPRESSION CASSETTE DOES MIMIC 
ENDOGENOUS K 5  EXPRESSION IN THE ADULT MOUSE
The expression data obtained using the bovine keratin 5 minigene driven P
galactosidase transgenic lines mimics the expected expression pattern of the 
endogenous keratin 5 gene. This pattern of expression was identical in the two 
founder transgenic lines investigated, suggesting that the expression pattern was 
dictated by the K5 regulatory gene sequences rather than being influenced by 
transgene integration site.
In adult transgenic mice X-Gal staining showed high levels of pgalactosidase 
activity in the basal, proliferative layers of the epidermis and well as in the root bulb
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of the hair follicles which lies deep in the dermis (Lersch and Fuchs 1988). There 
does appear to be some staining in the epidermal suprabasal layers which is 
unexpected as kératinocytes down-regulate K5 and K14 in this area and up-regulate 
the keratin co-expression pair K1 and KIO (Fuchs and Green 1980; Moll, Franke et 
al. 1982). This suprabasal Lac Z staining could be an artefact caused by leeching of 
the X Gal into the neighbouring cells due to the high levels of Lac Z activity or 
simply that residual Lac Z protein remains after differentiation and suprabasal 
migration. The p-galactosidase cDNA used in the formation of the expression 
cassette did not include a nuclear localisation sequence (NLS) which would have 
reduced the non-specific staining of the lac Z gene product out of the cell. Another 
group (Ramirez, Bravo et al. 1994) using a similar bovine keratin 5-lac Z expression 
also found suprabasal expression of the Lac Z which did not correlate with 
endogenous keratin 5 gene expression. This group were also using E, Coli Lac Z 
with no NLS.
Interestingly though, there is the suggestion of a quantitative difference in the 
staining pattern within different areas of the basal layer of the epidermis. This may 
correlate with differing degrees of ongoing proliferation/differentiation in the 
epidermis. Hair growth, for example, which is also associated with interfollicular 
growth, occurs as waves of proliferation in a cranial to caudal direction. Staining of 
other stratified epithelia in the tongue (Dhouailly, Xu et al. 1989) and oesophagus 
indicated a lower degree of lac Z expresion and a more distinctly basal pattern with 
no suprabasal staining. In the transgenic mice the epithelium of the forestomach 
(Schweizer, Rentrop et al. 1988) also stained in the basal layer indicating keratin 5 
expression. In contrast the epithelium of the hindstomach stained with X Gal in both
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the transgenic and the control mouse. This background staining precluded any 
comment being made regarding keratin 5 expression at this site.
Cellular proliferation in the cornea of the eye occurs at the junction of the iris and 
the cornea in a region called the limbic area. This area is ideal for proliferation as its 
is highly vascular. The cells in the cornea then leave the proliferative area and 
differentiate over the region of the cornea overlying the pupil. Any vascular 
elements, vital for proliferating cells, in this region would severely affect vision. 
The transgenic mice show a very discrete expression pattern limited to the limbic 
region in keeping with the normal endogenous expression of keratin 5 and its down- 
regulation in the more differentiated comeal cells (Fig 30), which then co-express 
the suprabasal keratins K3 and K12 (Schermer, Galvin et al. 1986).
Interestingly, it is known that patients with the severe form of Epidermolysis bullosa 
simplex due to mutations in the keratin 5 gene can have oesophageal and comeal 
problems in addition to the severe epidermal blistering problems that it normally 
associated with the condition.
The only tissue in which expression of the transgene deviated from that of the 
endogenous gene was in the basal layer of the intestinal epithelium, where the 
endogenous gene is not expressed, but a low level expression pattern of the 
transgene was detected. The original staining was noted in paraffin embedded 
sections of the small intestine. However, the small intestinal lining is coated with 
mucin and colonised with bacteria that may themselves have |3-galactosidase 
activity. As mentioned previously, the cDNA sequence of the p galactosidase used 
in the keratin 5 expression construct was originally cloned from E. Coli. Therefore, 
it was necessary to confirm this staining result using small intestine that had been 
treated to remove the mucin and bacterial coating. A whole mount of the small
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intestine was treated with an anti-mucogen and stained for P-galactosidase activity. 
The lacZ-staining pattern in the intestinal epithelium was also observed in whole 
mount preparation suggesting that it was intrinsic to the intestinal epithelium and not 
the concomitant bacterial flora. The Lac Z staining was not seen in the control 
mouse, which had been similarly treated. As this expression pattern was seen in both 
transgenic founder lines, it suggests the expression pattern is due to the specific 
regulatory sequences found in the bovine keratin 5 minigene rather a secondary 
effect due to the influence of cis-acting modifying sequences at the site of the 
transgene integration. This is interesting, as the epithelium lining the intestinal villi 
is a simple columnar rather than a stratified epithelium.
Allowing for this intestinal tissue expression deviation, the results from this 
transgene indicates that the 8.5 kb fragment containing both 5’ and 3’ regulatory 
sequences of the bovine keratin 5 gene are sufficient for high levels of ectopic gene 
expression in a keratin 5 tissue and cell specific manner. The presence of this 
exogenous gene transcribed from the keratin 5 regulatory sequences does not appear 
to have a detrimental impact on the cell.
A similar study (Byrne and Fuchs 1993) using 5 kb of the 5’ keratin 5 regulatory 
sequences found comparable results to those described here with the exception that 
Byrne et al found no staining in either the epithelium of the forestomach or 
oesphagus of the transgenic mice. The internal control in this study, the use of 
immunohistochemistry for endogenous keratin 5 protein did detect the endogenous 
protein at these sites, suggesting that the regulatory sequences used in the transgenic 
construct lacked the ability to target full tissue specificity. In view of this, it was 
surprising that deleting the promoter to only 90 bp was sufficient to target gene 
expression, albeit to a lesser extent, to those same tissue (Byrne and Fuchs 1993;
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Ramirez, Bravo et al. 1994), However, using this severely truncated form of the 
promoter it was noted that although the tissue specificity of the expression pattern 
was retained, the cellular differentiation pattern was lost, as staining was seen in the 
suprabasal cells within the epithelium. It is difficult to reconcile this result in light of 
results by Ramirez et al (Ramirez, Bravo et al. 1994) in which they failed to obtain 
any tissue-specific keratinS Lac Z expression using 1.5 Kb of the keratin 5 
5’regulatory sequenees. They examined 10 transgenie lines and found no 
expression, with the exeeption of a few epithelia cells in the nasal cavity. It can only 
be assumed that there was a secondary reason for the intrinsic failure of expression 
fi'om this expression cassette, although it is very difficult to draw any conclusions 
from such a negative result. It is worth noting that in none of the transgenic mice 
produced by Byrne et al was expression seen in the intestine.
From the results shown here, the keratin 5 minigene expression cassette appears to 
bean excellent vector for the expression of exogenous genes in an epidermal 
population of kératinocytes which are capable of proliferation and therefore may, in 
theory, harbour long term gene expression. In addition, the keratin5-lac Z transgenic 
mice would form an ideal positive control in studying modes of gene transfer to the 
epidermis as the epidermis of these mice would represent the 100% transfection 
scenario. Possible means of non-viral epidermal gene transfer have included 
application of ‘naked’ DNA- intradermal ‘tatooing’ (Hengge, Chan et al. 1995), 
particle bombardment (Ciemik, Krayenbuhl et al. 1996) and liposome-mediated (Li 
and Hoffman 1995). These methods would allow tissue-specific targeting of 
reeombinant proteins and the additional use of a keratin-specific promoter would 
prevent promiscuous gene expression in other tissues, which can occur with viral 
vectors as mentioned previously (Daly, Okuyama et al. 1999).
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It was unfortunate that time prevented the formation of a keratin 5-0TC^^° 
especially in view of the unexpected expression pattern in the intestinal epithelium. 
Although there is no evidenee for the expression of CPS I in the epidermis, the 
intestinal expression driven by the keratin 5 minigene in the presence of a partial 
OTC cycle may have had an interesting phenotype.
In the clinical setting, it is the adult expression pattern of the keratin 5 minigene that 
is of interest. However, in future murine studies utilising this expression cassette to 
express less inert proteins, it is important to know the expression pattern during 
development, as this will have repercussions on the phenotype seen in the mouse
4 .2 .2  K e r a t i n  5 /L  a c Z  e x p r e s s i o n  p a t t e r n  d u r i n g
EMBRYOGENESIS.
During embryogenesis expression of K5 and K14 have been detected as early as the 
bi-layered epithelial phase (Dale, Holbrook et al. 1985; Moll, Moll et al. 1982). K14 
expression has been noted in the inner embryonie layer and on later stratifieation is 
restricted to the innermost layer (Kopan and Fuchs 1989). In conjunction with the 
later temporal expression of keratin 1 and 10, this body of work suggests that there 
are strong parallels between embryonic and adult epidermal keratin expression 
patterns.
Studies by Byrne et al (Byrne, Tainsky et al. 1994) using a 5 kb keratin 5 promoter 
driven LacZ reporter sequence showed initial K5 expression over the dorsal lateral 
region of the embryo overlying the somites at day 9.5. In addition, there appeared to 
be some expression over the head region. In the results presented here, there was 
faint staining over the lateral somites but no staining was observed over the head 
area. At this gestational stage even the staining pattern over the somites was very
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faint and difficult to visualise. However, the later Lac Z expression pattern appeared 
to mirror those found in the earlier study. The staining at dlO.5 also showed a very 
similar staining pattern except that in addition, the results obtained in this study 
showed moderate expression in the mandibular branch and weaker expression in the 
maxillary branch of the first branchial arch as well as the nasal pit. In general the 
embryo at dlO.5 in this study appeared to be slightly more advanced that the 
equivalent dlO.5 embryo demonstrated in the Byrne et al study which could account 
for this variation in expression seen (Byrne, Tainsky et al. 1994). In both transgenic 
systems the expression included the first branchial arch and then slowly extended 
rostrally and caudally over the dorsal lateral ectoderm overlying the somites. 
Evidence that this expression pattern represented the true endogenous gene 
expression came from in situ hybridisation data performed by Byrne et al which was 
indistinguishable from the lac Z staining pattern from the transgenic embryo 
although it was significantly less sensitive.
The K5 induction in the first branchial arch ectoderm followed soon after the 
proposed migration of the underlying mesenchyme, of neural crest origin (Nichols 
1981). This is particularly interesting as the formation of many later epidermal 
appendage such as hair follicles etc are dependent on the underlying dermal cues 
(Hardy 1992).
K5 expression was found throughout the epidermis at day 12.5 but with marked
sparing of the head and dorsal aspects of the embryo relating perhaps to the rapidly
expanding neural tissue underlying these areas of epithelium. This is particularly
interesting as other cranial features such as the maxillary hair follicles showed
markedly increased staining compared with the more caudal pelage hair follicles.
Histological sections taken at dl2.5 interestingly showed that the lac Z staining was
not limited to ectodermal tissue alone. Althought the nasal cavity and developing
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fibrissae in the maxillary area show distinct ectodermal staining, the sections 
through the developing eye and skin appear to show mesodermal cell-specific Lac Z 
staining, which was not commented upon in the study by Bryne et al. It should be 
noted in the current study that the ectodermal tissue shows very high levels of Lac Z 
staining compared to Byrne et al.
It is difficult to ascribe the staining seen in these tissues to a staining artefact, 
although this could be easily investigated by means of in situ hybridisation. This 
technique would separate staining due to cell expression of the keratin 5 gene from a 
staining artefact due to cellular overspill of the lac Z gene product. However, in the 
future more specific staining could be achieved by utilising a Lac Z cDNA with a 
nuclear localisation sequence. By day 13.5 almost the entire embryo surface is 
expressing keratin 5 as indicated by the Lac Z staining, although the most distal 
areas of the fore and hind limbs still stained negative with marked interdigital 
sparing.
Interestingly, the results obtained here did correlate well temporally and spatially 
with those obtained by Byrne et al using 6 kb of the regulatory sequences. However, 
another group using 5 kb of 5 ’ regulatory sequences of the bovine keratin 5 showed 
very delayed expression pattern. The transgene was not expressed until dl3.5 and 
their control comprising immunohistochemistry for the endogenous keratin 5 did not 
show endogenous expression before dl 1.5. It should be noted that this group did not 
study the dlO.5 embryo but concentrated on 48 hr increments in developmental 
patterning. The difference in control endogenous keratin 5 gene expression pattern 
seen between these two groups (Byrne, Tainsky et al. 1994; Ramirez, Bravo et 
al. 1994), is most likely attributable to the sensitivites of the two techniques used 
with in situ hybridisation being the more sensitive. With regard to the Lac Z staining
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pattern, Bryne et al found this technique to be more sensitive than in situ 
hybridisation whilst Ramirez found it to be less sensitive than
immunohistochemistry. The results presented here correlate well with those found 
by Byrne et al showing expression 3 days prior to that seen by Ramirez et al. This 
body of work emphases the need to carefully characterise specific regulatory 
elements used in the formation of tissue-specific expression constructs rather than 
extrapolate expression patterns from previously published mouse models.
4.2.3 Conclusion
The major conclusion from this study is that the skeletal muscle may not be an 
effective target organ for the exogenous expression of recombinant OTC to correct 
OTC deficiency. This is most likely due to lack of other enzymatic components of 
the urea cycle. One other study has demonstrated proof of principle for the use of 
genetically modified muscle to act as a ‘metabolic sink’ and it is conceivable that 
viral vectors which drive expression of two or more urea cycle enzymes could be 
used for correction of OTC deficiency in muscle tissue. Nevertheless, much work 
remains to be performed to explore this avenue effectively.
In the meantime the liver remains the obvious choice as the clinically relevant tissue 
for OTC gene supplemantation therapy. However, the current study and other 
published works suggest that fundemental questions concerning the spectrum of 
molecular pathologies of OTC need to be addressed before gene supplementation 
therapy for OTC deficiency in humans can be regarded as appropriate to all patients. 
In particular it should be ascertained whether any mutation can positively interfere 
with oligomerisation of wild type proteins, which would preclude the use of gene 
supplementation therapy in the liver.
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stock Solutions for Pronuclear Injection
Component g/100ml
F(lOx) NaCl
KCl
NaH2P04 
MgCbôHsO 
Na lactate 
Glucose
5.534 
0.110 
0.047 
0.100 
3.4mls of 60% syrup 
1.00
B(lOx)
G(lOOx)
NaHCOs
Na pyruvate
Penicillin
Streptomycin
CaCl22H20
Hepes
H(lOOx)
E(lOx)
Adjust to pH 7.4 with NaOH 
BSA
2.16
0.3
0.06 xlO^i.u. 
0.050 
2.60 
5.97
0.400
Stock solution T6 pH 7.6 H6 pH7.4
F
B
G
H
E
Phenol red
Water(Analar)
BSA(Sigma)
1.0
1.0
0.1
0.1
0
50pl
7.8
40mg/10ml
1.0
1.0
0.1
0.1
0.84
0
7.8
40mg/10ml
Check pH and store at -4°C
Appendix I rSolutions used in transgenic technology
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